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Summary 
 
Post-stroke cognitive impairment is associated with poor long-term outcomes and increased functional 
dependency.  The overall study aim was to explore the relationships between global cognition, executive 
function and metacognition in a stroke population, to examine correlates and potential predictors of 
cognitive impairment and to determine the relationship between cognitive impairment and stroke in a 
Bahraini stroke sample in comparison to an age- and sex- matched control group. A sample of 130 stroke 
patients (case group) were recruited from the largest medical complex in Bahrain and 55 control 
participants from the non-stroke general population were recruited from two primary local health centres 
in the country. General demographic data, clinical assessment and neuropsychological battery of cognitive 
assessments was conducted on participants. The study found that individuals not affected by stroke have 
proportional risk factors to a stroke population in Bahrain. Approximately 48% of the stroke sample group 
had some degree of cognitive impairment with greater stroke severity being more significantly associated 
with worse overall cognitive impairment. Poorer performance on global cognition was correlated with 
executive dysfunction and more functional dependency. Stroke patients with higher levels of cognitive 
impairment were more likely to report lower cognitive self-consciousness levels, indicating an impairment 
in their metacognitive thought processes. Similarly, participants who performed poorly in the memory 
components of cognitive testing tended to subjectively report higher confidence in their memory skills, 
indicating an impairment in metamemory. Though no significant correlations were reported between 
total Metacognitive Questionnaire-30 scores and executive function and global cognition, the 
Metacognitive Questionnaire-30 was shown to be a good predictor of anxiety and depression post-stroke. 
The development of a tool that can consolidate both subjective and global objective assessment and 
thereby measure the full breadth of metacognitive function is necessary and may have important 
implications for future rehabilitation. 
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Chapter One: Introduction 
Section One: Stroke 
1.1 Overview 
Stroke is defined as rapidly developing clinical signs of focal or global disturbance of cerebral function, 
with symptoms lasting 24 hours or longer or leading to death, with no apparent cause other than of 
vascular origin.(1) According to the World Stroke Organization, approximately 15 million people 
worldwide suffer a stroke and 6 million people die from stroke each year.(2) The management of stroke 
is challenging requiring both acute treatment and long-term care. In addition, stroke is one of the leading 
causes of disability (3) giving rise to a greater range of impairments in comparison to any other 
condition.(4) The various implications of stroke not only lead to a decreased quality of life and disability 
foƌ the iŶdiǀidual, theǇ also fƌeƋueŶtlǇ affeĐt the suƌǀiǀoƌ͛s faŵilǇ ŵeŵďeƌs, ǁho ŵight Ŷeed to take oŶ 
the role of the caregiver. Stroke also has a major impact on the wider community with considerable 
productivity loss due to morbidity and mortality as well as costs of informal caregiving.(5, 6) Furthermore, 
despite advances in treatment, the proportion of stroke survivors with residual deficits continues to 
increase (7) with up to 20% of survivors reporting poor health related quality of life for at least 5 years 
after the acute event.(8) All these implications are in turn reflected in both the direct and indirect 
economic cost of stroke.(5, 9, 10) The need for urgent care in the acute phase and the sequelae of wide 
and complex disabilities requiring rehabilitative care alongside its high incidence and heavy burden on 
healthcare systems worldwide makes stroke a significant global public health issue. The following chapter 
will discuss the epidemiology of stroke with a focus on its incidence in the Kingdom of Bahrain, followed 
by a discussion on its aetiology, classification and consequences. 
1.2 Epidemiology of Stroke 
Stroke is the second commonest cause of death and the sixth leading cause of disease burden globally.(11, 
12) There are an estimated 6 million stroke deaths and this is expected to rise to 8 million by 2030.(13) In 
the Arab world, stroke is increasingly becoming a major health problem, with projections that its mortality 
will nearly double by 2030.(14) Over the past few decades, the Kingdom of Bahrain has experienced a 
rapid growth in population with associated economic, social and lifestyle changes.(15, 16) Chronic 
diseases such as diabetes and hypertension have become the leading health problems in the country.(15, 
17) Despite the decreasing trend of stroke incidence in high-income countries (18), the incidence of stroke 
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among the Bahraini population (110 per 100,000) has nearly doubled since 1995.(16, 17) In addition, 
stroke patients in Bahrain were found to have a much higher prevalence of many of the risk factors for 
stroke in comparison to their western comparators including diabetes (54%), hypertension (75%) and 
hyperlipidaemia (34%).(17) Most alarming is that in addition to the high prevalence of risk factors, the 
Bahraini stroke population is ten years younger than their western comparators.(17, 19, 20). With its 
ageing population, Bahrain is likely to see a continuing rise in the incidence of stroke, and with many 
surviving the acute phase, a greater number of people with stroke will have to return, integrate and 
function in society. Therefore, the country has to be well equipped to handle the multivariate 
consequences that the burden of stroke will have on the community. 
1.3 Pathophysiology and Aetiology of Stroke 
Stroke is a cerebrovascular disease that results from impairment in brain perfusion leading to sudden focal 
neurological deficit and subsequent damage to the brain. The reduced cerebral circulation impairs 
cerebral electrical activity and causes episodes of metabolic stress.(21) A stroke can be either 
haemorrhagic or ischaemic. A haemorrhagic stroke occurs as a result of rupture of a cerebral blood vessel 
resulting in damage to the surrounding neural tissue. An ischaemic stroke results from a sudden 
interruption of cerebral blood flow caused by a clot or occlusion to the arteries supplying the brain. 
Despite differing underlying pathogeneses in both types, the clinical manifestations of ischaemic and 
haemorrhagic stroke depend on the territory of the arterial vessels involved. Nevertheless, delineating 
whether a stroke is ischaemic or haemorrhagic has practical implications during acute management as the 
treatment will vary. There are three main pathogenic mechanisms in ischaemic stroke: large artery 
atherosclerosis in either extra- or intra-cranial arteries, cardio-embolism, or lacunar infarcts (small-artery 
occlusions). Other less common causes (which account for approximately 5% of ischemic strokes) include 
venous thrombosis, arteritis, coagulation abnormalities and arterial dissection.(22) Determining the 
underlying aetiology has important implications as many treatment decisions, both in acute care and 
secondary prevention, are based on the identified cause. Furthermore, prognosis can at times differ for 
different stroke subtypes and this will in turn have implications on planning long-term care. 
The neurological manifestations of a stroke vary depending on size and location of the lesion.(23) There 
is a large degree of specialization of function within the brain with different neurological functions divided 
amongst different brain regions. The clinical manifestations of a stroke depends on which specialized 
centres have been affected with subsequent loss of the neurological function that these centres govern. 
However, despite localization of brain function, it is necessary to emphasize that brain function is an 
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integrated process requiring interaction and feedback of multiple systems in an interconnected and 
cohesive manner.(23) 
1.4 Classification of Stroke 
As stroke is a heterogeneous disease with several aetiologies, subtypes, clinical manifestations, outcomes 
and treatment strategies, it is therefore important to classify strokes from both a clinical and research 
perspective. There are several ways of classifying stroke. Two of the most widely used schemes to classify 
stroke are the Trial of Organon in Acute Stroke (TOAST) classification (24) and the Oxfordshire Community 
Stroke Project (OCSP) classification.(25) 
The TOAST classification subdivides stroke into 5 categories based on aetiology (large-artery 
atherosclerosis, small-artery occlusion (lacunar), cardio-embolism, stroke of other determined aetiology, 
and stroke of undetermined aetiology). The classification in TOAST depends on a combination of clinical 
signs and symptoms, radiological findings and any other ancillary investigations.(22) The Oxfordshire 
Community Stroke Project classification subdivides strokes based on lesion location into total anterior 
circulation syndrome (TACS), partial anterior circulation syndrome (PACS), lacunar syndrome (LACS) and 
posterior circulation syndrome (POCS).  
Despite the usefulness of classification schemes for stroke in guiding further management, it should be 
noted that neither the TOAST nor OCSP classifications take into account stroke severity or disability. For 
this reason, other scales or measures that capture these domains need to be used. For example, the 
National Institutes of Health Stroke Scale (NIHSS)(26) is a measure used to objectively quantify stroke 
severity or the level of impairment cause by a stroke. The NIHSS consists of 11 items, each of which can 
be given a score ranging from 0-4, with zero indicating normal function and higher scores indicating some 
level of impairment.(26) The individual scores are summed from each item to give the total NIHSS score 
in which the maximum possible score is 42 and the minimum possible score is zero.(26-28) The modified 
Rankin Scale (mRS) or the Barthel Index (BI)(29, 30) are objective measures of restrictions in daily living or 
disability. For example, the Barthel Index uses ten variables as a measure of activities of daily living (ADL) 
and mobility. These variables include dependency in feeding, grooming, continence, toilet use, and 
mobility, with higher scores indicating a greater likelihood of independent living following discharge from 
hospital.(29, 30) 
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1.5 Consequences of Stroke on Physical Function, Perceptual-Motor Function, and Speech and 
Language  
Disability-adjusted life years (DALYs) are defined as the sum of life-years lost to pre-mature death and 
years lived with disability adjusted for severity.(31) Stroke is the fourth leading cause of DALYs worldwide 
(32) and one of the leading causes of chronic adult disability.(33) This is because depending on the region 
affected in the brain and the severity, stroke can virtually impact any function. Approximately one-third 
to one-half of stroke survivors are left with persistent significant long-term disability in one or more 
domains.(34) These impairments range from physical impairments affecting mobility, fine motor ability 
and activities in daily living, to impairments in sensation, perception, vision, language and speech, 
cognition, memory and mood.(7) These wide range of disabilities have serious implications for the stroke 
suƌǀiǀoƌ͛s ƋualitǇ of life.  
1.5.1 Consequences on Physical Function 
Physical Consequences of Stroke and Their Impact on ADL 
One of the most common consequences of stroke is physical impairment or limitation. Stroke frequently 
presents with either hemiparesis or hemiplegia. Hemiparesis is defined as weakness affecting one side of 
the body and can cause difficulty in walking, impaired ability to grasp objects, loss of balance, tremor, 
slowness, decrease in movement precision and lack of coordination.(7) It affects approximately eight out 
of ten people with stroke.(35) Hemiplegia, complete paralysis of one side of the body, also frequently 
results due to stroke. The initial severity of these symptoms during presentation is indicative of the 
likelihood of successful recovery (36) with improvements in motor function most likely happening within 
the first one to three months post-insult.(37) 
These phǇsiĐal ĐoŶseƋueŶĐes iŵpaĐt a stƌoke suƌǀiǀoƌ͛s aďilitǇ iŶ ĐaƌƌǇiŶg out ďasiĐ tasks of dailǇ liǀiŶg 
such as the ability to perform household tasks, meal preparation, or shopping.(38) Some stroke survivors 
are left with permanent long-term physical impairments.(39) Nearly one-third of people with stroke who 
present with initial paralysis of the lower extremity do not regain useful function and between one-fifth 
to one-quarter of people with stroke are left unable to walk without physical assistance.(40) These 
impairments turn into long-lasting difficulties with carrying out everyday tasks as the ability to live 
independently after stroke relies heavily on motor function.(7) For example, a study by Pohjasvaara et al. 
found that two-thirds of stroke survivors still experienced problems carrying out at least one ADL at five 
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years post-stroke and that a relatively small proportion of patients are able to fully regain everyday 
functioning.(41) 
1.5.2 Perceptual-Motor Function 
Unilateral Neglect and Apraxias  
Unilateral neglect is a defined as a failure by an individual to process, perceive or respond to stimuli on 
one half of the body of the environment despite normal vision and somatosensory input.(42) It is a 
common phenomenon observed in stroke, characteristically involving right parietal lobe lesions.(43) The 
incidence of unilateral neglect in patients with right hemispheric stroke varies between 22-46%.(44). 
Cherney et al. Ŷoted that patieŶts ǁith uŶilateƌal ŶegleĐt ͞ofteŶ do Ŷot oƌieŶt people appƌoaĐhiŶg theŵ 
from the coŶtƌalateƌal side…[aŶd] ŵaǇ ďe Ŷoted Ŷot to dƌess the ĐoŶtƌalateƌal side of the ďodǇ oƌ shaǀe 
the contralateral side of the face. Some may fail to eat food on the contralateral side of their plates, 
uŶaǁaƌe of the food theǇ haǀe left.͟(45) Though this deficit may at times seem subtle, unilateral neglect 
ĐaŶ gƌeatlǇ iŶteƌfeƌe ǁith a peƌsoŶ͛s aďilitǇ iŶ ĐaƌƌǇiŶg out eǀeƌǇdaǇ tasks aŶd is a pƌediĐtoƌ of pooƌ ADL 
and overall recovery.(46, 47) It ĐaŶ ďe detƌiŵeŶtal to the ƌehaďilitatioŶ pƌoĐess due to the patieŶt͛s 
inability to engage in both sides of their body and is associated with a reduced speed of information 
processing, longer length of stay in rehabilitation, slower rates of improvement and poorer mobility.(23) 
Therefore it is a poor prognostic indicator and has been suggested to be a major cause of disability.(48) In 
additioŶ, aŶosogŶosia ;laĐk of kŶoǁledge oƌ aǁaƌeŶess of defiĐitͿ aŶd/oƌ laĐk of oǁŶeƌship of oŶe͛s ďodǇ 
ŵaǇ aĐĐoŵpaŶǇ ŶegleĐt ĐausiŶg the patieŶt͛s to ďe uŶaǁaƌe of theiƌ iŵpaiƌŵeŶts aŶd fuƌtheƌ hiŶdeƌ the 
rehabilitative process.(47) 
Apraxia is another consequence of stroke. Apraxia is a disorder of motor planning defined as an inability 
to execute willed, purposeful movements which cannot be accounted for by weakness, incoordination, 
sensory loss or by incomprehension or inattention to commands.(49) Approximately one-third of left 
hemispheric stroke patients will have some degree of apraxia.(50) Studies have shown that there is a 
significant relationship between apraxia severity and dependency in physical functioning (51) and that 
apraxia has a detrimental effect on improving rehabilitation measures.  
Somatosensory loss 
Somatosensory function is defined as the ability to detect, recognise and interpret bodily sensations.(52) 
It includes light touch, crude touch, vibration, temperature detection, pain (nociception) and 
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proprioception (awareness of the location and movement of oŶe͛s oǁŶ ďodǇ paƌts iŶ spaĐeͿ. The 
soŵatoseŶsoƌǇ sǇsteŵ is a Đoŵpleǆ aŶd ǀital sǇsteŵ ƌespoŶsiďle foƌ a peƌsoŶ͛s ĐoŶsĐious eǆpeƌieŶĐe aŶd 
awareness of their surroundings.(7) PeƌĐeptioŶs ǀia soŵatoseŶsoƌǇ fuŶĐtioŶ iŶ tuƌŶ ƌesult iŶ people͛s 
actions, interactions and adaptations within their environment. 
Studies have reported that as high as 50-60% of people after a stroke experience loss of proprioception 
or asteriognosis (inability to identify an object by touch without other sensory input).(53-55) These deficits 
iŵpaiƌ aŶ iŶdiǀidual͛s aďilitǇ to eǆeĐute siŵple eǀeƌǇ tasks aŶd iŵpede pƌeĐisioŶ aŶd speed of ŵoǀeŵeŶt. 
Patients can even experience major difficulty in performing tasks that combine cognitive function with 
fine motor skills such as writing.(56) Furthermore, patients might lose the ability to unconsciously 
communicate through body language.(56) 
It is evident that somatosensory loss ĐaŶ haǀe aŶ oŶgoiŶg aŶd Ŷegatiǀe iŵpaĐt iŶ stƌoke patieŶts͛ aďilities 
in carrying out their daily activities contributing to decreased level of function, reduced independence and 
quality of life and greater rehabilitative needs.(7) 
1.5.3 Consequence of Stroke on Speech and Language Function 
Second to hemiparesis, dysphagia, dysarthria and aphasia are the most frequent neurological deficits that 
occur in stroke.(57) The reported incidence of dysphagia (difficulty in swallowing) in the acute phase of 
stroke approximates 55% (58) whereas dysarthria ranges between 25-42%.(57, 59) Dysarthria is a 
disturbance in muscular control of the speech mechanism resulting in abnormal neuromuscular execution 
of speech.(60, 61) Dysarthria is commonly characterized by slurred, spastic, monotonous, or explosive 
speech and is commonly seen in stroke.(62) Approximately 15% of patients who present with dysarthria 
in stroke will be left with long-term residual dysarthria.(63, 64) Dysarthria can often cause social and 
emotional disruptions to stroke survivors and patient sentiments of stigmatization due to their dysarthria 
have frequently been reported.(65) 
Aphasia is defined as an impairment of language, affecting the production or comprehension of speech 
and the ability to read and write.(66) The incidence of aphasia is between 23-35% in the acute phase of 
stroke.(67) Approximately 10-18% of patients with aphasia are likely to be left with long-term residual 
aphasia that can significantly impact communication.(63) The two commonest types of aphasia are 
BƌoĐa͛s aphasia, iŶ ǁhiĐh theƌe is ŶoŶ-fluent, hesitant and laboured speech with intact comprehension, 
aŶd WeƌŶiĐke͛s aphasia, iŶ ǁhiĐh theƌe is flueŶt uŶiŶtelligiďle speeĐh ǁith pooƌ ĐoŵpƌeheŶsioŶ. “iŶĐe 
approximately more than one half of aphasic patients are left with residual deficits, it often leads to an 
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increased use of rehabilitation services (68) and a reduced probability of return to work.(69) 
Consequently, aphasia is a strong predictor of poor outcome. 
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Section Two: Stroke, Cognitive Function and Mood 
2.1 Stroke and Cognitive Function 
Stroke is an important risk factor for cognitive impairment and dementia. Cognitive dysfunction can impair 
a peƌsoŶ͛s atteŶtioŶ, oƌieŶtatioŶ, ŵeŵoƌǇ, ĐalĐulatioŶ, aŶd judgement.(22) Cognition is often impaired in 
the early phase after stroke and at least 50% of stroke survivors will experience some degree of cognitive 
deficit in the early or chronic phase of the insult.(70-73) Studies have reported that memory, orientation,  
language and attentional functions are be the most commonly defective domains after stroke.(70) In 
particular however, executive function, attention and speed of information processing are what seem to 
be most affected post-stroke (70, 74) and can persist for a long time even after good clinical recovery.(75)  
Mild and subtle attentional deficits have also been shown to be associated with poor social functioning. 
For example, a study that examined stroke suƌǀiǀoƌs͛ ĐogŶitiǀe status siǆ months post-stroke via a Mini-
Mental State Exam (MMSE) reported that those with an MMSE of at least 18 showed impaired 
performance in a series of computer-based attentional tasks in comparison with healthy older adults.(7, 
76) These deficits were negatively correlated with degree of social engagement and participation in 
everyday activities. In some cases, these subtle cognitive deficits remain undetected and can often result 
in substantial functional problems that can affect both rehabilitation and secondary stroke 
prevention.(77) The presence of cognitive impairments after stroke has important functional 
consequences irrespective of the degree of physical or perceptual-motor impairments as it has been 
significantly correlated with dependent living after discharge even after adjusting for physical 
impairment.(70) 
Vascular cognitive impairment (VCI) refers to the continuum of mild vascular cognitive impairment to 
vascular dementia.(23) Approximately one-fourth of stroke patients develop vascular dementia.(78) 
Vascular dementia is defined as loss of cognitive function resulting from ischaemic brain lesions due to 
cerebrovascular disease or cardiovascular pathology.(23) According to the DSM-IV criteria, vascular 
dementia is diagnosed by the development of multiple cognitive deficits manifested by memory 
impairment and at least one or more of the following cognitive disturbances: aphasia, apraxia, agnosia, 
and/or disturbance in executive functioning. These cognitive deficits must be associated with focal 
neurological signs and symptoms or laboratory evidence indicative of cerebrovascular disease (e.g. 
multiple infarctions involving the cortex and underlying white matter) that are judged to be aetiologically 
related to the disturbance. The deficits should not occur exclusively during the course of a delirium and 
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should cause significant impairment in social or occupational functioning, representing a significant 
decline from previous level of functioning.(79) 
According to the NINDS-AIREN criteria, the criteria for the diagnosis of definite vascular dementia include 
a) clinical criteria for probable vascular dementia; b) histopathologic evidence of cerebrovascular disease 
obtained from biopsy or autopsy; c) absence of neurofibrillary tangles and neuritic plaques exceeding 
those expected for age; and d) absence of other clinical or pathological disorder capable of producing 
dementia. The criteria for the clinical diagnosis of probable vascular dementia includes the following: 1) 
Cognitive decline from a previously higher level of functioning, manifested by impairment of memory and 
two or more cognitive domains (orientation, attention, language, visuospatial function, executive 
function, motor control and praxis), severe enough to interfere with activities of daily living and not due 
to the physical effects of stroke alone; 2) Cerebrovascular disease, defined by the presence of focal signs 
on neurologic examination consistent with stroke with evidence of disease by brain imaging; 3) A 
relationship between the two disorders (e.g. onset of dementia within 3 months following a recognised 
stroke, abrupt deterioration in cognitive functions, stepwise progression of cognitive deficits).(80) 
2.2 Variables Associated with Cognitive Impairment in Stroke 
The cognitive deficits associated with stroke vary in type and severity from individual to individual 
depending on the associated variables and risk factors involved. The variables associated with cognitive 
impairment influence the degree of impairment and overall prognosis and recovery.(81, 82) The variables 
associated with cognitive impairment will be discussed in the following paragraphs.  
Several studies have shown an association between cognitive impairment and age in stroke, with a higher 
prevalence of cognitive impairment in an older stroke population.(70, 83) Some studies have also reported 
a significant associations between cognitive impairment and the female sex.(70, 84) Few studies have 
examined race or ethnicity as a variable associated with cognitive impairment with some reporting racial 
differences playing a role.(85) Lower socioeconomic status and lower level education have both been 
reported as variables associated with a higher level of cognitive impairment in stroke populations.(86, 87) 
Other factors reported also include pre-morbid cognitive status,(88, 89) affeĐt aŶd the iŶdiǀidual͛s oǁŶ 
personality traits(90, 91) and coping mechanisms.(92) 
Several studies have also reported that individuals with a previous history of stroke have a higher risk of 
cognitive impairment or dementia in comparison to those with no previous history even after adjustment 
for potential co-founding variables.(89, 93) Some studies also report that cognitive impairment varies by 
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stroke severity and stroke syndrome with cognitive impairment more frequently seen in large infarcts and 
with infarcts involving the dominant anterior and posterior cerebral  artery territories.(81, 94) 
Some studies have examined the temporal trends of cognitive impairment following stroke. Longitudinal 
studies have demonstrated that most patients have a relatively stable cognitive performance in the first 
two years post-stroke but some improve whereas other decline.(95) Studies have yielded conflicting 
results regarding the variables impacting risk of cognitive impairment with time. Patel et al. examined the 
natural history of cognitive impairment following stroke over the course of three years and found that the 
prevalence rates of cognitive impairment were comparable over the course of three years.(88) By 
contrast, Tham et al. examined the prevalence of cognitive impairment in a post-stroke population over 
a one year period and concluded that the cognitive performance in stroke patients changes over time with 
soŵe patieŶts͛ ĐogŶitiǀe leǀel deteƌioƌatiŶg aŶd otheƌs͛ iŵpƌoǀiŶg suggestiŶg fuƌtheƌ ƌeseaƌĐh to ideŶtifǇ 
the risk factors for deterioration in cognitive function.(96) 
With regards to biomarkers associated with post-stroke cognitive impairment, some studies have 
reported that high levels of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were 
associated with worse performance in cognitive tests, particularly memory scores.(97) However, the most 
commonly studied biomarker in vascular and neurodegenerative diseases is Apolipoprotein E (ApoE).(98, 
99) ApoE is a serum glycoprotein with three common isoforms (E2, E3 and E4) and it plays an important 
role in lipid metabolism and transport.(99) It is significantly expressed in the central nervous system as it 
is involved in cholesterol transport to neurons.(99) The Apoliprotein E gene is located at chromosome 19q 
13.2 and consists of four exons and three introns spanning 3,596 nucleotides. The protein is encoded by 
three alleles (E2, E3, E4) which give rise to six genotypes.(100)  The genotypes containing the E4 allele are 
associated with increased cholesterol levels and the genotypes containing the E2 allele are associated 
with decreased levels. An association has been observed between E4 carriers and ischaemic heart disease 
and cerebral amyloid angiopathy. The E4 allele has also been associated with poor outcome after various 
other neurological events such as subarachnoid haemorrhage and traumatic brain injury.(101) 
The liŶk ďetǁeeŶ ApoE aŶd Alzheiŵeƌ͛s disease is the stƌoŶgest aŶd ŵost ǁell estaďlished.;ϭϮϰ-126) More 
specifically, the protein isoform involved in cognitive decline in late-onset Alzheiŵeƌ͛s disease is the 
ApoE4 (E4/E4 alleles) as it seems to be involved in amyloid deposition in the blood vessels.(124)  The 
correlation between ApoE4 and cognitive decline seems to be most prominent in tasks involving memory 
function and delayed recall which are early indicators of dementia.(124)  
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Pathophysiologically, ApoE4 also seems to modulate the effects of atherosclerosis in cognitive decline.(99)  
Both stroke and ApoE4 are associated with cognitive impairment and the primary cause of ischemic 
strokes is atherothrombosis which raises the question of whether ApoE4 is involved in the pathogenic 
mechanism of cognitive decline in stroke.(99)  There has been some investigation regarding the role of 
ApoE in stroke and its association with cognitive deficits and overall stroke outcome.(99, 100, 102, 103) A 
cross-sectional study by Wagle et al. examining 152 in-hospital stroke rehabilitation patients found that 
the presence of the E4 allele (either the homozygous or heterozygous type) was associated with cognitive 
impairment 2-3 weeks after the insult.(104) However, the precise relationship between stroke and ApoE 
and the mechanisms which delineate how they cause cognitive impairment is still inconclusive and further 
studies need to be conducted to confidently determine an association.(99, 104, 105) 
2.3 Executive Function  
Executive function is defined as the group of complex cognitive processes responsible for monitoring and 
controlling cognitive, emotional and behavioural functions during novel tasks.(106, 107) Executive 
function is what enables and drives adaptive and goal-directed behaviours and includes the ability to 
generate thought and think flexibly, the ability to update continuously incoming information and the 
ability to inhibit irrelevant information to current goals while adjusting behaviour as appropriate to the 
present context.(108) Intact executive functions are essential for adapting to a continually changing 
environment. The four main components of executive function include working memory, inhibition, 
mental set shifting and fluency.(109, 110) Working memory is defined as a limited capacity system that 
enables an individual to temporarily process, store and manipulate information in conscious 
awareness.(111) Intact working memory is vital for higher-level tasks such as planning and decision 
making as it allows an individual to actively scan incoming necessary information.(111, 112) Inhibition is 
the ability to hold back a predominant, automatic or previously learned response that may be irrelevant 
to the present context in order to meet the current goal.(111) Patients who are cognitively disinhibited 
have difficulty actively ignoring irrelevant stimuli. Set shifting indicates the ability to flexibly modify 
attention in response to changing circumstances and demands.(111) Set shifting depends on both intact 
working memory and intact response inhibition. This demonstrates the interconnectedness of the 
different components of executive function. Fluency is the ability to maximise the production of verbal or 
visual information within a specific time frame while avoiding repeated responses.(111) 
All components of executive function work together to facilitate the cognitive constructs of planning and 
organization. This allows an individual to identify, prioritize and coordinate sequential and multiple steps 
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needed to achieve a goal in an efficient manner while simultaneously adapting any necessary 
changes.(113) Deficits in executive function manifest as poorly controlled, disjointed and disinhibited 
cognitive processes (114) leading to disproportionate impairment in function and activities of daily 
living.(115) Depending on the anatomic location and size of lesion(s), stroke can produce a constellation  
of executive function deficits in addition to motor, sensory, perceptual and other cognitive deficits.(94, 
116, 117) Several studies have identified executive function deficits in up to 44-92% of individuals 
following stroke and as one of the primary deficits of cognitive impairment after stroke.(117-119) 
Executive dysfunction has also been found to predict poor functional outcome one year post-stroke.(120-
122) 
2.4 Memory Function  
A stroke rarely occurs in the brain structures predominately involved in memory encoding and retrieval 
(e.g. medial temporal lobe, hippocampus).(112) However, as with other cognitive functions, memory 
operates in a cerebral network, connecting various parts of the brain (e.g. medial temporal lobe, anterior 
thalamus nucleus, mammillary body, prefrontal cortex) with each other.(123) A stroke in any of these 
structures or in their connections could result in memory impairment,(112, 124) with studies identifying 
stroke as a predictor of poorer neuropsychological performance on recall and recognition memory 
tasks.(125) MeŵoƌǇ fuŶĐtioŶ is kŶoǁŶ to ǀaƌǇ depeŶdiŶg oŶ aŶ iŶdiǀidual͛s pƌe-morbid cognitive, 
emotional and physical status.(83) In addition, larger stroke volume, previous silent infarcts, pre-stroke 
medial temporal lobe atrophy and white matter lesions are all associated with post-stroke decreased 
memory function. 
Memory deficits from stroke also frequently co-exist with language, visuospatial and/or executive 
deficits.(124) This is because two broad stroke-related damage mechanisms causing impairment in 
memory have been hypothesized.(124) The first being infarction or haemorrhage involving any structure 
within the hippocampal or amygdala circuits and the second being stroke occurring outside of the limbic 
circuitry impairing perceptual, cognitive, attentional or executive capacities essential for some aspect of 
memory processing.(124) 
Memory problems may have a profound impact after stroke especially in the chronic stage and they are 
usually a major concern for patients.(70, 126, 127) Stroke survivors have been known to report memory 
complaints years after the acute event.(128, 129) Despite this, there are few formal studies investigating 
the course of post-stroke memory dysfunction.(123, 130) A systematic review by Snaphaan and Leeuw 
25 
 
reported that the prevalence of  post-stroke memory dysfunction varied from 23-55% at 3 months post-
stroke and 11-31% at one year post-stroke indicating potential for some recovery and the need to provide 
efficient memory training programmes for patients.(123, 129)  
2.5 Stroke and Mood 
Mood disorders such as depression and anxiety are becoming commonly recognised as a consequence of 
stroke. Post-stroke depression is considered to be one of the most frequent and significant 
neuropsychiatric consequences of stroke. Some studies have shown that post-stroke depression occurs in 
as high as 60% of patients,(131-133) with major depression being approximately 27%.(22) There is a high 
but wide range in the frequency of depression post-stroke and this is accounted for by methodological 
differences in the various studies, including different background populations, different instruments and 
criteria used for diagnosis and the point in time in which the patients were assessed in relation to stroke 
onset.(22)  
Potential causes for post-stroke depression include neuroanatomic mechanisms. However, in a systematic 
review examining post-stroke depression with lesion location,(134) no significant correlation was found. 
Psychological mechanisms, such as difficulty in facing and adjusting to new limitations have also been 
proposed.(135) As ǁith otheƌ illŶesses, depƌessioŶ afteƌ stƌoke ŵaǇ also ďe ƌelated to a peƌsoŶ͛s ďeliefs 
and feelings about their disease.(136) Patients with post-stroke depression report significantly more 
negative cognitions and beliefs and less positive cognitions relating to their stroke than non-depressed 
patients.(137) Typically, depressive symptoms tend to occur within the first two years following 
stroke.(133) 
Depression has been positively correlated to stroke severity and the patieŶt͛s leǀel of depeŶdeŶĐe afteƌ 
discharge.(138) Other risk factors include previous depression, female gender and a history of psychiatric 
and emotional liability in the first days after stroke.(135) Depressed patients have also been shown to 
have more cognitive impairments in comparison to their non-depressed counterparts especially impaired 
concentration and attention, memory difficulties and decreased speed of information processing.(91) In 
addition to its detrimental effect on mental health, post-stroke depression also has a major impact on 
functional recovery and results in poorer long-term and rehabilitation outcome.(131, 139) Depressed 
stroke patients have reduced independence in activities of daily living, reduced participation in social and 
leisure activities and failure to return to work.(140) Post-stroke depression has also been associated with 
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rehospitalisation, increased incidence of recurrent stroke, and increased disability and mortality.(132, 
141-144) 
In terms of anxiety, it is estimated that approximately one-quarter of stroke survivors suffer from anxiety 
at some point after the event.(131, 145) However, it has been suggested that anxiety is frequently 
undiagnosed in stroke patients.(145) Like depression, anxiety also has a negative impact on recovery after 
stroke. For example, stroke survivors suffering from anxiety tend to be more dependent on others in 
carrying out activities of daily living.(145) Both anxiety and depression are characterised by attention and 
concentration difficulties and poor motivation.(146) These factors are likely to exacerbate cognitive 
impairment and hinder the rehabilitative process as it may be difficult to engage the individual in 
treatment activities.(7, 146) Co-morbidity between depression and anxiety post-stroke has also been 
reported and linked to poor health related quality of life.(147) 
2.6 The Implications of Cognitive Impairment and Mood on Rehabilitation 
Of the 15 million people who suffer a stroke each year, approximately five million are left with severe 
residual deficits.(7) The impact that stroke has on physical function is what is usually given the most 
attention. However, it is only one of the many domains affected as a consequence of stroke. Stroke is a 
major cause of long-term cognitive, emotional and social impairment. Even patients that present with 
what is classified as a mild stroke report residual changes such as depression and cognitive change.(75) 
These ĐoŵpliĐatioŶs aƌe ofteŶ ŶegleĐted despite the faĐt that theǇ ofteŶ haǀe a gƌeat iŵpaĐt oŶ oŶe͛s 
quality of life. 
Stroke rehabilitation is generally defined as any aspect of stroke care (usually non-surgical and non-
pharmaceutical) that aims to reduce disability and promote activity and independent participation in 
everyday activities.(7, 148) Rehabilitation focuses on restoring abilities required to perform activities for 
independent living. Individuals with cognitive impairment or mood disorders often have difficulties during 
rehabilitative activities. For example, they frequently report reduced motivation and decreased levels of 
concentration. Consequently, this affects their abilities in remembering or holding information in working 
memory and their ability to re-learn.(7) In addition, this group of patients commonly have a lack of insight 
or awareness on their deficit which in turn greatly impacts the rehabilitative process. These difficulties are 
not always apparent in the clinical setting and are often not the focus of therapy. This is why it is 
imperative to focus screening and assessment of these impairments in any patient undergoing 
rehabilitative care. 
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Section Three: Metacognition 
 3.1 Definition and Assessment 
Metacognition generally refers to any knowledge an individual has about their own cognitive abilities and 
the regulation of these activities through cognitive monitoring.(149) The term was first coined by John 
Flavell in 1979.(150) It consists of metacognitive knowledge which includes knowledge about cognitive 
abilities and strategies, and metacognitive regulation, which includes cognitive monitoring and cognitive 
control (planning, error correction, and resource allocation).(106) Research on metacognitive function 
was originally initiated and has subsequently been well established in educational theory and 
practice.(151, 152) However, as of recent, sufficient interest as arisen in its clinical application in both 
traumatic and acquired brain injury.(153-155) 
Cognitive assessments have primarily focused on global cognition and executive function. However, it can 
be argued that gloďal oƌ ďƌoad oďjeĐtiǀe ŵeasuƌeŵeŶts of ĐogŶitioŶ do Ŷot adeƋuatelǇ assess a patieŶt͛s 
ability or capacity in executing self-regulatory cognitive, physical or social activities. Impairments in 
higher-oƌdeƌ ĐogŶitiǀe fuŶĐtioŶs ǁill hiŶdeƌ aŶ iŶdiǀidual͛s aďilitǇ to ƌeĐogŶize theiƌ defiĐits ĐausiŶg theŵ 
to engage in activities that exceed their capabilities, set unrealistic performance goals and fail to utilize 
adaptive compensatory strategies.(156, 157) Therefore, those with cognitive deficits can only reach their 
potential for independent functioning if metacognitive abilities are primarily addressed. For this reason, 
there has recently been increased interest in exploring metacognitive deficits in line with cognitive 
function in stroke. 
There is a strong overlap between executive function and the self-regulatory component of 
metacognition. However, although both metacognition and executive function involve top-down self-
regulatory processes that guide, direct and manage cognitive functions, metacognition also involves 
kŶoǁledge aŶd suďjeĐtiǀe assessŵeŶt of oŶe͛s oǁŶ ĐogŶitiǀe ĐapaĐities aŶd aďilities.(106)  
Since metacognition is a broad term encompassing both knowledge and regulation of cognitive activity, 
interpretations of the term have extended beyond its original definition and now encompass many 
functions that relate back in some form to a component of cognitive function. As a result, several 
comparable terms (e.g self-awareness, self-monitoring, self-regulation, subjective cognitive complaints) 
or terms that focus on a domain of metacognition have emerged. Such a domain that has emerged is 
metamemory. 
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Metamemory is defined as the knowledge, beliefs and perceptions about the function, development and 
ĐapaĐities of oŶe͛s oǁŶ ŵeŵoƌǇ.(126, 158, 159) This involves factual knowledge, (knowledge about the 
functioning of memory and the strategic behaviours used for tasks requiring memory process), memory 
monitoring, memory-related affect (emotional states associated with memory) and memory self-efficacy 
;oŶe͛s seŶse of ŵasteƌǇ oƌ aďilitǇ to use ŵeŵoƌǇ effeĐtiǀely).(127, 159) Impaired metamemory and 
underestimation of memory deficits could result in patients not seeking help regarding their memory 
problems. Therefore, order to deliver appropriate rehabilitation interventions relating to adequate 
ŵeŵoƌǇ tƌaiŶiŶg, kŶoǁledge of aŶ iŶdiǀidual͛s oǁŶ peƌĐeptioŶs of theiƌ ŵeŵoƌǇ skills thƌough 
metamemory needs to be addressed. However, few studies have been conducted on deficits of 
metamemory in stroke.(126-128, 160, 161)   
The development of all these facets of metacognition has led to a wide array of assessment tools 
developed in an attempt to measure metacognitive function or one of its components. A literature search 
was conducted in order to examine the concept of metacognition and to identify the definitions and 
assessment tools used to quantify the concept in relation to stroke care, assessment and management. 
The results of the literature review were published in the Journal of Neurology, Neurosurgery and 
Psychiatry. (See Appendix 1 for full article) A computer search was performed on databases: MEDLINE 
(1976-2014), PsychINFO (1972-2014), CINAHL (1978-2014), Cochrane library databases (2007-2014), 
Scopus (1959-2014) and Web of Science (1974-2014). The following keywords were used: 
͞ŵetaĐogŶitioŶ͟ AND ͞stƌoke͟ AND ͞ŵeasuƌeŵeŶt͟ ;see Table 3.1 for associated words with keywords 
used in the database search). 
Table 3.1 Initial key search terms and associated words 
Main Search Terms  Relevant associated words 
Metacognition   Self-awareness AND/OR Unawareness AND/OR Self-regulation AND/OR Self-
monitoring AND/OR Self-evaluation AND/OR Self-knowledge AND/OR Self-
predictions AND/OR Subjective cognitive complaints AND/OR Agnosognosia 
AND/OR Metamemory AND/OR Agnosia  AND/OR self-identity AND/OR Frontal 
Network Syndrome 
Stroke Cerebrovascular Accident AND/OR CVA AND/OR Transient Ischemic attack AND/OR 
TIA AND/OR Acquired brain injury   
Measurement   Measure AND/OR Assessment AND/OR evaluation AND/OR Tool AND/OR 
Questionnaire AND/OR Survey 
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Articles were included if they fulfilled the following criteria: 
a. They used standardized questionnaires measuring metacognition or a component of 
metacognition in cross-sectional, longitudinal, interventional or single case studies. 
b. The sample population compromised or included patients with stroke or stroke was a patient 
group within a study. 
c. They published peer-reviewed research in the English language from which the full text was 
available. 
 
Figure 3.1 Diagram of Selection of Studies 
 
A flow diagram of study selection is shown in Figure 1. Of the 1,412 studies identified, 34 studies met the 
inclusion criteria. Of these studies, five examined metacognition in relation to cognitive and/or emotional 
functioning,(162-166) four examined the concept of metamemory,(126-128, 160) three investigated the 
relationship between driving and metacognition,(167-169) three examined metacognition in relation to 
motor or functional restrictions including activities of daily living,(170-172) three investigated the use of 
an assessment tool,(77, 173, 174) and two studies examined the effect of metacognition on employment 
status.(154, 175) Tables 3.2 (cross-sectional) and 3.3 (longitudinal, interventional and single case) present 
a summary of the studies reviewed. 
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Study design and Sample Characteristics 
Twenty-two studies were cross-sectional in design,(77, 126-128, 154, 160, 163-174, 176-179) two were 
longitudinal,(162, 175) nine were interventional(153, 180-187) and one was a descriptive single case 
study.(188) The sample size and type varied between the studies. Twelve studies examined metacognitive 
function exclusively in stroke patients.(77, 127, 128, 160, 162, 165, 169, 170, 174, 183, 186, 188) The 
remaining 22 studies consisted of other patient groups alongside stroke (e.g. traumatic brain injury, 
tumour or hypoxic event). Sample sizes varied across the cross-sectional studies ranging from 25 – 437 
participants, however in studies that examined a mixed sample of aetiologies the stroke subgroups were 
of a small size. The mean age (average of reported means) was 48.2 (SD 13.2). The timing of assessment 
also varied ranging from one week post-insult to 10.1 years. Only one study examined metacognitive 
function in the acute phase of stroke.(186)  
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Table 3.1: Overview of cross-sectional studies (n=22) measuring metacognition or associated functions in stroke 
Study 
reference 
(year) 
a. Study aim 
b. Metacognition (or other term 
used) and definition 
Study Design 
a. Sample size 
b. Age and 
gender 
c. Time of 
assessment 
a. Metacognition measures 
b. Other cognition measures 
Findings 
Ide et al. 
(1999)  
a. To investigate metamemory or 
memory awareness among Japanese 
nursing facility residents with varying 
degrees of cognitive function, and to 
investigate the influence of depression 
and health on metamemory. 
b. Metamemory is defined as the 
knowledge, perceptions and beliefs 
about the functioning, development 
aŶd ĐapaĐities of oŶe͛s oǁŶ ŵeŵoƌǇ 
and the human memory system.   
a. n=117 nursing 
facility residents (n=48 
CVA) 
b. Mean age: 83.0 (32 
males, 85 females) 
c. Not specified 
a. MIA 
b. MMSE 
 
Depression was found to be a key 
factor for explaining metamemory. 
There was no difference between the 
mild cognitive impaired and the 
cognitively intact group. When 
depression was considered as a 
moderating factor, a difference arose 
between the two cognitive levels.   
Ownsworth et 
al. (2000) 
 
 
 
a. Development and standardization of 
the SRSI 
b. Metacognitive knowledge and self-
regulatory strategies involves assessing 
the ĐlieŶt͛s leǀel of aǁaƌeŶess, 
conscious reflection, and self-
regulatory mechanisms. 
a. n=61 ABI (n=7 CVA) 
n= 43 non-ABI 
b. Mean age: 34.5 (46 
males, 15 females) 
c. Mean length of time 
post-injury: 8.5 years 
a. SRSI, SADI 
b. Vocabulary subset, 
Health and Safety Scale, 
TTT 
In comparison to the control group, 
participants with ABI had significantly 
lower levels of Awareness and Strategy 
Behaviour, but the level of Readiness to 
Change was not significantly different 
between the two groups. The significant 
relationship between SRSI factors and 
neuropsychological functioning 
measures confirmed the concurrent 
validity of the scale and supports the 
value of the SRSI for post-acute 
assessment. 
Grigsby et al. 
(2002) 
 
a. To examine the relative contribution 
of several cognitive and clinical 
variables to the ability to engage in 
activities of daily living among stroke 
patients.  
a. n=246 CVA 
b. Mean age: 77.5 
years (96 males, 150 
females) 
c.  Not specified 
a. BDS 
b. MMSE 
The BDS was strongly correlated with 
concurrent functional capacity and 
was somewhat superior to mental 
status in this regard. The ability to use 
intentions to guide purposeful 
behaviour appears to be an important 
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b. Self-regulation, regulation of 
attention, planning and anticipating 
possible consequences of action, 
ŵoŶitoƌiŶg aŶd eǀaluatiŶg oŶe͛s oǁŶ 
behaviour. 
contributor to everyday functioning 
among older adults.  
Ownsworth et 
al. (2002) 
 
a. To investigate the relative 
contribution of psychological and 
neuropsychological factors underlying 
deficits in awareness and self-
regulation. 
b. Self-awareness, self-regulation: no 
definition 
a. n=61 (stroke cases 
not specified) 
b. Mean age: 34.5 
years (26% female, 
74% male) 
c. Mean time since 
injury: 8.5 years 
a. SADI, SRSI 
b. Assessment of 
neuropsychological factors 
(IQ based on WAIS-R, Health 
and Safety subset, TTT) 
Neuropsychological factors underlie 
deficits in awareness and self-
regulation more directly than 
psychological factors. The role of 
psychological factors is evident in the 
interactions with neuropsychological 
factors which differed according to the 
aspect of self-awareness and self-
regulation examined. 
Cock et al. 
(2003) 
a. To explore whether patients 
relearning to walk after acquired brain 
injury and showing cognitive-motor 
interference were aware of divided 
attention difficulty and whether their 
perceptions concurred with those of 
treating staff. 
b. Impaired self-awareness, insight into 
mental changes. 
a. n=50 (n=33 CVA) 
b. Mean age: 50.18 
years, (28 male, 22 
female) 
c. Mean time since 
onset of injury: 16.36 
months 
a. Questionnaire consisted of 
eight items designed to 
eǆploƌe patieŶts͛ peƌĐeptioŶs 
by self-report of their current 
ability to carry out more than 
one cognitive task at a time.  
(Discrepancy score between 
patient and 
neurophysiotherapist) 
b. Gait decrement task 
Patients and staff exhibit awareness of 
divided attention difficulty, but with a 
limited degree of concurrence. 
Patients and staff may be sensitive to 
different aspects of the deficit. 
Fischer et al. 
(2004) 
 
a. To compare the patient-staff rating 
method with the predictive 
peƌfoƌŵaŶĐe ŵethod ǁith patieŶts͛ 
awareness of activity limitations. 
b. Self-awareness. No definition. 
a. n=46 (n=24 patients 
with brain injuries of 
which n= CVA 13, 
n=22 patients with 
orthopaedic disorders 
as controls) 
b. Brain injury group: 
mean age: 48.6 years, 
(15 male, 9 female) 
c. Brain injury group: 
Mean time since 
injury: 141 days 
a.Patient-staff rating 
discrepancy in the PCRS, 
Discrepancy between 
predicted and actual 
performance in a cognitive 
and motor task 
b.WRAT3, WAIS-R  
Patients with brain injuries 
overestimated their level of 
functioning in comparison to 
orthopaedic patients and staff ratings. 
In the predicted performance tasks a 
similar pattern could be observed. 
However, agreement between both 
awareness measures (PRCS and 
predicted performance) was only low, 
indicating that they might measure 
different aspects or levels of self-
awareness. 
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Ownsworth & 
Fleming (2005) 
a. To examine the association between 
metacognitive skills and measures of 
executive function and emotional 
status following acquired brain injury. 
b. Metacognition: an aspect of 
executive functioning that is important 
for adaptive functioning as it assists 
with the transfer and generalization of 
skills. 
 
a. n=67 ABI (n=16 
CVA) 
b. Mean age: TBI = 
34.0, other ABI = 44.0 
(45 males, 22 females) 
c. Mean time since 
injury: 4.4 years 
 
a. SADI, SRSI 
b. Standardized 
measures of 
executive function 
Higher levels of metacognitive skills 
were associated with greater 
emotional adjustment and better 
performance on measures of executive 
functioning. Individuals with a low 
level of intellectual awareness were 
found to have reduced independence 
while those with greater deficits in 
error self-regulation experienced less 
favorable occupational outcomes. 
 
Wise et al. 
(2005) 
a. To examine the convergent validity 
of three measures of self-awareness 
and their correlation with employment 
status in adults with acquired brain 
injury. 
b. Impaired self-awareness ranges 
from a complete lack of recognition 
that any injury has occurred to 
reduced awareness of selective areas 
of impairment. 
 
a. n=38 (n=11 CVA) 
b. Mean age: 38.3 
years, (27 male, 11 
female) 
c. Mean time since 
injury: 4.3 years  
a. SADI, SRSI, AQ 
 
Significant correlations were found 
between the SADI total score and the 
AQ discrepancy score and between the 
total SADI score and the SRSI indices. 
The work status rating scale was 
significantly correlated with the SADI 
and the SRSI but not the AQ. 
Bach & David 
(2006)  
a. To explore the correlates of 
behavioural disturbance in acquired 
brain injury: cognitive, theory of mind 
and self-awareness. 
b. Self-awareness: a process by which 
an individual is able to rate their 
behavioural responses (physical, 
somatic, cognitive and affective) in 
accordance with the ratings of some 
objective standard usually from an 
informant who knows the individual 
well. 
 
a. n=40 (n=7 CVA) 
b. Mean age: 37.6 
years (sex ratio not 
specified) 
c. Time since injury 
not specified 
a. Modified PCRS 
b. Neurobehavioral Rating 
Scale, general cognitive 
function (intellect, memory, 
attention)  
Lack of social self-awareness predicts 
behavioural disturbance in acquired 
and traumatic brain injury 
independent of cognitive and 
executive function.  
Current neuropsychological measures 
may be insensitive tools for the 
assessment of self-awareness. 
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Hoffmann & 
Schmitt (2006) 
a. To validate an assessment of a 
frontal network syndrome score 
b. Metacognition, Frontal network 
syndromes: no definition 
a. n=80 (CVA) 
b. Mean age: 45.7 
years (53% females) 
c. Within four weeks 
of stroke 
 
a. FNSS 
b. Neuropsychological 
testing: Executive function 
(WCST, TMT, TOL), FRSBE 
The FNSS is a valid, practical measure 
of frontal syndromes in stroke.  
Ownsworth et 
al. (2006) 
a. To investigate self-awareness and 
emotional well-being according to 
change in employment outcome in 
people with acquired brain injury. 
b. Metacognitive skills: self-awareness, 
self-monitoring 
a. n=50 (n=13 CVA) 
b. Mean age: 38.4 
years (male 68%) 
c. 4.3 years 
a. SADI, SRSI 
 
Improved employment status was 
associated with an increased 
intellectual self-awareness, whereas 
there was no significant improvement 
in emotional well-being and self-
monitoring.  
Schönberger et 
al. (2006) 
a. To investigate the relationship 
ďetǁeeŶ patieŶts͛ ĐoŵpliaŶĐe aŶd 
awareness and outcome of brain injury 
rehabilitation. 
b. Awareness was defined as impaired 
awareness of difficulties and impaired 
awareness of the implications of these 
diffiĐulties foƌ the patieŶts͛ liǀes. 
a. n=98 (n=58 CVA) 
b. Mean age: 43.5 
years (58% male) 
c.55% of the patients 
entered the 
programme within 
one year of injury and 
90% within two and a 
half years. 
a. Two staff members (a 
neuropsychologist and a 
physiotherapist) 
retrospectively and 
sepaƌatelǇ ƌated patieŶts͛ 
awareness and their 
compliance, discrepancy 
score between patient and 
relative ratings on the EBIQ 
b. D2 test of concentration 
There is a positive relationship 
between compliance and both 
therapist-rated awareness and 
awareness measures and the 
disĐƌepaŶĐǇ ďetǁeeŶ patieŶts͛ aŶd 
ƌelatiǀes͛ ƌatiŶgs. Although the fiŶdiŶg 
was significant for the EBIQ core scale 
only, the predicted trend was found in 
all three EBIQ scales (somatic, 
cognitive and core scales). 
Lundqvist et al. 
(2007) 
a. To study whether metacognition is a 
prerequisite for coping at the tactical 
level of driving. 
b. Metacognition includes conscious 
kŶoǁledge aďout oŶe͛s oǁŶ ĐogŶitiǀe 
capacity and self-regulation, it controls 
the use of cognitive functions and is 
the link between cognitive functioning 
and activity performance.  Awareness 
is seen as a dynamic interaction 
between knowledge, beliefs, task and 
contextual demands. 
a. n=30 (n=14 CVA) 
b. Mean age: 51.6 
(70% male) 
c. Time since injury: 21 
months 
a. Self-rating of on-the-road 
driving performance against 
a Đeƌtified dƌiǀiŶg iŶspeĐtoƌ͛s 
evaluation  
b. Complex reaction time 
tests, K test, Simultaneous 
Capacity test, Listening span 
test, TMT 
All subjects reported similar cognitive 
dysfunctions and had had cognitive 
impairments assessed by the 
neuropsychological test battery. The 
patients who passed their driving test 
did not differ from patients who failed 
the driving test in terms of cognitive 
functions. The patients who failed the 
driving test over-estimated their 
performances as compared to the 
dƌiǀiŶg iŶstƌuĐtoƌ͛s assessŵeŶt. The 
group that passed the test made more 
accurate self-ratings. 
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Duits et al. 
(2008)  
a. To evaluate the diagnostic 
contribution of subjective information 
obtained by a standardised checklist, 
to the identification of patients with 
cognitive impairment in the early 
phase after stroke 
b. No definition 
  
a. n=61 CVA 
b. Mean age 54 (28 
males, 33 females) 
c. CLCE-24: within 2 
weeks after discharge, 
neuropsychological 
examination post-
stroke mean time: 5 
weeks  
a. CLCE-24 
b. Abstract reasoning 
(RCPM), memory (RBM), 
executive functioning 
(Category Fluency from 
Groninger Intelligence Test, 
TMT, TOL) 
Cognitive complaints hindering daily 
life are frequently reported in the early 
weeks after stroke but are no 
indication for impaired cognitive 
performance.  
Aben et al. 
(2009) 
a. To explore the predictive value of 
Memory Self-Efficacy on two kinds of 
memory tests in stroke patients 
b. Metamemory is broadly conceived 
as cognitions about memory. It entails 
four dimensions – knowledge about 
memory function, memory monitoring, 
memory-related affect and memory 
self-efficacy.  
a. n=57 CVA 
b. Mean age: 55.0 (36 
male, 21 female) 
c. Mean time post-
stroke: 46.98 days 
a. MIA 
b. RBMT, AVLT 
MSE significantly predicts memory test 
performance both the AVLT and 
RBMT. When adjusted for age, gender, 
education and location of stroke the 
predictive value of the MSE remained 
significant for the AVLT. 
Aben et al. 
(2011) 
a. To examine whether memory 
capacity and MSE can predict the 
presence of memory complaints in 
stroke patients; to study which 
variables are the best predictors of 
MSE. 
b. MSE refers to the feeling of control 
aŶd ŵasteƌǇ of oŶe͛s ŵeŵoƌǇ 
functioning and does not focus only on 
complaints, but also on certain beliefs 
about capacity, changeability of 
memory functioning and anxiety about 
performing memory tests or being in 
memory –demanding situations. 
a. n=136 CVA 
b. Mean age: 58.8 
years (70 male, 66 
female) 
c. Mean time after 
onset: 51.3 months 
a. MIA 
b. BADS, RBMT, AVLT, BNT, 
TMT, Word Fluency test, 
Token test 
 
Memory complaints in patients in the 
chronic phase after stroke are 
determined by MSE rather than 
memory capacity.  
36 
 
Griffen et al. 
(2011) 
a. To examine the relationship 
between neuropsychological and on-
road driving evaluations among adults 
with ABI and the extent to which the 
relationship is moderated by 
awareness of deficit.  
b. Self-awareness of deficits, 
anosognosia: inability to recognize the 
presence of or adequately appreciate 
the severity of deficits in sensory, 
perceptual, motor, affective, or 
cognitive functioning evident to 
clinicians or caregivers. 
Operationalized as the difference 
ďetǁeeŶ a peƌsoŶs͛ self-assessment 
and an external criterion of the 
peƌsoŶ͛s aďilitǇ.  
a. n=62 (n=31 CVA) 
b. Mean age: 49.5 
years (19 women, 43 
men) 
c. Mean time since 
injury: 30.3 months 
a. Barriers of Driving 
Questionnaire and Driving 
Survey, Awareness of deficit 
was assessed using AQ 
Difference score 
b. On-road driving 
evaluation, 
Neuropsychological 
functioning 
Awareness of deficit has a 
considerable influence on driving 
outcomes both directly and as a 
moderator between the relationship of 
neuropsychological functioning and 
driving performance.  
McKay et al. 
(2011) 
a. To examine self-awareness of driving 
simulator and neuropsychological 
performance among stroke patients 
and to compare them with healthy 
controls. 
b. Self-awareness, metacognition: 
kŶoǁiŶg aďout oŶe͛s oǁŶ ĐogŶitioŶs. 
a. n=30 CVA, n=30 
controls 
b. Mean age: 54.3 
(case group), 48.5 
(control group),  45% 
male (both groups) 
c. Mean time since 
injury: 46 months. 
(Have driven within 3 
months prior to stroke 
or within 3 months 
prior to assessment 
for controls). 
a. Pre-test and post-test 
predicted performance self-
ratings  (metric scale from 0-
100) based on the Advanced 
Mobile Operation System 
interactive simulator and 
neuropsychological battery 
b. TMT, Symbol Digit 
Modalities Test, Controlled 
Oral Word Association Test, 
Judgment subset of 
Neuropsycholgical 
Assessment Battery 
The use of standardized metacognitive 
discrepancy scores can provide valid 
measures of self-awareness and ability 
to benefit from feedback in 
neurologically impaired individuals. 
Self-awareness remains a critical 
moderating variable between 
neurocognitive impairments and 
functional outcome in the community. 
Gu et al. 
(2013) 
a. To create a profile of subjective 
cognitive complaints in mild cognitive 
impairment and vascular mild cognitive 
impairment. 
b. Subjective cognitive complaints – no 
definition 
a. n=40 (n=20 VaMCI, 
n=20 MCI) (stroke 
cases not specified) 
b. Mean age: 66 years 
– not specified 
c. Not specified 
a. NIS 
b. MMSE, BNA 
MCI and VaMCI patients achieved 
similar scores on measures of 
objective cognitive function. However, 
the VaMCI group had more subjective 
complaints than the MCI group, 
particularly in critical items (cognitive 
efficiency, memory, verbal learning). 
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ABI, acquired brain injury; ABNAS, A-B Neuropsychological Assessment Schedule; AQ, Awareness Questionnaire; AVLT, Rey Auditory Verbal Learning Test; BADS, Behavioural 
Assessment of the Dysexecutive Syndrome; BDS, Behavioural Dyscontrol Scale; BNA, Behavioural Neurology Assessment; BNIS, Barrow Neurological Institute Screen for Higher 
Cerebral Functions; BNT, Boston Naming Test; CLCE-24, Checklist for Cognitive and Emotional Consequences following Stroke; CFQ, Cognitive Failures Questionnaire; CVA, 
cerebrovascular accident; EBIQ. European Brain Injury Questionnaire; FNSS, Frontal Network Syndrome Score; FRSBE, Frontal Systems Behavioural Scale; IQ, intelligence 
quotient; MCI, mild cognitive impairment; MIA, Metamemory in Adulthood Questionnaire; MMSE, Mini-mental state exam; MSE, memory self-efficacy; NIS, Neuropsychological 
IŵpaĐt “Đale; PC‘“, PatieŶt CoŵpeteŶĐǇ ‘atiŶg “Đale; ‘APM, ‘aǀeŶ͛s AdǀaŶĐed Pƌogƌessiǀe MatƌiĐes; RAVLT, Rey Auditory Verbal Learning Test,  RBANS, Repeatable Battery for 
the Assessment of Neuropsychological Status; RBMT, Rivermead Behavioural MeŵoƌǇ Test; ‘CPM, ‘aǀeŶ͛s Colouƌ Pƌogƌessiǀe MatƌiĐes;  “ADI, “elf-awareness of Deficits 
Interview; SCT, Star Cancellation Test; SSS, Social Skills Scale; SRSI, Self-Regulation Skills Interview; TBI, traumatic brain injury; TMT, Trail Making Test; TOL, Tower of London Test; 
TTT, Tinker Toy Test; VaMCI, vascular mild cognitive impairment; WAIS-R, Wechsler Adult Intelligence Scale – Revised; WCST, Wisconsin Card Sorting Test; WRAT-3, Wide Range 
Achievement Test-3. 
 
Lamb et al. 
(2013)  
a. To investigate the impact of 
objective cognitive impairment, 
negative affect, and fatigue on 
cognitive complaint in a post-acute 
sample of patients with ischaemic 
stroke  
b. No definition  
a. n=25 CVA 
b. Mean age: 67 (16 
men, 9 women) 
b. Meant time of 
assessment: 6.64 
months post-stroke.  
a. ABNAS 
b. RBANS 
Cognitive complaints are reported by 
almost all patients after a stroke. 
Although 50% of participants had 
objective evidence of a cognitive 
impairment, neither objective 
cognitive impairment nor fatigue 
predicted cognitive complaint 
independently of a negative affect.  
Boosman et al. 
(2014) 
a. To determine whether patients with 
stroke with good functional outcome 
have intact awareness and over- or 
under-estimation of memory 
functioning. 
b. Impaired awareness: diminished 
insight of a specific deficit in sensory, 
perceptual, motor, behavioural or 
cognitive functioning. 
 
a. n= 54 CVA 
b. Median age: 55.0 
(64.8% male)  
c. Median time post-
stroke: 10 weeks 
a. BNIS 
b. Neuropsychological 
assessment: BNT, RAPM, 
RAVLT, TMT, SCT, Stroop 
Colour and Word Test. 
Impaired awareness of memory 
functioning can be observed in stroke 
patients with good functional 
outcome. Compared to good-
estimators, over-estimators had 
significantly lower scores for all 
cognitive domains. Under-estimators 
had significantly poorer affect 
compared to good-estimators.  
Maaijwee et 
al.  (2014) 
a. To investigate the prevalence of 
subjective cognitive failures in patients 
with stroke in young adulthood and 
their relation with objective cognitive 
impairment. 
b. Subjective cognitive failures, no 
definition 
a. n=437 (n=277 CVA) 
b. Mean age: 40.3 
(males: 198) 
c. Mean time since 
injury: 10.1 years 
a. CFQ 
b. MMSE, Working Memory, 
Immediate memory, Delayed 
Memory, Executive 
Functioning 
Subjective cognitive failures are highly 
prevalent in patients after a stroke at a 
young age, but these were not strongly 
related to objective cognitive 
impairment.  
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Table 3.2: Overview of longitudinal, interventional and single case studies (n=12) measuring metacognition or associated functions in stroke 
Study reference (year) a. Study aim 
b. Metacognition (or other 
term used) and 
definition 
Study Design 
a. Sample size 
b. Age and gender 
c. Time of assessment 
a. Metacognition 
measures 
b. Other cognition 
measures 
Findings 
Longitudinal Studies 
Ownsworth et al. (2007) a. To identify awareness 
typologies and compare 
iŶdiǀiduals͛ eŵotioŶal 
adjustment and psychosocial 
outcome over time. 
b. Awareness of deficits: the 
ability to recognize deficits, 
understand the functional 
implications of deficits and set 
realistic goals accordingly. 
a. n=86 (n=24 CVA) 
b. Mean age: 38.4 years 
(Other ABI: 53% male, TBI: 
75% male) 
c. Mean time since injury: 
3.9 years (T0= time of 
assessment T1= 12 month 
follow up). 
a. SADI, AQ 
b. Symptom Expectancy 
Checklist, Marlow-Crowne 
Social Desirability Scale, 
Sydney Psychosocial 
Reintegration Scale 
The study identifies 
awareness typologies 
following ABI that were 
characterized by awareness 
of deficits, symptom 
reporting, defensives and 
error regulation. Individuals 
with good self-awareness 
and high defensiveness 
demonstrated the most 
favorable emotional 
adjustment and psychosocial 
outcomes.  
Björkdahl et al. (2012) a. To compare the subjective 
experiences of social, cognitive 
and emotional problems of the 
patient and his/her next of kin 
and explore if this is related to 
cognitive testing. To explore how 
these ƌesults ƌefleĐt the patieŶt͛s 
awareness. 
b. Self-awareness: the ability to 
reflect upon thinking or action 
patterns 
a. n= 35 CVA 
b. Mean age: 51.3 years 
(71% male) 
c. Longitudinal study: 
measurements done at 
discharge, 3 weeks, 3 
months and 1 year after 
discharge. 
a. EBIQ discrepancy score 
(patient and next of kin), 
BNIS 
There were significant 
differences between patient 
and next of kin assessments 
on all occasions, apart from 
at discharge. The patients 
changed their perception of 
their problems towards an 
experience of fewer 
problems during the first 3 
weeks after discharge, and 
after that there were no 
significant changes. 
Correlations between the 
patieŶts͛ ƌatiŶgs oŶ the EBIQ 
and BNIS were only found at 
the 1-year follow up.  
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Interventional Studies 
Ownsworth et al. (2000) a. To evaluate changes in 
levels of self-awareness and 
self-regulation skills in people 
with ABI via a 16-week group 
support programme. 
b. Self-awareness regarding 
deficits in everyday life. 
a. n=21 (n=3 CVA) 
b. Mean age: 33.5 years (15 
male and 6 female) 
c. Mean time since injury: 
8.6 years 
a. SADI, SRSI  
 
 
At baseline, the group had 
a relatively high level of 
intellectual self-awareness 
regarding their deficits, a 
low to moderate level of 
self-regulation of skills and 
significant psychosocial 
impairment. A post-
intervention assessment 
indicated that participants 
had significantly improved 
levels of self-regulation 
skills and psychosocial 
functioning. 
Ownsworth et al. (2004) a. To examine the degree to 
which patients with 
awareness deficits related to 
neuropsychological factors 
are responsive to 
rehabilitation compared to 
patients with awareness 
deficits related to 
psychological factors. 
b. Self-awareness. Self-
awareness has been 
consistently identified as a 
major influence of successful 
rehabilitation whereby 
patients with deficits in 
awareness may be resistant 
or indifferent towards 
treatment. 
a. n=28 (n=5 CVA) 
b. Mean age: 36.0 years, 19 
male and 9 female 
c. Mean time since injury: 
7.4 years 
a. SRSI, Heal and Safety Subset of 
the Independent Living Scales (was 
selected to measure violition) 
b.  TTT (purposive behaviour), 
Personality-related denial 
(Marlow-Crowne Social Desirablity 
Scale), Coping-related denial 
(Symptom Expectancy Checklist)  
 
Individuals with deficits in 
executive functioning were 
able to benefit from a 
group programme 
designed to enhance 
awareness, strategy 
behaviour and 
psychosocial functioning. 
Noé et al. (2005)  a. To investigate the factors 
contributing to deficit in self-
awareness following acquired 
brain injury and to study 
change in self-awareness 
a. n=62 (n=7 CVA) 
b. Mean age: 35.4 years, (44 
male, 18 female) 
c. Mean time since injury: 
295 days 
a. PCRS 
b. MMSE, Neuropsychological 
battery (WAIS-III, WCST, BNT, 
TAVEC, Colour TMT, Corsi Block 
Test). 
Patients with appropriate 
perception of their deficits 
showed less 
psychopathological 
symptoms, better 
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during a group support 
programme. 
b. Self-awareness: the ability 
to recognize the problems 
caused by impaired brain 
function, when impairment 
has been related to reduced 
motivation for rehabilitation, 
leading to difficulties in 
community integration and 
vocational re-entry. 
neuropsychological 
function and higher 
functional independence 
than those with impaired 
self-awareness. The level 
of self-awareness after 
acquired brain injury is a 
useful prognostic index of 
the neuropsychological, 
psychopathological and 
functional status of the 
patient.  
Roberts et. al (2006) a. To investigate the utility of 
feedback brain-imaging 
findings as an intervention for 
improving impaired 
awareness and mood. 
b. Impaired awareness: 
inability to appreciate deficits 
and comprehend the effects 
of these impairments on daily 
functioning. 
a. n=30 (n=9 CVA) 
b. Mean age: 43.5 years 
(53.3% male) 
c. Mean time since injury: 
41.97 months 
a. AQ, SADI 
b. WCST, WASI, WMS-III, Tower 
Test, Verbal Fluency Test.  
 
Individuals with an 
acquired brain injury may 
benefit (a decrease in 
impaired awareness) from 
a feedback procedure 
where the findings of brain 
scans are presented. 
Ownsworth et al. (2008) a. To ideŶtifǇ a paƌtiĐipaŶt͛s 
perspective of his experiences 
throughout an intervention 
designed to improve self-
awareness and self-
regulation. 
b. Metacogniton, self-
awareness. Metacognitive 
skills include the capacity to 
(a) accurately appraise 
ĐhaŶges to self aŶd oŶe͛s 
abilities, (b) understand the 
functional impact of these 
changes (c) set realistic goals, 
(d) recognize problems as 
they occur in day-to-day 
a. n=1 CVA 
b. 38 years, male 
c. 5 years post-injury  
a. SADI  
b. Comprehensive 
neuropsychological assessment 
including executive function 
Awareness intervention 
promoted greater 
understanding of 
benchmarks and the value 
of feedback and enabled 
learning through practical 
experience. The 
importance of tailoring 
rehabilitation according to 
the iŶdiǀidual͛s 
backgrounds and personal 
goals was also recognized.  
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situations and (e) anticipate 
the difficulties related to 
particular deficits will be 
experienced in the future. 
Lundqvist et al. (2010) a. To evaluate the effects of a 
group therapy programme for 
anticipatory self-awareness 
and coping strategies. 
b. Self-awareness and self-
regulation: the ability to 
compare and control the 
outĐoŵe of oŶe͛s oǁŶ 
cognitive functioning with an 
intended result. 
Metacognitive functioning: 
self-awareness of 
impairments and using 
compensatory strategies.  
a. n=21 (n=5 CVA) 
b. Mean age: 44.8 (43% 
males) 
c. Months since injury 
onset: 53 months 
a. SRSI, Self-report questionnaire A structured group 
therapy programme helps 
patients with acquired 
brain injury understand 
the consequences of their 
neuropsychological 
deficits, helps them 
improve awareness of 
their impairments and 
helps them develop coping 
strategies.  
Ownsworth (2010) a. To describe the 
implementation of a 
metacognitive contextual 
approach for facilitating 
return to work for individuals 
with acquired brain injury 
(ABI) 
b. Metacognition is an aspect 
of executive function which 
refers to self-awareness of 
post-injury changes, and the 
capacity to self-monitor and 
self-regulate behaviour during 
task performance 
a. n=3 ABI (n=1 CVA) 
b. mean age: 42 (2 male, 1 
female) 
c. 4.8 years post-injury 
 
a. SADI 
b. Measures not specified; 
Cognitive domains assessed 
(General intellectual disability, 
visual perception, verbal skills, 
processing speed, basic attention, 
higher-order attention, motor 
speed, memory, executive 
function) 
 
The study provided 
preliminary support 
regarding the efficacy of a 
metacognitive contextual 
approach in vocational 
rehabilitation following 
ABI. 
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Skidmore et al. (2011) a. To examine the feasibility 
of administering a form of 
metacognitive strategy 
training, Cognitive 
Orientation to Occupational 
Performance, during inpatient 
rehabilitation. 
b. Metacognitive strategy 
training is an approach that 
can be used to increase 
awareness of impaired skills 
or processes (through self-
assessment and self-
monitoring). 
a. n=1 (embolic stroke) 
b. 31 year old male 
c. 7 days post-stroke 
a. CO-OP 
b. RBANS, selected subsets of the 
Delis-Kaplan Executive Functioning 
System  
Meta-cognitive strategy 
training was feasible 
during inpatient 
rehabilitation and 
warrants further 
evaluation to determine its 
effectiveness. 
Lloréns et al. (2012) a. To examine the therapeutic 
effectiveness of a virtual 
reality game in self-awareness 
after acquired brain injury. 
b. Self-awareness: the 
knowledge ABI patients have 
about their own impairments 
and their implied limitations. 
a. n=10 (stroke cases not 
specified) 
b. Mean age: 41.1 years (7 
males, 3 females) 
c. Mean time since injury: 
402 days 
a. SADI 
b. SSS 
According to the scores in 
the SADI and SSS tests, the 
system has provided 
successful results in the 
rehabilitation of self-
awareness and social 
cognition. New studies 
must be carried to 
compare it to other 
rehabilitation 
programmes. 
Single Case Studies 
Palermo et al. (2013) a. To present a patient with a 
selective right anterior 
cingulate ischemic injury and 
impaired awareness of 
deficits. 
b. Awareness of illness: the 
ability to perceive, recognize, 
and evaluate a specific deficit 
in sensory, perceptual, motor, 
a. n=1 CVA 
b. 76 year old male 
c. Post-acute phase (T0 – 15 
days after injury) and 
Stabilization phase (T1 – 15 
months post-injury) 
a. SRSI, Awareness Questionnaire 
for Dementia  
b. Premorbid intellectual 
efficiency, Global cognitive 
functions, Dysexecutive syndrome, 
Perceptive taking abilities, MMSE, 
MoCA (at T0 and T1) 
Cingulo-frontal area 
dysfunction may represent 
one of the corresponding 
neurobiological substrates 
of persistent unawareness. 
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ABI, acquired brain injury; AQ, Awareness Questionnaire; BNIS, Barrow Neurological Institute Screen for Higher Cerebral Functions; BNT, Boston Naming Test; CO-OP, 
Cognitive Orientation to daily Occupational Performance; CVA, cerebrovascular accident; EBIQ. European Brain Injury Questionnaire; MMSE, Mini-mental state exam; 
PCRS, Patient Competency Rating Scale; RBANS, Repeatable Battery for the Assessment of Neuropsychological Status; SADI, Self-awareness of Deficits Interview; SRSI, Self-
Regulation Skills Interview; SSS, Social Skills Scale; TAVEC, Complutense Verbal Learning Test; TBI, traumatic brain injury; TMT, Trail Making Test; TTT, Tinker Toy Test; WAIS-III, 
Weschler Adult intelligence scale-III; WASI, Wechsler Abbreviated Scale of Intelligence; WCST, Wisconsin Card Sorting Test; WMS-III, Wechsler Memory Scale  
 
  
affective, or cognitive 
functioning and also to 
consider the impact of these 
disturbances on basic and 
instrumental daily life 
activities. (A complex 
construct encompassing the 
ability to recognize deficits, 
understand the related 
functional implications and 
set realistic goals 
accordingly.) (Self-awareness 
refers to a broad range of 
metacognitive skills, from the 
ability to recognize deficits 
and understand the cognitive 
and functional implications 
deriving from them to setting 
realistic goals and anticipating 
possible future difficulties 
related to illness.) 
Conceptual Basis and Definition of Metacognition 
Only seven studies (167, 173, 175, 183-186) adheƌed to the oƌigiŶal defiŶitioŶ ͞ ŵetaĐogŶitioŶ͟ iŶ liŶe ǁith 
generic and historical literature of the term.  The majority of the studies defined only a single dimension 
of the concept. Self-awareness was the predominant term used and component examined in the studies. 
Tǁo studies used aŶ opeƌatioŶal defiŶitioŶ of ŵetaĐogŶitioŶ ;e.g. disĐƌepaŶĐǇ ďetǁeeŶ a peƌsoŶ͛s self-
assessŵeŶt aŶd aŶ eǆteƌŶal ĐƌiteƌioŶ of the peƌsoŶ͛s aďilitǇͿ.(168, 178)  Seven studies did not define the 
term.(77, 164-166, 172, 174, 177) Sixteen studies made reference to a theoretical framework or model to 
describe a component of metacognition.(126, 127, 153, 154, 162, 163, 167, 170, 176-178, 180, 181, 183, 
184, 188) The ŵaiŶ theoƌetiĐal fƌaŵeǁoƌk disĐussed ǁas CƌossoŶ et al.͛s thƌee leǀel ŵodel of self-
awareness. The model has three hierarchical levels of awareness. The first level, intellectual awareness, 
ƌefeƌs to aŶ iŶdiǀidual͛s aďilitǇ to ƌeĐogŶize that a paƌtiĐular function or skill is impaired compared to 
premorbid levels and to acknowledge the implications that these deficits may have on activities of daily 
liǀiŶg. The seĐoŶd leǀel, eŵeƌgeŶt aǁaƌeŶess, ƌefeƌs to aŶ iŶdiǀidual͛s aďilitǇ to ƌeĐogŶize a pƌoďleŵ as it 
oĐĐuƌs duƌiŶg aŶ aĐtiǀitǇ. The thiƌd leǀel, aŶtiĐipatoƌǇ aǁaƌeŶess, ƌefeƌs to aŶ iŶdiǀidual͛s aďilitǇ to 
anticipate a particular problem that could arise during a particular task.(163, 189) 
None of the studies referred to the preliminary models of metacognition. These models include Nelson 
aŶd NaƌeŶs͛(149) model of metacognitioŶ aŶd AdƌiaŶ Wells͛ ŵulti-process Self-Regulatory Executive 
Function (S-REF) model.(190, 191) Nelson and Narens͛ model of metacognition splits cognitive processes 
into two inter-related levels, the ͚meta-level͛ and the ͚object-level͛, in which the flow of information 
between these two inter-related levels is dominated by cognitive monitoring and cognitive control.(106, 
149) The S-REF model identifies a common set of processes and structures, models cognition within an 
explicit cognitive architecture and emphasizes a top-down or strategic influence on processing while 
incorporating an emphasis on metacognitive beliefs in underpinning the coping styles leading to 
psychological distress.(190) 
Assessment of Metacognition  
Eighteen different assessment measures were identified in the studies reviewed. The most common 
assessment tools utilized were the Self-awareness of Deficits Interview (192),(192, 193) the Self-
regulation Skills Interview (SRSI),(173) the Patient Competency Rating Scale (PCRS)(194) and the 
Awareness Questionnaire (AQ).(195) The PCRS and the AQ use a discrepancy based method, comparing 
the patieŶt͛s self-rating of function with that of an iŶfoƌŵaŶt oƌ allied health pƌofessioŶal͛s ƌatiŶg. The 
SADI is a structured interviewer-scored approach that measures intellectual awareness after acquired 
45 
 
brain injury.(177) The SRSI is a semi-structured interview that assesses self-regulation skills by focusing on 
a main area of difficulty experienced by the patient in an activity of daily living.(177) In most studies 
assessing metacognition with the SADI and SRSI, these measures were both included.  
Even though a modest number of studies examined a component of metacognition, a limited number 
adhered to the original definition of the term and studied the concept fully including all its components 
(self-awareness, self-regulation and self-monitoring). The first arm of the metacognitive concept, self-
awareness, was given the most attention, whereas the self-regulatory and self-monitoring arms were 
mostly overlooked.  
Few studies examined stroke populations exclusively and there was a broad variation of domains assessed 
in relation to metacognitive deficits (e.g. memory, cognitive impairments, driving and employment). All 
of these elements, alongside the large variability in sample sizes and timing of assessments, makes 
comparison between the studies complex and reduces the possibility of reporting a definitive outcome 
that can be spanned across the majority of studies and generalized to the concept as a whole. 
This literature review outlined some of the key conceptual difficulties that exist in the literature in relation 
to metacognitive function. These difficulties include a lack of consistent definitions and a deficiency in the 
use of an appropriate metacognitive theoretical framework as a basis for clinical research. The use of 
teƌŵs ͚͛self-aǁaƌeŶess͛͛ aŶd ͚͚ŵetaĐogŶitioŶ͛͛ iŶteƌĐhaŶgeaďlǇ adds aŶ additioŶal laĐk of ĐlaƌitǇ of the 
broader sense of the concept. The wide array of assessment tools was in keeping with the scope of 
different dimensions that can be examined in relation to metacognitive impairments. The heterogeneity 
of the measures creates challenges as it is difficult to compare tools examining a specific function with 
others that attempt to assess function more globally. Regardless of the specificity or generality of the 
measures, most measures, with the exception of the SRSI, only examined self-awareness and not self-
regulation. 
The majority of assessment tools (153, 154, 162, 167, 168, 171, 172, 176, 178, 179, 182, 188) applied 
disĐƌepaŶĐǇ sĐoƌes, a ĐoŵpaƌisoŶ ďetǁeeŶ the patieŶt͛s self-rating and that of a proxy rater (e.g. 
caregiver, significant other or health professional), based on the operational definition of self-awareness 
deficits. A possible drawback of this method could be rater bias or the inaccuracy of the family member 
oƌ ĐliŶiĐiaŶ to estiŵate the iŶdiǀidual͛s tƌue aďilities.(154, 178, 196) This may be due to various reasons, 
foƌ eǆaŵple the ĐliŶiĐiaŶ͛s uŶfaŵiliaƌitǇ ǁith the iŶdiǀidual pƌioƌ to the iŶjuƌǇ oƌ the Đaƌegiǀeƌ͛s oǁŶ leǀel 
of anxiety and depression influencing their assessment of the patient.(154, 196) Other studies used semi-
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stƌuĐtuƌed iŶteƌǀieǁs oƌ Đoŵpaƌed the patieŶt͛s self-ratings with specific functional tasks such as driving. 
This approach would minimize the subjectivity in caregiver or clinician scores but could also limit the 
number of functions of metacognition that could be assessed.(154) Some studies emphasized the 
importance of using a combination of approaches to tackle metacognitive function.(154, 178, 184). 
Although there are strengths and limitations to all types of assessment, the need to consolidate existing 
measures by combining subjective and global objective assessment is evident.  
Most of the studies examined individuals with chronic stroke and injury and only one study examined 
metacognitive impairment in the acute phase of recovery.(186) Though there may be barriers with 
evaluating patients in this critical phase, providing metacognitive assessment, detecting impairments and 
providing strategy training may be optimal in the acute phase given the evidence that supports early 
rehabilitation intervention.(186, 197)  Feǁ ĐoŵŵeŶts ǁeƌe ŵade ƌegaƌdiŶg the ŵeasuƌeŵeŶts͛ ĐliŶiĐal 
utility (ease of use, time required for assessment, training required by test administrator, ease of 
interpretation of results)(198) and this is an imperative element to consider in the clinical setting. 
Concerns also exist regarding validity of these assessment tools in the specific context of stroke as they 
were mainly utilized in traumatic brain injury.  
The concern with assessing metacognition is that is it both a complex and broad concept.(199, 200) This 
is primarily  due to the ͞doŵaiŶ geŶeƌalitǇ͟ of ŵetaĐogŶitiǀe pƌoĐesses (199) and its pervasiveness in all 
tasks ranging from the cognitive, involving learning or memory, to driving, motor functional limitations, 
employment status or any activity of daily living requiring higher-order thought. It is also important to 
consider coping patterns, premorbid personality traits and baseline level of function as, in line with 
cognition, they largely interplay with metacognitive function and influence rehabilitation outcome.(92, 
178)  
In summary, there has been no consensus on the definition or of the use of a standard theoretical 
framework for metacognition. Assessment of metacognition has tended to focus more on specific 
components of the concept such as self-awareness masking the self-regulatory component. Studies have 
focused on traumatic and other acquired brain injury in comparison to stroke studies exclusively. Despite 
evidence in support of early rehabilitation intervention, the majority of the studies that have examined 
metacognition in stroke did not assess patients in the acute phase. No tool emerged that was able to 
consolidate subjective and global objective assessment and thereby measure the full breadth of 
metacognitive function. 
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 3.2 Metacognition in Stroke Rehabilitation 
Metacognitive deficits may cause stroke survivors to overestimate their level of function and 
underestimate stroke impact.(201) Few studies have explored the relationship between metacognition 
and stroke location, type and severity or its clinical application in stroke care and rehabilitation.(201-203) 
A major component of metacognition, self-awareness, is what has received the most attention in the 
neuropsychological literature.(204) There have been some reviews on self-awareness and its clinical 
application in brain injury rehabilitation (202, 205, 206) but there is a scarcity in the literature examining 
the concept in relation to stroke. In a review examining the association between awareness deficits and 
rehabilitation outcome after acquired brain injury, the reviewers reported an association between greater 
awareness of deficits and more favourable rehabilitation outcomes.(206) Only one review (202) examined 
the clinical application of self-awareness in stroke rehabilitation exclusively.  This review indicated that 
there is no consensus as to which tool is the most useful for assessing self-awareness, resulting in 
researchers adopting different treatment approaches to address self-awareness. However, these reviews 
do not encompass the full composition of metacognition, as they only address self-awareness and 
overlook the second major constituent which is the utilization of self-regulatory and compensatory 
strategies including cognitive monitoring and cognitive control. 
Stroke survivors may be particularly susceptible to metacognitive deficits as neurospsychological 
disorders such as magnitude estimation deficit,(207) anosognosia or anosodiaphoria, spatial neglect, and 
problems with emotional semantics and abstraction in stroke are common.(201) These deficits are 
associated with poor stroke outcome.(208) Assessments evaluating cognitive impairment as an objective 
primary measure might fail to detect and incorporate the impact of these deficits on the rehabilitative 
process. Initial studies suggest that treatments focused on improving metacognitive processes in acquired 
brain injury could lead to better functional outcomes.(209)  
Even though there has been some recent attention given to metacognition in stroke, there remains a 
scarcity of quantitative research on the subject as stroke rehabilitation continues to focus mainly on 
physical disability and cognitive impairment. The studies that examined how metacognition impacts 
rehabilitation and post-stroke outcome reported that higher levels of metacognitive skills correlated with 
greater adjustment and better task performance.(163, 167, 175, 176, 182) Interventional studies showed 
that participants had significantly improved levels of self-regulation skills and psychosocial functioning at 
post-intervention assessment.(180, 181, 185) This indicates that metacognition is a critical variable that 
links cognitive impairments and functional outcome. 
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Decreased self-awareness and the inability to monitor and regulate cognitive processes impede functional 
recovery and therefore, in accordance with this premise, they should be the primary assessments 
undertaken in cognitive rehabilitation in stroke. Therefore, metacognition is a key area that needs to be 
addressed at the onset of any rehabilitation intervention. 
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Section Four: Thesis Rationale 
 4.1 Study Aims and Thesis Rationale 
The overall study aim is to explore the relationships between global cognition, executive function and 
metacognition in a stroke population and to determine the relationship between cognitive impairment 
and stroke in a Bahraini stroke sample in comparison to an age- and sex- matched control group. Much of 
the focus on metacognition has been in relation to learning and educational theory and practice.(151, 
152) However, the valuable outcomes of assessing metacognitive impairments and incorporating 
metacognitive rehabilitation clinically has recently come to light.(153-155) This has mainly been reported 
in traumatic brain injuries (185, 210) and in neuropsychiatric conditions such as generalized anxiety 
disorder, panic disorder and depression and to a lesser extent in schizophrenia,(211) but few studies have 
examined the relationship between metacognition and its clinical application in stroke care and 
rehabilitation.(201, 202)  
Stroke survivors may be particularly susceptible to metacognitive deficits,(201) as conditions such as 
anosognosia are prevalent in this population group. These deficits are associated with poor stroke 
outcome, and even mild unawareness of impairments could lead to poor rehabilitation and recovery.(208) 
Preliminary studies seem to suggest that treatments focused on improving metacognitive processes could 
lead to better functional outcomes in stroke patients.(209)  The gap in the literature in delineating the 
interplay between metacognitive function and stroke specifically, the consequences of metacognitive 
impairment on stroke rehabilitation and the clinical utility of assessing metacognition with a goal towards 
better rehabilitation outcomes for stroke survivors is what formed the rationale for this study. However, 
because metacognition is a relatively novel concept, associations between it and executive function and 
global cognition in stroke is what formed the basis of this research. In addition, currently no data has been 
established on the relationship between ApoE and cognitive impairment in a Middle Eastern population. 
Therefore, examining a biological marker as a potential predictor of cognitive deficits in stroke was 
another study aim.  
Although there have been some epidemiological data on stroke in Bahrain, (16, 17) there have been no 
studies examining the main correlates and predictors for cognitive impairment in a post-stroke population 
in the country. To the best of our knowledge, there have been no reported studies examining the cognitive 
sequeale of stroke in an Arab population in general. Moreover, many of the neuropsychological 
assessment tools used to measure cognitive impairment have not been validated in the Arabic language. 
These additional factors formed further motive to pursue this study. 
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With an ageing population and a high incidence of many of the risk factors for stroke, a rise in stroke 
incidence in Bahrain is expected.(17) Therefore, the prevention of risk factors and optimal management 
of stroke should be a national health priority. Stroke management is complex, requiring intervention from 
multiple disciplines and at multiple stages post-insult. We thought it necessary to shed light on 
metacognitive deficits, an important yet often overlooked possible consequence of stroke that could 
potentially improve rehabilitative outcomes considerably if addressed in the early stages of intervention. 
4.2 Study Objectives 
The specific study objectives were as follows: 
- To describe the demographic profile, socio-demographic and clinical characteristics of a stroke 
population in Bahrain in comparison to an age- and gender-matched control group. 
- To describe the cognitive profile of a stroke population group in Bahrain in terms of global and 
executive function in comparison to an age- and gender matched control group. 
- To examine the relationship between stroke type, localization and severity with global cognitive 
function, executive function and metacognition in stroke patients. 
- To examine the association between executive function and global cognition in a stroke 
population in comparison to an age- and gender matched control group. 
- To examine the association between global cognitive function to metacognition in a stroke 
population in comparison to an age- and gender matched control group. 
- To examine the association between executive function and metacognition in a stroke population 
in comparison to an age- and gender matched control group. 
- To examine memory performance in a stroke population in comparison to an age- and gender 
matched control group. 
- To examine the association between objective recall as a function of memory to metamemory in 
the acute phase of stroke in comparison to an age- and gender matched control group. 
- To investigate the relationship between anxiety symptoms and global cognition, executive 
function and metacognition in a stroke population in comparison to an age- and gender matched 
control group. 
- To investigate the relationship between depressive symptoms global cognition, executive 
function and metacognition in stroke patients in comparison to an age- and gender matched 
control group. 
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- To examine the relationship between cognitive function and other associated factors including 
the biomarker ApoE in a stroke population in comparison to an age- and gender matched control 
group. 
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Chapter Two: Materials and Methods 
Section Five: Materials and Methods 
5.1 Introduction 
Appropriate methodological choice is imperative to addƌess aŶǇ ƌeseaƌĐh ƋuestioŶ aŶd fulfil a studǇ͛s aiŵs 
aŶd oďjeĐtiǀes ĐoheƌeŶtlǇ. MethodologǇ foƌŵs the ďasis of aŶǇ studǇ͛s fƌaŵeǁoƌk aŶd Ŷaǀigates ďoth the 
direction and findings of the research.(212) ChoosiŶg the ŵost suitaďle ŵethodologǇ to addƌess a studǇ͛s 
research aims ensures that the validity of the findings are maintained and that the information is 
reliable.(212) 
Research on cognitive disorders is particularly challenging and methodological issues in this field 
frequently arise.(213, 214) This is because cognition is a complex activity involving interconnected 
networks between cerebral and mental processes. Any research on cognition must take into account the 
multifarious nature of cognitive function and its own interplay within itself alongside the influence of non-
cognitive functions and external factors such as mood, motivation, and coping patterns.(92) Therefore, 
any researcher tackling cognition must methodologically consider these factors and the influence of 
variables related to the subjects assessed (e.g. age, education, pre-morbid function), the lesion examined 
(size, aetiology), the test tools employed and the various testing conditions.(213) 
The puƌpose of this Đhapteƌ is to pƌeseŶt the ŵethodologiĐal appƌoaĐh utilized iŶ oƌdeƌ fulfil this studǇ͛s 
aims and objectives. The chapter will outline the study design, subject recruitment, assessment tools used 
and the data collection procedure. The ApoE genotyping methods and statistical analysis will also be 
addressed.  
5.2 Study Design 
Quantitative research can be defined as explaining phenomena by collecting numerical data that are then 
analysed using statistically based methods.(215) In order to fulfil the study objectives, a quantitative 
approach was used. The study was a cross-sectional case-control study. Cross-sectional studies examine 
the relationship between variables of interest in a defined population group at a single point in time.(216) 
A cross-sectional design was used in this study as multiple variables of interest and several outcomes and 
relationships were to be examined. Data on stroke participants were compared with an age- and sex- 
related control group in order to address the study objects such as delineating risk factors for cognitive 
impairment and metacognitive deficits and potential predictive biomarkers in the case group.  
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5.3 Subjects 
5.3.1 Background 
The main hospital providing Secondary Health Care Services in the Kingdom of Bahrain is Salmaniya 
Medical Complex (SMC). This governmental hospital is a multi-specialty healthcare facility and is the 
primary centre for admitting stroke patients in the country. Primary health care services are provided via 
24 Local Health Centres (LHCs) distributed across Bahrain. With the exception of one health centre, all 
patients requiring secondary or inpatient care are referred to SMC.  
  5.3.2 Case group 
The target case population were patients admitted to Salmaniya Medical Complex, with a confirmed 
diagnosis of stroke (defined as rapidly developing clinical signs of focal or global disturbance of cerebral 
function, with symptoms lasting 24 hours or longer, with no apparent cause other than of vascular origin 
and in accordance with ICD-10 codes I61, I63 and I64). Between July 2014 and February 2015, all 
consecutive admissions to SMC with a confirmed diagnosis of stroke were tracked for eligibility to 
participate in the study. The case group was evaluated within one month of stroke onset. The case group 
will also be referred to as the stroke group or stroke patients from this point forward interchangeably.  
 Inclusion Criteria 
Subjects who met the following criteria were eligible for the study: 
- ш ϭϴ years of age and consent to participate.  
- Clinical diagŶosis of a fiƌst oƌ ƌeĐuƌƌeŶt isĐhaeŵiĐ oƌ haeŵoƌƌhagiĐ stƌoke ч oŶe ŵoŶth duƌatioŶ 
at the time of assessment. 
- Ability to participate in interview assessment with sufficient language (English or Arabic) and 
cognitive function.  
- Language function was assessed using the shortened version of the Frenchay Aphasia Screening 
Test (FAST) with a cut-off sĐoƌe of шϭϰ.  
Exclusion Criteria 
- A diagnosis of subarachnoid hemorrhages (ICD-10 code I60), subdural or extradural hematomas 
(ICD-10 code I62), transient ischemic attacks (ICD-10 code G45) or traumatic brain injury (ICD-10 
S06.2). 
- Too medically unstable to participate in the study.  
- Formal diagnosis of pre-stroke vascular dementia or pre-stroke cognitive impairment. 
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- Aphasia or, as deteƌŵiŶed ďǇ a sĐoƌe of чϭϯ/ϯ0 on the FAST. 
- Other severe communication difficulties that would hinder participation in assessments (e.g. 
visual or hearing impairment, insufficient understanding of English or Arabic). 
- Recent history of psychiatric conditions (e.g. suicide attempts, alcohol or drug misuse, diagnosed 
personality or mood disorders) 
- Otheƌ ŶeuƌodegeŶeƌatiǀe disease ;e.g. PaƌkiŶsoŶ͛s, deŵeŶtiaͿ 
  5.3.3 Control Group 
Appropriate selection of the control group subjects is crucial in any case-control study. The aim is to select 
individuals with as comparable a background distribution as that of the cases in the absence of  the disease 
or variables under investigation.(216) Ideally, the source of controls is dependent on the source of 
cases.(216) For the control group, age- and sex-matched volunteers were required. The accessible 
population of controls were individuals who attended the Local Health Centres. As the same subgroup of 
patients visiting the LHCs would attend SMC in a secondary care setting and all health centres are within 
Đlose pƌoǆiŵitǇ ;ч oŶe houƌͿ to “MC and to each other, it was deemed justifiable to recruit the control 
group from the LHCs. Between December 2014 and January 2015, samples from the non-stroke general 
populatioŶ atteŶdiŶg tǁo LHCs ;A͛ali Health CeŶtƌe aŶd NatioŶal BaŶk of BahƌaiŶ Health CeŶtre – Arad) 
were recruited to participate in the study. The Gulf Cooperation Council (GCC) countries have a high 
prevalence of non-communicable disease (217, 218). Therefore, it was deemed satisfactory to include 
some controls with a history of hypertension, hyperlipidemia and hyperglycemia, in order to include a 
valid control group for the region. 
Inclusion Criteria 
- Adults that are age and gender matched with the case group participants.  
- Ability to participate in interview assessment with sufficient language (English or Arabic) and 
cognitive function.  
Exclusion Criteria 
- Previous history of stroke 
- Recent history of psychiatric conditions (e.g. suicide attempts, alcohol or drug misuse, diagnosed 
personality or mood disorders) 
- Previous use of anti-psychotropic medication (e.g. anti-psychotics, mood stabilizers) 
- Formal diagnosis of cognitive impairment 
- Diagnosis of neurodegenerative disease (e.g. PaƌkiŶsoŶ͛s, deŵeŶtia)  
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- Communication difficulties that would hinder participation in the interview process and 
neuropsychological assessments (e.g. visual or hearing impairment). 
5.4 Assessment Tools 
5.4.1 Stroke Type 
The Oxfordshire Community Stroke Project classification was used to subdivide strokes based on lesion 
location into total anterior circulation syndrome (TACS), partial anterior circulation syndrome (PACS), 
lacunar syndrome (LACS) and posterior circulation syndrome (POCS).(219) The TOAST classification 
system was also used.(26) The TOAST classification subdivides stroke into 5 categories based on aetiology 
(large-artery atherosclerosis, small-artery occlusion (lacunar), cardio-embolism, stroke of other 
determined aetiology, and stroke of undetermined aetiology. Both classifications were based on clinical 
and radiological criteria.  
5.4.2 Stroke Severity  
Stroke severity was assessed using the National Institutes of Health Stroke Scale (NIHSS) as it is widely 
accepted as the definitive clinical assessment of stroke severity.(220) The 11-item scale evaluates severity 
through the assessment of a wide variety of functions including level of consciousness, visual fields, 
extremity strength, facial muscle function, sensory function, ataxia, aphasia, dysarthria and hemi-neglect. 
The NIHSS has both established reliability and validity for use in clinical trials and predictive value for long-
term outcome in stroke.(26, 221, 222) Both researchers involved in the recruitment of case participants 
were certified in the American Heart Association NIHSS assessment training. 
  5.4.3 Aphasia Screening 
The Frenchay Aphasia Screening Test is a tool that evaluates comprehension, verbal expression, reading, 
and writing.(223) It is the most widely used tool for aphasia screening among stroke patients presenting 
iŶ the aĐute phase aŶd ǁas theƌefoƌe utilized iŶ this studǇ. The test͛s ƌeliaďilitǇ aŶd ǀaliditǇ as a sĐƌeeŶiŶg 
tool has been well established for use in stroke populations.(69) 
  5.4.4 Global Cognitive Function and Executive Function 
The Mini-mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) are both 
routine cognitive assessment tools used to evaluate global cognitive impairment.(224)  Cut-off scores 
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were based on the  National Institute for Health and Care Excellence (225)  guidelines for the MMSE (226) 
and the suggested cut-off sĐoƌes ƌeĐoŵŵeŶded ďǇ the tool͛s deǀelopeƌs for the MoCA.(227)  
The Trail Making Test (TMT) measures executive function, mental flexibility and cognitive processing (228) 
and was used as an additional indicator of cognitive function in the study population. It was been widely 
used to assess executive dysfunction post-stroke.(229) The TMT is administered in two parts. In part A, 
participants are instructed to draw a continuous line joining the circled numbers 1-25 in an ascending 
pattern. In part B, the participants are instructed to draw continuous line in an ascending pattern from 
Ŷuŵďeƌ to letteƌ ;ϭ to A; A to Ϯ; Ϯ to BͿ. The diffeƌeŶĐe sĐoƌe ;ΔTMTͿ is theŶ ĐalĐulated ǁith ΔTMT < 70 
seĐoŶds ƌepƌeseŶtiŶg good eǆeĐutiǀe fuŶĐtioŶ, ΔTMT ϳϬ – 156 seconds representing intermediate 
eǆeĐutiǀe fuŶĐtioŶ aŶd ΔTMT > ϭϱϲ seĐoŶds ƌepƌeseŶtiŶg pooƌ eǆeĐutiǀe function.(230) Total scores of 
the MMSE and Moca measures were used in conjunction with the TMT and DSM-IV criteria to stratify 
cognitive function (Table 5.1). 
Table 5.1 Classification of cognitive impairment 
1. Stroke with no cognitive vascular impairment (NVCI): 
a.  MM“E sĐore ш Ϯϰ ;ǁith Ŷo eduĐatioŶ add Ϯ poiŶts, > 8Ϭ years of age add ϭ 
point) 
b.  MoCA sĐore ш Ϯ6 ;add Ϯ poiŶts if чϭϮ years eduĐatioŶͿ 
c. Trail making score: Trail A < 78 seconds, Trial B < 273 seconds  
2. Vascular cognitive impairment with no dementia (VCIND) 
a. Mild: 
i.  MMSE score 21-24 
ii. MoCA score 18-25 
iii.  Trail making score: Trial A > 78 seconds, Trial B > 273 seconds 
b. Moderate: 
i. MMSE score 10-20 
ii. MoCA score 10-17 
iii. Trail making score: Trail A >78 seconds, Trail B > 273 
3. Vascular dementia (VaD): classified according to the DSM-IV dementia criteria  
4. Mixed dementia: classified according to the DSM-IV dementia criteria 
DSM-IV, Diagnostic and Statistical Manual IV; MMSE, Mini-mental Status Examination; MoCA, Montreal 
Cognitive Assessment. 
Pre-morbid cognitive function was assessed using the Informant Questionnaire on Cognitive Decline in 
the Elderly (IQCODE) when possible. The IQCODE is a widely used screening test for dementia and 
cognitive decline (231) consisting of a 26-iteŵ ƋuestioŶŶaiƌe Đoŵpleted ďǇ the paƌtiĐipaŶt͛s faŵilǇ 
member or caregiver. 
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5.4.5 Memory Function 
Memory performance was assessed by examining performance on the recall subscale in the MMSE and 
the delayed recall subscale in the MoCA. These subscales were used rather than a comprehensive 
assessment of memory performance as they are the primary screening tools initially used by clinicians 
that prompt further assessment if required. In the MMSE recall subscale, participants are required to 
recall three unrelated objects that they were prompted to remember earlier, with one point given to each 
response. Subjects were classified as good performers in the MMSE if they were able to recall two or more 
objects and classified as poor performers if they were only able to recall one object or no object. In the 
MoCA delayed recall subscale, participants are required to recall five words that they were prompted to 
remember earlier, with one point given to each un-cued response. Subjects were classified as good 
performers in the MoCA if they were able to recall three or more words and classified as poor performers 
if they were able to recall zero to two words. 
5.4.6 Metacognitive Function 
As there is no standard assessment tool for metacognitive function, the Metacognitive Questionnaire 
(MCQ-30) was administered to participants as an assessment of metacognition. The MCQ-30 was used 
instead of other measures such as the SRSI and SADI as they only measure a specific arm of the 
metacognitive component and are chiefly used in the chronic phase of an acquired brain injury.(232) The 
MCQ-30 was also utilized as it is primarily based on the Self-Regulatory Executive Function model (S-REF), 
which is one of the original models developed for metacognition. 
The MCQ-30 is a 30-item questionnaire that assesses metacognitive beliefs, metacognitive monitoring, 
and judgements of cognitive confidence.(233) It is divided into five categories each consisting of six 
statements each. The five categories are 1) Cognitive Confidence 2) Positive Beliefs 3) Cognitive Self-
Consciousness 4) Uncontrollability and Danger and 5) Need to Control Thoughts. The Cognitive Confidence 
ĐategoƌǇ eǆaŵiŶes aŶ iŶdiǀidual͛s oǁŶ ĐoŶfideŶĐe leǀel iŶ theiƌ ŵeŵoƌǇ skills, the Positive Beliefs 
ĐategoƌǇ eǆaŵiŶes aŶ iŶdiǀidual͛s attitude toǁaƌds ǁoƌƌǇiŶg aŶd ǁhetheƌ theǇ peƌĐeiǀe ǁoƌƌǇiŶg 
positively or negatively, the Cognitive Self-ĐoŶsĐiousŶess ĐategoƌǇ eǆaŵiŶes aŶ iŶdiǀidual͛s aǁaƌeŶess of 
their thinking pattern and whether they examine and monitor their thoughts, the Uncontrollability and 
DaŶgeƌ ĐategoƌǇ eǆaŵiŶes ǁhetheƌ aŶ iŶdiǀidual͛s ǁoƌƌǇiŶg thoughts peƌsist aŶd the degƌee to ǁhiĐh 
worrying thoughts can impact their daily life and the Need to Control Thoughts category examines 
58 
 
whether an individual can control their thinking patterns and their attitude towards an inability to control 
certain thoughts (refer to Appendix 4, pages 175 and 176 for the assessment tool).  
The MCQ-30 has been used in patients with depression and anxiety disorders,(211) patients with 
PaƌkiŶsoŶ͛s disease (234) and in cancer populations (235). In those populations, the MCQ-30 showed good 
convergent validity and internal consistency, and acceptable to good test-retest reliability.(191) 
Therefore, as the MCQ-30 was utilized in both psychiatric and neurodegenerative disease and due to the 
close relationship between cognition and emotion regulation observed in post-stroke populations, the 
test was deemed the most suitable to use in the assessment of metacognitive function. In addition, the 
MCQ-30 also displayed good psychometric properties when translated into other languages.(236, 237) 
However, to the best of our knowledge, it has not been utilized in a stroke population or an Arabic 
speaking population.  
For evaluating metamemory, the delayed recall components of the MMSE and MOCA were used as 
objective measures of memory function alongside the Cognitive Confidence subset of the MCQ-30 which 
was used to evaluate subjective memory complaints. 
 5.4.7 Assessment of Mood 
The Hospital Anxiety and Depression Scale (HADS) consists of 14 items each rated from 0 to 3 according 
to severity of an anxiety or depressive symptom experienced. The depression (HADS-D) and anxiety 
(HADS-A) subscale totals are then summed separately. The scores can then be interpreted as indicating 
mild, moderate, or severe in either category.(238). The HADS is accepted as one of the best validated self-
report scales for identifying anxiety or depressive symptoms and in assessing symptom severity (239). It 
has also been validated for use in stroke survivors (240) and was therefore used as an assessment of mood 
in this study. 
  5.4.8 Physical Function and Dependency 
The Barthel Index is a scale that uses ten variables as a measure of activities of daily living and mobility. 
These variables include dependency in feeding, grooming, continence, toilet use, and mobility, with higher 
scores indicating a greater likelihood of independent living following hospital discharge.(29) The Barthel 
Index displays good psychometric properties (29, 241) and is commonly used as a standard measure of 
ADLs in stroke survivors (29, 242).  It was therefore used as a measure of physical function and 
dependency in this population group.  
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5.4.9 Translation Procedure and Guidelines  
Questionnaires and neuropsychological assessments needed to be available in both English and Arabic as 
the population group consisted of a predominately Arabic speaking population. As the MMSE and MoCA 
are the most widely used instruments for quantitative assessment of cognitive function and dementia 
screening, translated and validated (243, 244) Arabic versions of both measures were available and 
utilized for the purpose of this study. 
The Frenchay Aphasia Screening Test, Trail Making Test, Hospital Anxiety and Depression Scale, Informant 
Questionnaire of the Elderly, Metacognitive Questionnaire and the Best Language and Dysarthria sections 
of the NIHSS were translated into the Arabic language by a licensed professional translator. The 
instruments were translated in adherence to the International Society for Pharmacoeconomics and 
Outcomes Research (ISPOR) Task Force for Translation and Cultural Adaptation guidelines (245) and were 
reviewed by a bilingual researcher with background experience with both English-speaking and Arabic-
speaking populations. 
5.5 Procedure 
  5.5.1 Participant Consent 
Eligible patients or potential controls received both oral and written information about the study from 
the researchers involved prior to participation. The researchers went through the information sheet with 
the participants, answered any questions they may have had, and provided contact details should any 
further questions arise. Written informed consent was then obtained from individuals agreeing to take 
part in the study. The Information Sheet and Consent Forms were provided in either English or Arabic 
depending on the native tongue of the participant. (See Appendices 2 and 3) A signed copy of the consent 
form was retained by the researchers as a record of consent. The participants were also given a copy of 
the forms as per request.  
Participants were informed that their participation in the study was entirely voluntary and included the 
right to withdraw at any time. They were also assured that information identifying them would remain 
confidential and that their refusal to participate would not interfere with any current or ongoing health 
services provided.  
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  5.5.2 Clinical Background Information 
Once a participant agreed to take part in study, general demographic information and information 
regarding their previous medical history was collected. Demographic information included the 
partiĐipaŶts͛ date of ďiƌth, geŶdeƌ, nationality, number of years spent in formal education, occupation, 
ŵaƌital status aŶd liǀiŶg aƌƌaŶgeŵeŶts. IŶfoƌŵatioŶ ƌegaƌdiŶg the paƌtiĐipaŶt͛s ŵediĐal history was 
retrieved in the control group directly through interview and for the case group via their medical records. 
This included a previous medical history of any conditions, history of medications and the date of stroke, 
stroke type, lesion location and brain computer topography and/or magnetic resonance imaging 
radiological reports for the stroke participants. Relevant laboratory investigations (e.g. lipid profile, 
HbA1c) were also obtained from the medical records. 
5.5.3 Clinical Assessment   
After demographic information was collected a neuropsychological battery of assessments were 
administered to the participant. Either the English or Arabic battery of tests were used depending on the 
paƌtiĐipaŶt͛s Ŷatiǀe toŶgue (See Appendices 4 & 5 for the English and Arabic data collection packages).  
The complete assessment took approximately 50-70 minutes for each stroke participant (between one to 
two sittiŶgs as peƌ paƌtiĐipaŶt͛s ƌeƋuestͿ aŶd ďetǁeeŶ ϮϬ-40 minutes for each healthy participant (one 
sitting). These assessments tools examined global cognition, executive function, metacognition, mood, 
activities of daily living and pre-morbid cognitive function (see Table 5.2). The National Institute of Health 
Stroke Severity Scale and the Frenchay Aphasia Screening Test were administered to stroke participants 
oŶlǇ. The ƌeseaƌĐh studǇ oďjeĐtiǀes ǁeƌe disĐussed ǁith the paƌtiĐipaŶts͛ faŵilǇ ŵeŵďeƌs oƌ Đaƌegiǀeƌs 
when possible. The family members or caregivers were given the IQCODE to complete for the assessment 
of premorbid cognitive function after the explanation of study objectives and consent was obtained.  
In terms of the sequence of assessments, the NIHSS was the first test administered to stroke participants. 
IŶfoƌŵatioŶ aďout the paƌtiĐipaŶt͛s ĐoŵpƌeheŶsioŶ and language function would be obtained from this 
examination. If a score of >0 was obtained in the Best Language category, the researcher would then 
proceed with the FAST to determine if the participant would be eligible to partake in the study (obtaining 
a cut-off sĐoƌe шϭϰͿ. Neǆt, assessŵeŶts of ĐogŶitiǀe fuŶction were performed (MMSE, MoCA and TMT), 
followed by assessment of mood and metacognition. The researchers administered the assessment tools 
to the subjects in order to clarify any queries regarding the specific questions. Finally, nursing staff assisted 
the researchers in completing the Barthel Index. 
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Table 5.2 Assessments and measures used for the case and control group  
Generic Variable Name Instrument/Measure Name Case Group Control Group 
 
Participant demographics Age, gender, nationality, marital status, 
living situation, education and 
occupation, hand preference 
√ √ 
 
 
Clinical details Past medical history  
Oxfordshire Community Stroke Project 
(OCSP) Classification 
√ 
√ 
√ 
 
TOAST Classification of Stroke √ 
 Lesion location √  
 Affected side √  
 Length of hospital stay √  
Stroke Severity National Institute of Health Stroke 
Severity Scale (NIHSS) 
√  
Aphasia screening Frenchay Aphasia Screening Test (FAST) √ √ 
Global Cognition Mini-mental State Examination (MMSE) √ √ 
 Montreal Cognitive Assessment (MoCA) √ √ 
Executive function Trail-Making Test  √ √ 
 
Metaognition Metacognitive Questionnaire (MCQ-30) 
 
√ √ 
Pre-morbid Cognitive 
Functioning 
Informant Questionnaire on Cognitive 
Decline in Elderly (IQCODE)  
 
√ √ 
 
 
Mood Hospital Anxiety and Depression Scale 
(HADS) 
√ √ 
Activities of Daily Living Barthel Index (BI) √ √ 
Bio-markers Lipid profile, HbA1c, Homocysteine 
levels 
√ √ 
ApoE √ √ 
 
  5.5.4 Biomarker Analysis 
Sampling, Handling and Storage 
After the completion of clinical assessments blood was sampled from the participants for ApoE 
genotyping. Non-fasting venous blood samples were collected by venepuncture under aseptic technique 
by trained nurses at Salmaniya Medical Complex (SMC) in the case group and by trained laboratory 
technicians at the Local Health Centres in the control group.  
Blood (4-5ml) was collected in an ethylenediamine tetraacetic acid (EDTA) tube. Samples were then 
appropriately labelled and stored in the fridge available (1-5°C) for a maximum of 1-2 hours. The samples 
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were then transferred by the researchers involved to Al Jawahara Center for Molecular Medicine, which 
is a 1-2 minute drive from SMC and a 15-20 minute drive from the LHCs. Samples were transferred in box 
container on ice. Upon arrival at Al Jawhara Center, the EDTA tube samples were stored at 4°C. Samples 
were stored for a maximum of one week before DNA purification.   
DNA Purification 
For DNA purification, EDTA samples were retrieved from the 4°C fridge and centrifuged at 2,500g for 10 
minutes. Trials of both manual and automated DNA purification were attempted on the first 10 samples. 
Genomic DNA was isolated from buffy coat samples in both techniques (manual:200µl, automated:400µl). 
Refer to Appendix 6 for the DNA Purification Standard Operating Procedure (SOP). DNA concentration and 
purity of the samples were then measured using a spectrophotometer (NanoDrop). As the automated 
technique yielded a higher concentration and purer DNA, it was subsequently used in the remainder of 
samples. The tubes containing the DNA were then labelled appropriately and stored at -20°C for 
subsequent apolipoprotein E genotyping.  
ApoE Genotyping 
Conventional PCR was used for ApoE genotyping of both the case and control group. Real-time PCR was 
then implemented on the samples and this was completed by the second researcher involved in this 
project. Refer to Appendices 7 and 8 for conventional and real-time PCR ApoE genotyping SOPs. 
 5.6 Statistical Analysis 
The Statistical Package for Social Sciences (SPSS) Version 22 was used to analyse the data. Descriptive 
statistics were used to examine the characteristics of the case and control groups. SpeaƌŵaŶ͛s ĐoƌƌelatioŶ 
and PeaƌsoŶ͛s chi-squared were performed to investigate significant associations. Comparisons between 
case and controls group mean scores was determined using t-tests. The number of participants required 
to produce a statistically meaningful change in cognition between the stroke patients and healthy controls 
was calculated using the formula proposed by Bland (2000) for the comparison of two independent 
samples.(246) A sample of n=75 or more in each group was calculated to detect a minimum effect size in 
cognition with a power of 0.8 at a significance level of 0.05.  
To further investigate factors associated with cognitive impairment multivariate logistic regression was 
carried out in a number of discrete variables especially variables that showed a statistically significant 
correlation at the bivariate level. For the regression models, the Green (1991) formula was adhered to 
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where the minimum sample size should be greater than 50+8k, where k is equal to the number of 
independent variables.(247) Variables were checked for normal distribution to justify the use of 
parametric statistics. Non-parametric tests were used for analysing variables of non-normal distributions. 
Values were considered significant when p<0.05.  
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Section Six: Ethical Considerations 
 6.1 Ethical Approval 
The study protocol, along with the Research Ethics Committee (REC) Application forms, were submitted 
to both the REC of the Royal College of Surgeons in Ireland – Medical University of Bahrain (RCSI-MUB) 
and the Kingdom of BahƌaiŶ͛s MiŶistƌǇ of Health ;MOHͿ. Ethical approval was granted from both RECs 
(Appendices 9 and 10).  
 6.2 Data Management and Handling 
Data management and handling procedures were implemented iŶ aĐĐoƌdaŶĐe ǁith IƌelaŶd͛s Data 
Protection Commissioner guidelines.(248) All peƌsoŶal iŶfoƌŵatioŶ, suĐh as the patieŶt͛s Ŷaŵe, ǁas 
removed from the data collection forms and replaced with a participant number (249). A list linking the 
PN ǁith the suďjeĐt͛s Ŷaŵe, telephone number and identity card number was kept in a secure place 
separate from the data collection forms. Only the researchers involved had access to the data. All hard 
copy data was stored securely in RCSI-MUB premises in a locked storage cabinet. Electronic data was 
stored on two password protected computers. All data stored electronically was identifiable only by 
participant number and not personal details. 
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Chapter 3: Results 
Section Seven: Participant Recruitment and Demographic Profiles 
7.1 Participant recruitment 
From July 2014 to February 2015, 216 stroke patients admitted to Salmaniya Medical Complex were 
assessed for eligibility to participate in the study and approached for consent. Of the 216 admissions, 15 
patients refused to participate in the study, 26 were too medically unstable to participate, 17 patients 
ǁeƌe diagŶosed ǁith aphasia oƌ had had a FA“T sĐoƌe of ч ϭϯ, ϭϰ patieŶts had iŶsuffiĐieŶt uŶdeƌstaŶdiŶg 
of the Arabic or English language, 7 patients had visual or hearing impairments rendering assessments 
difficult, 6 patients had a previous history of a psychiatric condition or were on psychotropic medication 
at the time of assessment and one patient had a previous diagnosis of pre-stroke cognitive impairment. 
General demographic data was collected from the remaining 130 patients identified with a diagnosis of 
stroke. Eighty-five case group participants completed the MMSE, 81 completed the MoCA, 64 completed 
the HADS, 63 completed the MCQ-30 and 47 completed the TMT. 
From December 2014 to January 2015, eligible candidates attending the two primary LHCs used for the 
study recruitment, were approached to participate in the study. Fifty-five control participants from the 
non-stroke general population attending these LHCs agreed to participate in the study with time restraints 
limiting the recruitment of a larger control group sample. All the control group participants completed the 
MMSE and MoCA, n=50 completed the HADS, n=52 completed the MCQ and n=45 completed the HADS 
and TMT. 
7.2 Case group demographic and clinical characteristics   
Seventy-four percent of the case group participants were male. The mean age was 59 years with a 
standard deviation of 14. Over half of the patients (54%) were Bahraini. Seventy percent were living with 
family or friends and 14% were living alone prior to the stroke. Seventy-two percent were married and 
17% were widowed with the remaining sample being unmarried or divorced. Regarding education, 24% 
were illiterate, 23% had only received primary education, and 29% and 24% had received secondary and 
tertiary education respectively. Forty-three percent of the case group were retired or unemployed and 
31% and 26% were employed in manual and non-manual type labour respectively (see Table 7.1).  
Seventy-seven percent of patients presented with a first-ever stroke and ischemic strokes represented 
84% of stroke subtypes. Partial anterior strokes represented 36% of strokes, with lacunar and posterior 
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circulation strokes representing 42% and 14% respectively. Small and large artery occlusions represented 
the majority of the aetiologies as the determined causes of stroke (49% and 27% respectively). The 
commonest co-morbidities in the case group to emerge were hypertension (61%), diabetes (41%) and 
hyperlipidemia (38%). Forty-eight percent and 50% of the sample had mild and moderate stroke severity 
respectively while 2% had more severe strokes based on the NIHSS. The mean NIHSS score was 5.43 with 
a standard deviation of 4.71. Seventy-seven percent of the sample had some degree of functional 
dependency based on the Barthel Index (Table 7.1). 
7.3 Control group demographic and clinical characteristics 
Fifty-two percent of the control group participants were male and 95% were Bahraini. The mean age was 
58 years with a standard deviation of 8. Ninety-five percent of the participants were living with family or 
friends at the time of assessment. Ninety-four percent of the control group were married and none were 
widowed with the remaining sample being unmarried or divorced. Forty-nine percent of the control group 
had received secondary education, with 29% receiving third level education, 13% receiving primary level 
education and the remaining 13% being illiterate. Sixty-seven percent of the case group were retired or 
unemployed at the time of assessment with 22% and 11% in non-manual and manual labour respectively. 
The commonest risk factors to emerge were hypertension (55%), hyperlipidemia (49%) and diabetes 
(46%). All the case group participants were independent in activities of daily living based on the Barthel 
Index score (see Table 7.1). 
7.4 Demographic and clinical characteristic comparisons between the case and control groups 
Table 7.1 presents the general demographic characteristics, co-morbidities, and clinical characteristics 
between the case and control groups. Though the mean age was comparable in both groups (t=.750, 
182df, p=ns), males were represented in a larger proportion in the case group aŶd BahƌaiŶi͛s ǁeƌe 
represented in a larger proportion in the control group. Ninety-five percent of the control group sample 
were living with family or friends in comparison to only 70% in the case group (X2=13.75, 2df, p=.001). 
Ninety-four percent of the control group were married in comparison to 72% in the case group, with a 
larger proportion of the case group being widowed (X2=13.38, 3df, p=.004). Higher rates of illiteracy and 
lower education was more prevalent in the stroke population group than in the control group (47% vs 
26%, X2=7.02, 2df, p=.03). Also, in relation to occupation, the case group had higher rates of manual labour 
than the control group (31% vs 11%, X2=10.90, 2df, p=.004). Rates of diabetes, hypertension, 
hyperlipidemia and cardiovascular disease between the case and control groups were comparable. Higher 
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rates of smoking among the case group was reported (32% vs 13%, X2=7.24, 1df, p=.007). The control 
group was more independent in activities of daily living in comparison to the case group. 
Table 7.1. Comparison of demographic characteristics, co-morbidities, and clinical characteristics between the 
case group (n=130) and the control group (n=55)* 
Case group (stroke 
patients) 
Control group Statistics 
Age in years: mean (SD)  59.11 (14.14) 57.58 (8.03) t=.750, 182df,  p=.454 
Gender: n (%)     
        Male 96 (74) 29 (52) X2=7.87, 1df, p=.005 
Nationality: n (%)     
        Bahraini 
        Non-Bahraini 
71 (54) 
 59 (45) 
52 (95) 
3 (5) 
    X2=26.10, 1df, p<.001 
Living arrangement: n (%)    
        Living alone 15 (14) 0 (0)  
        Living with others – family/friends 
        Other 
Marital Status 
         Married                                                                        
         Not Married 
         Widowed 
         Divorced 
77 (70) 
  18 (16) 
 
73 (72) 
11 (11) 
17 (16) 
1 (1) 
52 (95) 
3 (5) 
 
50 (94) 
2 (4) 
0 (0) 
1 (2) 
   X2=13.75, 2df, p=.001 
 
 
 
 
   X2=13.37, 3df, p=.004 
Education    
Primary 
Secondary 
Third level 
Illiterate 
24 (23) 
31 (29) 
26 (25) 
25 (24) 
7 (13) 
25 (45) 
16 (29) 
7 (13) 
 
 
 
     X2=7.02, 3df, p=.071 
Occupation 
Manual 
Non-manual/self-employed 
Unemployed/retired 
 
34 (31) 
28 (26) 
46 (43) 
 
6 (11) 
12 (22) 
37 (67) 
 
 
 
X2=10.90, 2df, p=.004 
Co-morbidities: n (%)    
TIA 13 (11) 0 (0) X2=6.80, 1df, p=.009 
Stroke 27 (23) 0 (0) X2=15.20, 1df, p<.001 
Cardiovascular disease 15 (13) 7 (13) X2=.003, 1df, p=.954  
Atrial Fibrillation 15(13) 4 (7) X2=1.33, 1df, p=.249  
Hypertension 71 (61) 30 (55) X2=.582, 1df, p=.446  
Diabetes 47 (41) 25 (46) X2=.271, 1df, p=.603  
Hyperlipidemia 42 (38) 27 (49) X2=1.92, 1df, p=.166  
Smoker 38 (32) 7 (13) X2=7.24, 1df, p=.007 
Stroke subtype: n (%)    
        Ischaemic             102 (84)   
        Haemorrhagic  20 (16)   
Lesion Location 
        Right hemispheric 
        Left hemispheric 
        Brainstem 
 
56 (52) 
38 (35) 
14 (13) 
  
OCSP Classification: n (%)    
        Total anterior circulation              10 (8)   
        Partial anterior circulation 42 (36)   
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        Lacunar   50 (42)   
        Posterior circulation    16  (14)   
TOAST Classification: n (%)    
         Large artery atherosclerosis 32 (27)   
         Cardio-embolic 9 (8)   
         Small artery occlusion 57 (49)   
         Other determined aetiology 
         Undetermined aetiology 
17 (14) 
2 (2) 
  
NIHSS: mean (SD) 5.43 (4.71)   
      0-4: n (%) 42 (48)   
      5-15: n (%) 44 (50)   
      ш ϭϲ: n (%) 2 (2)   
Barthel Index: mean (SD)  70.06 (30.56) 99.52 (2.04) X2=67.28, 17df, p<.001 
      Independent: n (%) 18 (22.5) 55 (100)  
      Dependent: n (%) 62 (77.5) 0 (0)  
NIHSS, National Institute of Health Stroke Severity Scale; OCSP, Oxfordshire Community Stroke Project; SD, standard 
deviation; TIA, transient ischaemic attack; TOAST, Trial of Org 10172 in Acute Stroke Treatment. 
*Please note missing values for living arrangement, education, occupation, co-morbidities, stroke subtype, lesion 
location, OCSP classification, TOAST classification, NIHSS and Barthel Index in the case group. 
 
  
69 
 
Section Eight: Cognitive Profiles 
8.1 Cognitive profile of the stroke population 
The average score of the MMSE in the case group was 23.99 ± 4.85. Based on the NICE guidelines for 
stratification of MMSE, 41% of stroke patients had a normal performance and 17%, 33%, and 9% fell into 
the categories of mild/early, moderate and severe cognitive impairment respectively. The average score 
in the MoCA in the case group was 20.32 ± 6.47. Based on the MoCA scoring system, 25% of the case 
group were classified as having normal performance whereas 43%, 23%, and 9% had fell into the 
categories of mild, moderate or severe cognitive impairment respectively (Table 8.1). 
 
In terms of executive function based on the Trail Making Test, the average score for Trails A and B were 
100 ± 109 seconds and 223 ± ϭϵϬ seĐoŶds ƌespeĐtiǀelǇ. The aǀeƌage ΔTMT sĐoƌe ǁas ϭϰϬ ± 129 seconds. 
These results indicate that 37% and 25% of patients were deficient in Trail A and Trail B performance 
ƌespeĐtiǀelǇ aŶd that ďased oŶ the ΔTMT sĐoƌes ϯϬ% had good eǆeĐutiǀe fuŶĐtioŶ, ϰϱ% had iŶteƌŵediate 
executive function and 25% had poor executive function.  
 
When combining the total scores of both assessment measures in conjunction with the TMT to stratify 
cognitive function, 52% of the case group are classified as having stroke with no cognitive vascular 
impairment, 28% with mild vascular cognitive impairment and 20% with moderate cognitive impairment. 
 
Table 8.1 Stratification of cognitive function based on the MMSE and MoCA in the stroke group 
MMSE (%) MoCA (%) Statistic 
Normal performance 
Mild cognitive impairment 
Moderate cognitive impairment 
Severe cognitive impairment 
41 
17 
33 
9 
25 
43 
23 
9 
X2=155.83 df=9 p<.001 
8.2 Cognitive profile of the age- matched control group  
The average score of the MMSE in the control group was 27.96 ± 2.31. Based on the NICE guidelines for 
stratification of MMSE, 82% of the control group had a normal performance and 7% and 11%, fell into the 
categories of mild/early and moderate cognitive impairment respectively. The average score in the MoCA 
in the control group was 25.62 ± 3.44. Based on the MoCA scoring system, 64% of the control group were 
classified as having normal performance whereas 33% and 4% fell into the categories of mild and 
moderate cognitive impairment respectively. 
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In terms of executive function based on the Trail Making Test for the control group, the average score for 
Trails A and B were 65 ± 74 seconds and 115 ± ϱϬ seĐoŶds ƌespeĐtiǀelǇ. The aǀeƌage ΔTMT sĐoƌe ǁas ϵϱ 
± 76 seconds. These results indicate that 17% of the control group were deficit in the Trail A test whereas 
no control group participants weƌe defiĐieŶt iŶ the Tƌail B test. Based oŶ the ΔTMT sĐoƌes, ϲϳ% had good 
executive function, 31% had intermediate executive function and 2% had poor executive function.   
 
When combining the total scores of both assessment measures in conjunction with the TMT to stratify 
cognitive function, 89% of the control group would be classified as having no cognitive vascular 
impairment and 11% would be classified as having mild cognitive impairment with no participants falling 
into the category of moderate or severe cognitive impairment. 
8.3 Comparison of the cognitive profiles between the case and control groups. 
Table 8.2 presents a comparison of performance on the MMSE, MoCA and TMT between the case group 
and the control group. In terms of cognitive assessments, the case group performed poorer in both the 
MMSE (23.99 ± 4.85 vs 27.96 ± 2.31) and the MoCA (20.32 ± 6.47 vs 25.62 ± 3.44). Over 50% of the case 
group scored below the normal cut-off score in the MMSE in comparison to only 18% in the control group 
(X2=23.66, 3df, p<.001). A similar trend was observed for the MoCA scores. The cognitive domains most 
likely to be defective in the stroke participants in comparison with control subjects were orientation, 
attention and calculation, language and abstraction. 
The case group also performed poorer in the Trail Making Test in comparison to the case group. In the 
case group, 25% had poor executive function, with 45% displaying intermediate executive function and 
30% displaying good executive function. In comparison, only 2% of the control group had poor executive 
function, with 31% and 67% having intermediate and good executive function respectively (X2=16.49, 2df, 
p<.001).  
Twenty-eight percent of the case group fell into the category of mild cognitive impairment and 21% fell 
into the category of moderate cognitive impairment. In the control group, only 11% of the sample fell into 
the category of mild cognitive impairment with the remaining sample having normal function (X2=22.10, 
2df, p<.001). The TMT Trail A was the only cognitive assessment where there was no statistical significant 
difference reported between the case and control groups in terms of cognitive performance. 
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 Table 8.2 Comparison of performance on the MMSE, MoCA and TMT in the case and control groups 
Case group (stroke patients) Control group Statistics 
MMSE: mean (SD) 
24-30: n (%) 
21-23: n (%) 
10-20: n (%) 
<10: n (%) 
23.99 (4.85) 
33 (41) 
14 (17) 
27 (33) 
7 (8) 
27.96 (2.31) 
45 (82) 
4 (7) 
6 (11) 
0 (0) 
t=-6.51, 129df,  p<.001 
 
X2=23.66, 3df, p<.001 
MoCA: mean (SD) 
26-30: n (%) 
28-25: n (%) 
10-17: n (%) 
<10: n (%) 
20.32 (6.47) 
20 (25) 
35 (43) 
19 (23) 
7 (8) 
25.62 (3.44) 
35 (64) 
18 (33) 
2 (3) 
0 (0) 
t=-6.19, 128df,  p<.001 
 
X2=26..30, 3df, p<.001 
Executive function 
     TMT Trail A: mean (SD) 
 
100.17 (109.29) 
 
65.15 (74.25) 
 
t=-1.82, 83df,  p=.072 
<70 sec: n (%) 30 (63) 38 (83) X2=4.75, 1df, p=.029 
шϳϬ seĐ: n (%) 18 (37) 8 (17)  
     TMT Trail B: mean (SD) 223.47 (90.66) 115.69 (49.87) t=-3.74, 53df,  p<.001 
<273: n (%) 35 (75) 45 (100) X2=13.21, 1df, p<.001 
шϮϳϯ: n (%) 12 (26) 0 (0)  
     ΔTMT: ŵeaŶ ;“DͿ 142.69 (129.01) 94.82 (76.04) t=-2.08, 66df,  p=.041 
<70: n (%) 14 (30) 30 (67) X2=16.49, 2df, p<.001 
70-156: n (%) 21 (45) 14 (31)  
>156: n (%) 12 (25) 1 (2)  
MMSE, Mini-mental state examination; MoCA, Montreal Cognitive Assessment; TMT, Trail Making Test 
8.4 Stroke type, localization and severity and cognitive function 
Statistically significant correlations were found between both stroke type and severity and global 
cognitive function in stroke patients. Haemorrhagic strokes were more likely to be associated with lower 
MMSE (rho= -.243 p=.029) and MoCA scores (rho=-.255 p=.024). Higher NIHSS scores, indicating more 
severe strokes, were also significantly associated with poorer MMSE (rho=-.393 p<.001) and MoCA (rho=-
.443 p<.001) performance scores and a worse overall cognitive impairment stratification (rho=.424 
p<.001). Other correlations were reported between poorer performance on the TMT and haemorrhagic 
strokes (rho=.262 p=ns) and poorer performance on the TMT and higher NIHSS scores (rho=.127 p= ns). 
No statistical significant correlations were reported between stroke location and either global cognitive 
function or executive function. Table 8.3 presents an inter-correlation matrix of stroke type, localization, 
and severity in relation to global and executive function in the case group.  
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Table 8.3 Inter-correlation matrix of stroke type, localization and severity with global and executive cognitive function in the 
case group1  
 1 2 3 4 5 6 7 
1. Stroke type2        
2. Lesion location3 -.031       
3. NIH4 Stroke Severity 
Score 
-.091 -.025      
4. Total MMSE5 -.243* -.045 -.393**     
5. Total MOCA6 -.255* .048 -.443* .831**    
6. TMT7 Δ Score .262 -.084 .127 -.408** -.473**   
7. Cognitive Impairment8 .198 .012 .424** -.909** -.838** .469**  
8. Barthel Index .009 -.012 -.716** .511** .525** -.304* -.505** 
1Spearman ranking correlations 21=ischaemic, 2=haemorrhagic; 31= right hemispheric, 2= left hemispheric, 3= brainstem; 4National Institutes of 
Health; 5Mini-mental State Exam; 6Montreal Cognitive Assessment; 7 Trail Making Test; 81=no cognitive impairment, 2= mild cognitive impairment 
3=moderate cognitive impairment 4=severe cognitive impairment *.05 < p-value (two-tailed); **p-ǀalues ч .Ϭϭ ;tǁo-tailed) 
 
8.5 Executive function and global cognition in a stroke population. 
Tables 8.4 presents the relationship between performance on the Trail Making Test and performance on 
the MMSE in the case group. Significant negative correlations were reported between performance on 
Tƌail A, Tƌail B aŶd ΔTMT aŶd the total peƌfoƌŵaŶĐe sĐoƌe oŶ the MM“E ;rho=-.525 p<.001, rho=-.507 
p<.001, rho=-.405 p=.005 respectively). This indicates that a better performance on the MMSE, a measure 
of global cognition, correlated with a better performance in the TMT, a measure of executive function. 
Correlations also emerged between subsets of the MMSE and the TMT. For example, significant negative 
correlations were reported between the orientation to time and place MMSE subsets and the TMT 
performance scores. Also, better performance on the recall and naming MMSE subsets were significantly 
correlated with better performance on the Trail A and B components of the TMT. 
 
A similar significant pattern was reported between TMT performance and total MoCA scores (Trail A: rho=-
.579 p<.001, Trail B: rho=-.ϱϵϬ p<.ϬϬϭ, ΔTMT: ƌho=-.505 p<.001). Negative correlations also emerged 
between the majority of the MoCA subsets and the TMT, including visuospatial function/executive 
function, attention, delayed recall and orientation (see Table 8.5).   
 
When combining the results of the MMSE and MoCA together, a significant trend was seen between 
greater cognitive impairment and poorer performance on the TMT (Trail A: rho=.559 p<.001, Trail B: rho=-
.ϱϴϮ p<.ϬϬϭ, ΔTMT: ƌho=-.472 p<.001), indicating a significant relationship between global cognition and 
executive function.  
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Table 8.4 Correlation matrix of performance on the Mini-Mental State Examination and the Trail Making Test in the case group1 
 A B C D E F G H I J K Total Score 
Trail A -.603** -.464** 2 -.207 -.443** -.352* -.179 -.220 .023 .008 -.091 -.525** 
Trail B -.607** -.336* 2 -.180 -.380** -.387** -.195 -.175 .091 -.078 -.360* -.507** 
ΔTMT -.477** -.251 2 -.182 -.232 -.270 -.118 -.049 .138 -.110 -.436** -.405** 
A: Orientation to time; B: Orientation to place, C: Registration; D: Attention and calculation; E: Recall; F: Naming; G: Repetition; H: Three-stage 
command; I: Reading/Obeying Command; J: Writing; K: Drawing. 
1Spearman ranking correlations; 2Constant variable 
*.05 < p-value (two-tailed); **p-ǀalues ч .Ϭϭ ;tǁo-tailed) 
 
Table 8.5 Correlation matrix of performance on the Montreal Cognitive Assessment and the Trail Making Test in the case group1 
 
 
A: 
Visuospatial/Executive; B: Naming, C: Attention; D: Language; E: Abstraction; F: Delayed recall; G: Orientation;  
H: Three-stage command; I: Reading/Obeying Command; J: Writing; K: Drawing. 
1Spearman ranking correlations. 
*.05 < p-value (two-tailed); **p-ǀalues ч .Ϭϭ ;tǁo-tailed) 
8.6 Executive function and global cognition in the control group. 
Table 8.6 presents the relationship between performance on the Trail Making Test and performance on 
the MMSE in the control group. There were no statistically significant correlations between total score on 
the MMSE and performance on the TMT. The only statistically significant negative correlation to emerge 
was between performance on Trail A and the orientation to time subset on the MMSE. A similar pattern 
was seen with the MoCA in which most of the statistically significant correlations to emerge were in 
relation to Trail A (Table 8.7). A statistically significant correlation was seen between the total MoCA score 
and Trail A on the TMT (rho=-.573 p<.001). Subsets of the MoCA (visuospatial/executive function, 
attention, orientation) also had significant negative correlations with Trail A (rho=-.574 p<.001, rho=-.469 
p=.001, rho=-.517 p<.001).  
 
Table 8.6 Correlation matrix of performance on the Mini-Mental State Examination and the Trail Making Test in the control 
group1 
 A B C D E F G H I J K Total Score 
Trail A -.529** 2 2 .011 -.279 -.071 .095 .071 2 -.174 .027 -.076 
Trail B -.078 2 2 .033 -.203 -.014 .090 .014 2 -.133 .072 -.073 
ΔTMT .137 2 2 .204 -.128 .083 .014 -.083 2 -.232 .149 .163 
A: Orientation to time; B: Orientation to place, C: Registration; D: Attention and calculation; E: Recall; F: Naming; G: Repetition; H: Three-stage 
command; I: Reading/Obeying Command; J: Writing; K: Drawing. 
1Spearman ranking correlations; 2Constant variable 
*.05 < p-value (two-tailed); **p-ǀalues ч .Ϭϭ ;tǁo-tailed) 
 
 
 A B C D E F G Total Score 
Trail A -.670** -.082 -.375** -.253 -.152 -.455* -.532** -.579** 
Trail B -.483** -.147 -.327** -.264 -.134 -.477** -.539** -.590** 
ΔTMT -.415** -.120 -.251 -.283 -.116 -.417** -.442** -.505** 
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Table 8.7 Correlation matrix of performance on the Montreal Cognitive Assessment and the Trail Making Test in the control 
group1 
 
 
 
 
 
 
A: Visuospatial/Executive; B: Naming, C: Attention; D: Language; E: Abstraction; F: Delayed recall; G: Orientation;  
H: Three-stage command; I: Reading/Obeying Command; J: Writing; K: Drawing. 
1Spearman ranking correlations. 
*.05 < p-value (two-tailed); **p-ǀalues ч .Ϭϭ ;tǁo-tailed) 
8.7 A comparison of the relationship of executive function and global cognition between the case and 
control groups. 
Despite significant statistically correlations observed between performance on the MMSE and MoCA and 
the TMT in the case group, indicating a relationship between global cognition and executive function, this 
trend was not observed in the control group. In both groups, a statistically significant trend was observed 
between the total MoCA score and Trail A, a measure of cognitive processing speed. Trail A performance 
was also significantly correlated with the same MoCA subsets in the both the case and control group 
(visuospatial/executive function, attention and orientation).  
  
 A B C D E F G Total Score 
Trail A -.574** .043 -.469** .176 -.131 -.264 -.517** -.573** 
Trail B -.148 .048 .016 .065 -.298* -.074 -.087 -.160 
ΔTMT -.058 .019 .100 .176 -.013 -.126 .042 .012 
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Section Nine: Metacognitive Profiles 
9.1 Metacognitive Questionnaire-30 scores in the case and control groups 
The mean total score for the MCQ-30 in the case group was 61.64 ± 14.31. The mean average scores on 
the MCQ-30 subscales in the case group ranged from 10.34 to 14.18 (see Table 9.1). Over 50% of the case 
group participants scored a value above 14 in the Cognitive Self-consciousness subscale and over 40% 
scored a value above 14 in the Need to Control Thoughts subscale. Descriptive values of percentage of 
scores >14 in the case group are presented in Table 9.2. 
 
The mean total score for the MCQ-30 in the control group was 61.02 ± 14.97. The mean average scores 
on the MCQ-30 subscales in the case group ranged from 9.58 to 16.73 (Table 9.1). Over one-third of the 
control group participants scored a value >14 in the Cognitive Self-consciousness subscale. Over 50% of 
the control group participants scored a value of >14 in the Need to Control Thoughts subscale. Descriptive 
values of percentage of scores >14 in the control group is presented in Table 9.2. 
9.2 A comparison of MCQ-30 scores between the case and control groups 
The mean average total score on the MCQ-30 between the case (61.64 ± 14.31) and control (61.02 ± 14.97) 
groups were comparable. However, the mean average score for the Cognitive Self-consciousness subscale 
was greater in the control group than the case group (16.73 ± 5.27 vs 14.18 ± 5.18, t=2.62, 115df, p=.010) 
and the mean average Uncontrollability and Danger subscale score was greater in the case group than the 
control group (12.33 ± 4.81 vs 9.58 ± 4.98, t=3.05, 116df, p=.003). 
A larger proportion of the case group scored higher levels on the Uncontrollability and Danger (36% vs 
25%, X2=1.745, 1df, p=ns), Cognitive Confidence (27% vs 22%, X2=.364, 1df, p=ns) and Positive Beliefs (36% 
vs 31%, X2=.335, 1df, p=ns) subscales. The greater proportion of the control group scored significantly 
higher levels in the Cognitive Self-Consciousness subset in comparison to the case group (75% vs 54%, 
X2=5.561, 1df, p=.018). A comparison of outcomes the MCQ-30 between the case and control groups is 
presented in Tables 9.1 and 9.2. 
 
Table 9.1 Descriptive statistics for the Metacognition Questionnaire-30 subscales and total scale in the case and 
control groups 
Domain: mean (SD) Case group (strokes) Control group Statistics 
Cognitive Confidence  
Positive Beliefs 
10.34 (4.86) 
11.78 (5.38) 
9.88 (4.01) 
11.60 (5.09) 
t=.548, 115df, p=.585 
t=.185, 117df, p=.853 
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Cognitive Self-consciousness 
Uncontrollability and Danger 
Need to Control Thoughts 
Total Score 
14.18 (5.18) 
12.33 (4.81) 
12.84 (3.80) 
61.64 (14.31) 
16.73 (5.27) 
9.58 (4.98) 
13.94 (4.04) 
61.02 (14.97) 
t=2.62, 115df, p=.010 
t=3.05, 116df, p=.003 
t=1.53, 117df,  p=.128 
t=.225, 112df,  p=.822 
 
 
Table 9.2 Comparison of outcomes Metacognitive Questionnaire-30 between the case and control groups  
Case group (strokes) (%) Control group (%) Statistics 
Cognitive confidence  
      >14 
 
26.9 
 
22.0 
 
X2=.364, 1df, p=.547 
Positive Beliefs 
      >14 
 
35.8 
 
30.8 
 
X2=.335, 1df, p=.563 
Cognitive Self- consciousness 
      >14 
 
53.8 
 
75.0 
 
X2=5.561, 1df, p=.018 
Uncontrollability and Danger 
      >14 
 
36.4 
 
25.0 
 
X2=1.745, 1df, p=.187 
Need to Control Thoughts 
      >14 
 
43.3 
 
51.9 
 
X2=.887, 1df, p=.349 
Total Score 
      >45 
 
90.6 
 
90.0 
 
X2=.013, 1df, p=.911 
9.3 Metacognitive function and stroke type, localization and severity. 
No statistical significant correlations were reported between total metacognitive function based on scores 
in the MCQ-30 and stroke type, localization or severity. However, subjects with more severe strokes were 
more likely to report lower levels of cognitive self-consciousness (e.g. expressing that they are less likely 
to be constantly aware of their thinking, less likely to monitor their thoughts, and  less likely to constantly 
examine their thoughts) (rho=-.442 p<.001).  
9.4 Global cognitive function and metacognition in a stroke population. 
No statistically significant correlations were reported between total MCQ-30 scores and total MMSE, total 
MoCA scores or the classification of cognitive impairment. However, significant correlations were 
observed between the Cognitive Self-consciousness subscale on the MCQ-30 and total MMSE and MoCA 
scores. Higher levels in the Cognitive Self-consciousness subscale indicates that the individual subjectively 
reports that they are more constantly aware of their thinking, pay close attention to the way their mind 
works, constantly examine and monitor their thoughts and are aware of the way their mind works when 
they are thinking through a problem. Patients who scored higher on the MMSE and MoCA had higher 
levels of cognitive self-consciousness (rho=.281 p=.023, rho=.272, p=.029 respectively). Therefore, 
patients who were categorized with having higher levels of cognitive impairment were more likely to 
report less levels of cognitive self-consciousness (rho=-.245 p=.049). 
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The Cognitive Self-consciousness subscale also correlated with specific domains of the MMSE and MoCA. 
For example, patients who had higher scores on the Attention and Calculation subscales on the MMSE 
and Attention subscale on the MoCA had a higher cognitive self-consciousness score (rho=.269 p=.030, 
rho=.338 p=.006 respectively). Correlations between this MCQ-30 subscale and the Abstraction and 
Orientation categories in the MoCA were also observed (rho=.397 p=.001, rho=.254 p=.0410 respectively). 
 
Another correlation to emerge between subgroups was between the drawing subscale on the MMSE and 
the Uncontrollability and Danger and Need to Control Thoughts subscales on the MCQ-30. Those who 
scored better in the drawing subscale in the MMSE had lower Uncontrollability and Danger (rho=-.260 
p=.041) and lower Need to Control Thoughts (rho=-.302 p=.016) scores on the MCQ-30 indicating that 
they reported a greater degree of control over worrying thoughts and better ability to control thoughts in 
general.   
9.5 Global cognitive function and metacognition in the control group. 
No statistically significant correlations were reported between total MCQ-30 scores and the total MMSE 
score, total MoCA score or the classification of cognitive impairment in the control group. In addition, no 
statistically significant correlations were reported between the total MMSE and MoCA scores and 
subscales of the MCQ-30. Some statistically significant correlations between total MCQ-30 scores and 
subscales of the MoCA were observed. For example, control group participants who performed better on 
the language subscale in the MoCA (repetition and fluency) and the abstraction subscale had higher MCQ-
30 scores (rho=.450 p=<.001, rho=.281 p=.048 respectively).  
 
The Positiǀe Beliefs suďsĐale eǆaŵiŶes a paƌtiĐipaŶt͛s attitude toǁaƌds ǁoƌƌǇiŶg aŶd ǁhetheƌ theǇ 
perceive worrying positively or negatively. Control group participants who scored higher in the drawing 
component on the MMSE tended to have higher scores in the Positive Beliefs subscale on the MCQ-30 
(rho=.361 p=.009), indicating that they perceive their worrying thoughts more positively.  Control group 
participants who scored higher in the Cognitive Self-consciousness subscale on the MCQ-30 tended to 
have better performance in the drawing (rho=.334 p=.015) and writing (rho=.317 p=.032) components on 
the MMSE and the visuospatial/executive (rho=.291 p=.036) and abstraction components on the MoCA 
(rho=.326 p=.018). 
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Participants who scored higher on the Uncontrollability and Danger MCQ-30 subscale had poorer 
performance in orientation to time and place on the MMSE (rho=-.321 p=.020, rho=-.235 p=.019 
respectively) and the orientation component on the MoCA (rho=-.318 p=.022). A similar pattern was 
observed with the Need to Control Thoughts subscale and orientation (MMSE (orientation to time): rho=-
.269 p=ns, MMSE (orientation to place): rho=-.282 p=.043, MoCA (orientation): rho==.175 p=ns) Subjects 
who performed better in the MoCA language also had higher Uncontrollability and Danger scores 
(rho=.424 p=.002) and Need to Control Thoughts scores (rho=.499 p<.001). A positive correlation between 
the abstraction component on the MoCA and the Uncontrollability and Danger subscale was also observed 
(rho=.291 p=.036). 
9.6 A comparison of the relationship of global cognitive function and metacognition between the case 
and control groups. 
No statistically significant correlations were reported between total MCQ-30 scores and the total MMSE 
score, total MoCA score or the classification of cognitive impairment in either the case group or the control 
group. Statistically significant correlations were reported with total global cognition scores and MCQ-30 
subscales in the case group but not in the control group. A greater number of statistically significant 
correlations were reported with the Cognitive Self-Consciousness subscale in the case group than in the 
control group. In both the case and control group, participants who performed better in the abstraction 
subscale in the MoCA had higher Cognitive Self-consciousness scores. 
9.7 A comparison of the relationship of executive function and metacognition between the case and 
control groups 
No statistically significant associations were reported between the Trail Making Test, a measure of 
executive function, and the Metacognitive Questionnaire (total score and subscales) in either the case 
group or the control group. 
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Section Ten: Memory and Metacognition 
10.1 Memory performance in the case group. 
In the case group, 48% were able to recall all 3 objects on the MMSE, 28% were able to recall two objects 
and 13% and 11% were able to recall one object and no object respectively. Seventy-seven point five 
percent of the case group were classified as having a good performance in the recall component on the 
MMSE and 23.5% were classified as having poor performance. 
 
With regards to the MoCA, only 11% of the case group were able to recall all five words, 15% were able 
to recall four words, 12% were able to recall two and three words each, 17% were able to recall one word 
and 32% were not able to recall any words with no cues. Thirty-eight percent were classified as having 
good performance on the MoCA and 62% were classified as having poor performance. 
10.2 Memory performance in the control group. 
In the control group, 67% were able to recall all 3 objects on the MMSE, 31% were able to recall two 
objects and 2% were able to recall one object. No control group participants were unable to recall any 
object. Ninety-eight percent of the case group were classified as having a good performance and only 2% 
were classified as having poor performance in the recall component on the MMSE. 
 
In the delayed recall component of the MoCA, 18% of the control group participants were able to recall 
all five words, 20% were able to recall four words, 22% were able to recall three words, 18% were able to 
recall three words, 9% were able to recall one word and 13% were unable to recall any words. Sixty 
percent were classified as having good performance on the MoCA and 40% were classified as having poor 
performance. 
10.3 A comparison of memory performance between the case and control groups. 
A comparison between performance between the case group and the control group shows that the 
control group performed better in both the recall component of the MMSE (98% vs 77.5%, X2=12.346, 
1df, p<.001) and the delayed recall component of the MoCA (60% vs 38%, X2=6.208, 1df, p=.013) (Tables 
10.1 and 10.2). 
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Table 10.1 Performance on the Recall subscale in the MMSE and Delayed Recall subscale in the MoCA in the case 
group and the control group. 
Case group (strokes) Control group Statistics 
MMSE: Recall n (%) 
Recalls 0 objects 
Recalls 1 object 
Recalls 2 objects 
Recalls all 3 objects 
 
9 (11) 
11 (13) 
24 (28) 
41 (48) 
 
0 (0) 
1 (2) 
17 (31) 
37 (67) 
 
X2=12.897, 3df, p=.005 
MoCA: Delayed recall n (%) 
Recalls 0 words 
Recalls 1 word 
Recalls 2 words 
Recalls 3 words 
Recalls 4 words 
Recalls all 5 words 
 
26 (32) 
14 (17) 
10 (12) 
10 (12) 
12 (15) 
9 (11) 
 
7 (13) 
5 (8) 
10 (18) 
12 (22) 
11 (20) 
10 (18) 
 
 
X2=10.909, 5df, p=.053 
 
Table 10.2 Stratified performance on the Recall subscale in the MMSE and Delayed Recall subscale in the MoCA 
in the case group and the control group. 
Case group (strokes) Control group Statistics 
MMSE: Recall n (%) 
Poor performance 
Good performance 
 
20 (23.5) 
65 (77.5) 
 
 
1 (2) 
54 (98) 
 
 
X2=12.346, 1df, p<.001 
MoCA: Delayed recall n (%) 
Poor performance 
Good performance 
 
50 (62) 
31 (38) 
 
22 (40) 
33 (60) 
 
 
X2=6.208, 1df, p=.013 
10.4 Memory and Metacognition in the case group 
The Cognitive Confidence subset of the MCQ-30 eǀaluates oŶe͛s oǁŶ confidence in their memory function 
using a four-point Likert scale and was used to evaluate subjective memory complaints alongside the 
delayed recall component of the MMSE and MoCA which were used as objective measures of memory 
function (refer to Appendix 4, page 175 for items on the Cognitive Confidence Domain of the 
Metacognitive Questionnaire). Twenty-seven percent of the case group participants had a total score of 
шϭϰ oŶ the CogŶitiǀe CoŶfideŶĐe suďsĐale of the MCQ-30 indicating that their subjective evaluation of 
memory function is poor. More than 40% of patieŶts agƌeed ǁith the stateŵeŶts ͚I haǀe a pooƌ ŵeŵoƌǇ͛, 
͚MǇ ŵeŵoƌǇ ĐaŶ ŵislead ŵe at tiŵes͛ aŶd ͚I haǀe little ĐoŶfideŶĐe iŶ ŵǇ ŵeŵoƌǇ foƌ ǁoƌds aŶd Ŷaŵes͛. 
Over 35% of patients agreed with the statement ͚I do Ŷot tƌust ŵǇ ŵeŵoƌǇ͛.  
An inter-correlation matrix of stroke severity, performance on the recall categories on the MMSE and 
MoCA and subjective cognitive confidence in memory based on the MCQ-30 is presented in Table 10.3. 
81 
 
No statistically significant correlations between Cognitive Confidence scores and performance on the 
recall MMSE or MoCA categories were reported. A negative correlation was reported between NIHSS 
score and Cognitive Confidence (rho= -.227 p=ns), indicating that subjects with more severe strokes based 
on the NIHSS scale were more likely to report good levels of cognitive confidence in their memory skills 
(e.g. reporting that they trust their memory and are confidence in their memory for words, names or 
places). This was despite the fact that patients with a higher NIHSS score tended to perform worse on the 
recall components on the MMSE (rho=-.368 p<.001) and MoCA (rho=-.149, p=ns), indicative of impairment 
in metamemory. 
Table 10.3 Inter-correlation matrix of stroke severity, memory function, cognitive confidence in memory and metacognition in 
the case group1  
 1 2 3 4 5 6 
1. NIHSS2       
2. Recall MMSE3 -.368**      
3. Total MMSE -.442** .664**     
4. Recall MoCA4 -.149 .445** .531**    
5. Total MOCA -.463** .589* .891** .682**   
6. Cognitive Confidence 
(MCQ-30)5 
-.227 -.226 -.146 -.216 -.093  
7. Total MCQ-30 -.208 -.037 -.014 -.198 .007 .564** 
1Spearman ranking correlations; 2National Institutes of Health Stroke Scale; 3Mini-mental State Exam; 4Montreal Cognitive Assessment; 
5Metacognitive Questionnaire-30 *.05 < p-value (two-tailed); **p-ǀalues ч .Ϭϭ ;tǁo-tailed) 
10.5 Memory and metacognition in the control group 
Twenty-two percent of the control group participants had a total score of шϭϰ oŶ the CogŶitiǀe CoŶfideŶĐe 
subscale of the MCQ-30 indicating that their subjective evaluation of memory function is poor. More than 
35% of patieŶts agƌeed ǁith the stateŵeŶts ͚I do Ŷot tƌust ŵǇ ŵeŵoƌǇ͛. Oǀeƌ ϱϬ% agƌeed ǁith the 
stateŵeŶt ͚I haǀe a pooƌ ŵeŵoƌǇ͛ aŶd oǀeƌ ϲϬ% agƌeed ǁith the statement ͚MǇ ŵeŵoƌǇ ĐaŶ ŵislead ŵe 
at tiŵes͛.  No statistically significant correlations between Cognitive Confidence scores and performance 
on the recall MMSE or MoCA categories were reported in the control group (Table 10.4). 
Table 10.4 Inter-correlation matrix of memory function, cognitive confidence in memory and metacognition in the control 
group1  
 1 2 3 4 5 
1. Recall MMSE3      
2. Total MMSE .222     
3. Recall MoCA4 .365** .087    
4. Total MOCA .310* .630** .611**   
5. Cognitive Confidence 
(MCQ-30)5 
-.053 .143 -.144 -.006  
6. Total MCQ-30 -.164 .080 -.290* -.073 .610** 
1Spearman ranking correlations; 2National Institutes of Health Stroke Scale; 3Mini-mental State Exam; 4Montreal Cognitive Assessment; 
5Metacognitive Questionnaire-30 *.05 < p-value (two-tailed); **p-ǀalues ч .Ϭϭ ;tǁo-tailed) 
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10.6 A comparison of the association between memory and metacognition between the case and 
control groups.  
Agreement on components of the Cognitive Confidence subscale between the case group and control 
group was comparable with the only statistically significant proportional difference to emerge being a 
greater number of the case group participants reporting that they do not trust their memory (Table 10.5). 
Neither group showed significant statistical correlations between performance on the recall components 
on the MMSE or MoCa and the Cognitive Confidence subscale on the MCQ-30. 
 
Table 10.5 Agreement with the Cognitive Confidence subscale statements of the Metacognitive Questionnaire-
30 in the case group and the control group n (%) 
Case group 
(strokes) 
Control group Statistics 
I do not trust my memory 
I have a poor memory 
I have little confidence in my memory for actions 
I have little confidence in my memory for places 
I have little confidence in my memory for words 
and names 
My memory can mislead me at times 
26 (39) 
28 (42) 
24 (36) 
23 (34) 
29 (43) 
 
32 (48) 
18 (35) 
27 (52) 
14 (27) 
20 (39) 
25 (49) 
 
32 (62) 
X2=9.656, 3df, p=.022 
X2=7.529, 3df, p=.057 
X2=1.483, 3df, p=.686 
X2=3.440, 3df, p=.329 
X2=4.033, 3df, p=.258 
 
X2=5.507,3df, p=.138 
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Section Eleven: Anxiety and Depression 
11.1 Anxiety, global cognition, executive function and metacognition in the case group. 
In the Hospital Anxiety and Depression scale, scores for anxiety and depression each range from 0 to 21, 
with the scores classified as follows: normal 0-7, mild 8-10, moderate 11-14, and severe 15-21. In the 
anxiety component in the case group, 71% scored within the normal range, 11% were classified as having 
mild anxiety symptoms, 13% with moderate symptoms and 5% with severe symptoms (Table 11.1). 
 
No significant statistical correlations were reported between HADS Anxiety scores and global cognition 
(MMSE, MoCA, cognitive impairment stratification) or subscales of global cognition measures in the case 
group. No statistically significant correlations were reported between the HADS-A and executive function 
(Trail Making Test) either. However, statistically significant correlations were reported between the MCQ-
30 and HADS-A. Higher scores on the HADS-A correlated with higher total MCQ-30 scores (rho=.525, 
p<.001). In addition, the Cognitive Confidence, Cognitive Self-consciousness, and Uncontrollability and 
Danger subscales on the MCQ-30 correlated significantly with the HADS-A score (rho=.437 p<.001, 
rho=.304 p=.016, rho=.555 p<.001 respectively). An inter-correlation matrix of the MCQ-30 and HADS in 
the case group is presented in Table 11.2. No statistically significant correlations were reported between 
anxiety symptoms and lesion location. 
11.2 Anxiety, global cognition, executive function and metacognition in the control group 
For the HADS Anxiety component, 74% of the age-matched control group scored within the normal range, 
14% were classified as having mild anxiety symptoms, 10% with moderate symptoms and 1% were 
classified as having severe anxiety symptoms. 
 
No statistically significant correlations were reported between HADS-A scores and global cognition 
(MMSE, MoCA, cognitive impairment stratification). Some correlations were reported between subscales 
of the global cognition measures and HADS-A scores in the control group. More specifically, a negative 
correlation was reported between orientation to time (rho=.376 p=.007) and place (rho=-.224 p=119) on 
the MMSE and with the orientation subscale on the MoCA (rho=-.320 p=.002). A positive correlation was 
reported between the abstraction subscale in the MoCA and HADS-A (rho=.284 p=.043). No statistically 
significant correlations were reported between the HADS-A and executive function (Trail Making Test).  
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Significant correlations were reported between the MCQ-30 and HADS-A. Higher scores on the HADS-A 
correlated with higher total MCQ-30 scores (rho=.481, p=.001). In addition, the Cognitive Confidence and 
Uncontrollability and Danger subscales on the MCQ-30 correlated significantly with the HADS-A score in 
the control group (rho=.468, p=.001, rho=.660 p<.001 respectively). An inter-correlation matrix of the 
MCQ-30 and HADS in the control group is presented in Table 11.3. 
11.3 A comparison of the relationship between anxiety symptoms and global cognition, executive 
function and metacognition in the case and control groups 
The frequency of anxiety symptoms based on the HADS in the case and control groups were similar 
(X2=1.031, 3df, p=.794). Neither group showed significant statistical correlations between anxiety scores 
and global cognition and executive function. However, both groups showed a statistically significant 
positive correlation between HADS-A scores and total MCQ-30 scores and the Cognitive Confidence and 
Uncontrollability and Danger Subscales. The case group also showed positive correlations between the 
HADS-A and the Cognitive Self-Consciousness subscale on the MCQ-30. 
Table 11.1 Outcomes of the Hospital Anxiety and Depression Scale between the case and control groups 
Case group (strokes) Control group Statistics 
Anxiety: 
Normal (0-7): n (%) 
Mild (8-10): n (%) 
Moderate (11-14): n (%) 
Severe (15-21): n (%) 
 
45 (71) 
7 (11) 
8 (13) 
3 (5) 
 
38 (74) 
7 (14) 
5 (10) 
1 (2) 
 
 
X2=1.031,3df, p=.794 
Depression: 
Normal (0-7): n (%) 
Mild (8-10): n (%) 
Moderate (11-14): n (%) 
Severe (15-21): n (%) 
 
43 (68) 
11 (17) 
2 (24) 
7 (11) 
 
44 (84) 
7 (14) 
1 (2) 
0 (0) 
 
 
X2=7.248, 3df, p=.064 
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Table 11.2 Inter-correlation matrix of the Metacognitive Questionnaire subsets and the Hospital Anxiety and Depression 
Scale in the case group1  
 1 2 3 4 5 6 7 
1. Cognitive Confidence         
2. Positive Beliefs .078       
3. Cognitive Self-
consciousness 
.219 .346**      
4. Uncontrollability and 
Danger 
.267* .065 .134     
5. Need to Control 
Thoughts 
.126 .090 .210 .388**    
6. Total MCQ-302 .564** .566** .675** .602** .538**   
7. HADS-D3 .440** .028 .282* .485** .227 .478**  
8. HADS-A4 .437** .053 .304* .555** .123 .525** .677** 
1Spearman ranking correlations; 2Metacognitive Questionnaire–30; 3Hospital Anxiety and Depression Scale - Anxiety;  
4Hospital Anxiety and Depression Scale - Depression 
*.05 < p-value (two-tailed); **p-ǀalues ч .Ϭϭ ;tǁo-tailed) 
 
 
Table 11.3 Inter-correlation matrix of the Metacognitive Questionnaire subsets and the Hospital Anxiety and Depression 
Scale in the control group1  
 1 2 3 4 5 6 7 
1. Cognitive Confidence         
2. Positive Beliefs .245       
3. Cognitive Self-
consciousness 
.132 .165      
4. Uncontrollability and 
Danger 
.508** .259 .349*     
5. Need to Control 
Thoughts 
.210 .024 .354** .570**    
6. Total MCQ-302 .610** .579** .646** .807** .609**   
7. HADS-D3 .609** .189 .219 .657** .273 .553**  
8. HADS-A4 .468** .201 .182 .660** .201 .481** .521** 
1Spearman ranking correlations; 2Metacognitive Questionnaire–30; 3Hospital Anxiety and Depression Scale - Anxiety;  
11.4 Depression, global cognition, executive function and metacognition in stroke patients 
In the HADS Depression component in the case group, 68% scored within the normal range, 17% were 
classified as having mild depressive symptoms, 3% with moderate symptoms and 11% were severe 
depressive symptoms (Table 11.1). 
 
A significantly negative correlation was reported between the MMSE and the HADS-D score (rho=-.323 
p=.010) indicating that poorer performance on the MMSE was associated with a greater likelihood of 
reporting depressive symptoms. A similar pattern was reported with performance on the MoCA (rho=-
.255 p=.048) and subsequently cognitive impairment classification (rho=.242 p=.058).  
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Specific subsets of the MMSE that were significantly negatively correlated with HADS-D score included 
orientation to time (rho=-.294 p=.020), orientation to place (rho=-.298 p=.019), attention and calculation 
(rho=-.268 p=.035) and drawing (rho=-.285 p=.029). The orientation (rho=.-260 p=.003) and the 
visuospatial/executive (rho=.260 p=.041) subscales on the MoCA were also significantly negatively 
correlated with HADS-D scores. These results indicate that poorer performance in these categories is 
associated with more depressive symptoms. No statistically significant correlations were reported 
between the HADS-D and the Trail Making Test. 
 
Statistically significant correlations were reported between the MCQ-30 and HADS-D. Higher scores on 
the HADS-D correlated with higher total MCQ-30 scores (rho=.478, p<.001). The Cognitive Confidence and 
Uncontrollability and Danger subscales on the MCQ-30 correlated significantly with the HADS-D score in 
the case group (rho=.440 p<.001, rho=.485 p<.001 respectively). A positive correlation between HADS-D 
and Cognitive Self-consciousness was also reported (rho=.282 p=.027). An inter-correlation matrix of the 
MCQ-30 and HADS is in the case group presented in Table 11.2. No statistically significant correlations 
were reported between depressive symptoms and lesion location. 
11.5 Depression, global cognition, executive function and metacognition the control group 
In terms of HADS-D in the control group, 84% scored within the normal range, 14% were classified as 
having mild depressive symptoms, 2% with moderate symptoms and none were classified as having severe 
depressive symptoms (Table 11.1). 
 
No statistically significant correlations were reported between HADS-D scores and global cognition 
(MMSE, MoCA, cognitive impairment stratification) or global cognition subscales. In addition, no 
significant statistical correlations were reported between the HADS-D and the Trail Making Test. 
 
Significant correlations were reported between the MCQ-30 and HADS-D. Higher scores on the HADS-D 
correlated with higher total MCQ-30 scores (rho=.553, p<.001). In addition,  the Cognitive Confidence and 
Uncontrollability and Danger subscales on the MCQ-30 correlated significantly with the HADS-D score in 
the control group (rho=.609 p<.001, rho=.657 p<.001 respectively) (Table 11.2). 
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11.6 A comparison of the relationship between depressive symptoms and global cognition, executive 
function and metacognition in the case and control groups. 
Approximately twice as many stroke participants reported depressive symptoms in comparison to their 
age-matched counterparts (31% vs 16%, X2=7.248, 3df, p=.064). Though an inversely related and 
significant correlation was reported between global cognition measures and depressive symptoms in the 
case group, this pattern was not observed in the control group. Better performance on the global 
cognition measures in the case group was associated with less depressive symptoms. This was especially 
prominent in the orientation, attention and calculation and visuospatial/executive components tested. 
The statistically significant correlations that were reported between total MCQ-30 scores and HADS-D 
scores were comparable in both groups. The correlations to emerge between subscales on the MCQ-30 
and HADS-D scores in the case and control group were also comparable (Tables 11.2 and 11.3).  
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Section Twelve: Cognitive Function and Other Associated Correlates 
12.1 The relationship between cognitive function and other associated factors including the biomarker 
ApoE in a stroke population. 
Other variables examined correlated with cognitive function in the stroke sample. For example, increasing 
age ǁas assoĐiated ǁith a gƌeateƌ likelihood of ĐogŶitiǀe iŵpaiƌŵeŶt ;ƌho=.ϰϱϳ p<.ϬϬϭͿ. BahƌaiŶi͛s teŶded 
to perform poorer on global cognition measures (rho=.244 p=.026, rho=.199, p=ns) but were also more 
likely to fall into an older age group in comparison to non-Bahrainis. Subjects with higher level education 
performed better in global cognition measures (rho=.636 p<.001, rho=.600 p<.001). Subjects employed in 
non-manual type labour also tended to have better cognitive function in comparison to those who were 
in manual labour or unemployed (rho=-.244 p=.031). No statistically significant correlations were reported 
between cognitive function and gender, marital status or previous history of stroke. Better performance 
on the MMSE and MoCA was associated with more functional independence based on the Barthel Index 
(MMSE: rho=.511 p<.001, MoCA: rho=.525 p<.001). Also, a statistically significant inverse correlation was 
reported ďetǁeeŶ ΔTMT sĐoƌes aŶd Baƌthel IŶdeǆ sĐoƌes ;ƌho=-.304 p=.038) indicating that poorer 
performance on the Trail Making Test was also associated with higher levels of functional dependency. 
Therefore, higher levels of functional dependency was associated with poorer cognitive impairment. An 
inter-correlation matrix of cognitive function and performance on global cognition measures and other 
variables for the case group is presented in Table 12.1. 
 
The most common ApoE gene polymorphism in stroke sample group was E2/E3 (44%) followed by E3/E3 
(42%). No significant associations were reported between ApoE polymorphisms and stroke type, 
localization, classification or severity. No significant associations were found between cognitive 
impairment and ApoE polymorphisms (X2=2.736, 4df, p=.603) or between the MCQ-30 and ApoE 
polymorphisms (X2=6.078, 2df, p-.548) 
Table 12.1 Inter-correlation matrix of global cognitive function measures, socio-demographic characteristics and ApoE 
genotype in the case group1  
 1 2 3 4 5 6 7 8 9 10 
1. Cognitive 
impairment2 
          
2. MMSE3 score -.910**          
3. MoCA4 score -.853** .891**         
4. Gender5 .109 -.141 -.082        
5. Age .457** -
.429** 
-.484** -.010       
6. Nationality6 -.294** .244* .199 -.174 -.465**      
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*.05 < p-value (two-tailed); **p-ǀalues ч .Ϭϭ ;tǁo-tailed) 
1Spearman ranking correlations 21=no cognitive impairment, 2=mild cognitive impairment, 3=moderate cognitive impairment,4=severe cognitive 
impairment; 3Mini-mental State Exam; 4Montreal Cognitive Assessment.51=male, 2=female; 61=Bahraini, 2=Non-Bahraini,71=living alone, 2=living 
with spouse/family, 3=other; 81=illiterate, 2=primary education, 3= secondary education, 4=third level education; 91=manual, unemployed, or 
retired 2=non-manual; 101=married, 2=not married, 3=widowed, 4=divorced. 
 
12.2 The relationship between cognitive function and other associated factors including the biomarker 
ApoE in the control group. 
Education was found to be significantly associated with cognitive function in the control group. Control 
group participants with higher level education performed better in the global cognition measures (MMSE: 
rho=.570 p<.001, MoCA: rho=.357 p=.008). Subjects employed in non-manual type labour also tended to 
have better cognitive function in comparison to those who were in manual labour or unemployed (MMSE: 
rho=.297 p=.028, MoCA: rho=240 p=ns). Patients who were living with family, also tended to have better 
performance in the MMSE and MoCA (rho=.374 p=.001, rho=.248 p=.030 respectively). Older patients also 
tended to perform poorer on the MoCA and MMSE (rho=-.274 p=.043, rho=-.261 p=ns respectively). No 
statistically significant correlations were reported between cognitive function and gender, living status or 
marital status. An inter-correlation matrix of cognitive function and performance on global cognition 
measures and other variables for the case group is presented in Table 12.2. 
 
The most common ApoE gene polymorphism in control sample group was E2/E3 (62.5%) followed by 
E2/E4 (12.5%) and E3/E3 (12.5%). No significant associations were found between cognitive impairment 
and ApoE polymorphisms (X2=3.473, 4df, p=.482) or between the MCQ-30 and ApoE polymorphisms 
(X2=5.605, 4df, p=.231). 
Table 12.2 Inter-correlation matrix of global cognitive function measures, socio-demographic characteristics and ApoE 
genotype in the control group1  
7. Living status7 -.282* .374** .248* .301** -.167 .130     
8. Education8 -.647** .636** .600** -.279** -.455** .345** .057    
9. Occupation9 -.244* .165 .140 .181 .479** -.462** -.174 -.180   
10. Marital status10 .217 -.257* -.151 .397** .193 -.077 -.092 -.129 .096  
11. History of 
previous stroke 
-.089 .045 .073 .056 -.183 .173 .019 -.019 -.103 -.060 
 1 2 3 4 5 6 7 8 9 10 
1. Cognitive 
impairment2 
          
2. MMSE3 score -.733**          
3. MoCA4 score -.613** .630**         
4. Gender5 .249 -.271* -.086        
5. Age .140 -.261 -.274* -.623**       
6. Nationality6 -.086 .214 .097 -.067 -.088      
7. Living status7 -.086 .179 -.278 -.067 -.078 .295*     
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*.05 < p-value (two-tailed); **p-ǀalues ч .Ϭϭ ;tǁo-tailed) 
1Spearman ranking correlations 21=no cognitive impairment, 2=mild cognitive impairment, 3=moderate cognitive impairment,4=severe cognitive 
impairment; 3Mini-mental State Exam; 4Montreal Cognitive Assessment.51=male, 2=female; 61=Bahraini, 2=Non-Bahraini,71=living alone, 2=living 
with spouse/family, 3=other; 81=illiterate, 2=primary education, 3= secondary education, 4=third level education; 91=manual, 2=non-manual 
3=unemployed/retired; 101=married, 2=not married, 3=widowed, 4=divorced; 11Apolipoprotein E; 1=E2/E2, 2=E2/E3, 3=E2/E4,4=E3/E3, 5=E3/E4, 
6=E4/E4. 
 
12.3 A comparison of the relationship between cognitive function and other associated factors 
between the case and control groups. 
Although similar patterns and correlations were seen between the case group and the control group with 
age, education and occupation emerging as the prominent variables correlating with cognitive function, 
stronger and more statistically significant correlations between cognitive function and these variables 
were seen in the case group rather than the control group (Tables 12.1 and 12.2). 
 
The most common ApoE gene polymorphism in total sample group was E2/E3 (53%) followed by E3/E3 
(28%) and E3/E4 (12%). The E3/E3 polymorphism was more prevalent in the stroke group than in the 
control group (42% vs 12.5%, X2=16.84, 4df, p=.002). A table of the distribution of ApoE polymorphisms 
in both the case and control groups is presented in Table 12.3. 
 
Table 12.3 Comparison of ApoE1 polymorphisms between the case group (n=50) and the control group (n=48)* 
Case group (stroke 
patients) 
Control group Statistics 
E2/E2  0 (0) 1 (2.1) X2=16.84, 4df, p=.002 
E2/E3 22 (44.0) 30 (62.5)  
E2/E4  0 (0) 6 (12.5)  
E3/E3 21 (42.0) 6 (12.5)  
E3/E4 7 (14.0) 5 (10.4)  
1Apolipoprotein E 
  
8. Education8 -.329* .570** .357** .128 -.472** .190 .106    
9. Occupation9 -.189 .297* .240 .179 .127 -.316* -.081 -.311*   
10. Marital 
status10 
-.070 .109 -.057 .224 -.297* -.052 .131 .104 .010  
11. Smoker .136 -.197 -.123 .252 -.137 -.389** -.149 .078 .076 .083 
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Section Thirteen: Multivariate Analysis  
13.1 Multivariate Analysis Examining Associations of Cognitive Impairment 
In order to further investigate factors that are associated with cognitive impairment logistic regression 
was carried out in a number of discrete variables. A statistically significant correlation at the bivariate level 
between cognition impairment and stroke severity was reported and was therefore included in the 
analysis. Model 1 also included the HADS and MCQ-30 scores. Age and education also emerged as 
significant correlations at the bivariate level and were therefore added in Model 2 of the analysis to 
further delineate associations in relation to socio-demographic variables (see Table 13.1). Logistic 
regression models were also conducted in the control group (Table 13.2). For the purpose of the analysis, 
cognitive impairment was dichotomised as either ͚Ŷo ĐogŶitiǀe iŵpaiƌŵeŶt͛ oƌ ͚ĐogŶitiǀe iŵpaiƌŵeŶt͛. 
Education was also dichotomised with illiteracy and primary level education in one group and secondary 
and tertiary level education in another. 
 
Based on the logistic regression Model 2 for the stroke group, higher stroke severity (based on NIHSS) was 
associated with a greater likelihood of cognitive impairment (OR=1.3, p=.027). Stroke severity emerged 
as the most prominent variable associated with cognitive impairment after adjustment for education and 
age. The HADS score and MCQ-30 did not emerge as statistically significant predictors of cognitive 
impairment in either the case group or the control group. 
 
Table 13.1. Binary logistic regression models for cognitive impairment in the stroke group 
  Model 1   Model 2 
af   Independent variable  B1 S.E2 p3 OR4 95% CI5 B S.E p OR 95% CI 
          Constant  -3.429 1.760 .051 .03  -4.567 2.654 .085 .01  
           NIH6 Stroke Scale  .315 .102 .002 1.37 1.12 - 1.67 .263 .119 .027 1.30 1.03 - 1.66 
                  HADS7-Depression  .230 .103 .025 1.26 1.03 - 1.54 .214 .113 .059 1.24 .99 - 1.55 
                   HADS-Anxiety  -.248 .114 .030 .78 .62 - .98 -.262 .132 .048 .77 .59 - 1.00 
          MCQ-308  .028 .028 .304 1.03 .98 - 1.09 .023 .033 .482 1.02 .96 - 1.09 
Age       .020 .838 .597 1.02 .95 - 1.10 
           Education9       1.989 2.654 .018 7.31 1.42 - 37.77 
1Regression coefficient;2Standard error;3two-tailed test;4Odds ratio;595% confidence interval;6National Institutes of Health;7Hospital Anxiety 
and Depression Scale;8Metacognitive Questionnaire-30;9Illiteracy or primary level education 
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Table 13.2. Binary logistic regression models for cognitive impairment in the control group 
  Model 1   Model 2 
af   Independent variable  B1 S.E2 p3 OR4 95% CI5 B S.E p OR 95% CI 
          Constant  -1.368 2.082 .511 .511  -6.557 5.310 .217 <.01  
                  HADS6-Depression  .105 .183 .565 1.11 .77 - 1.59 .124 .207 .547 1.13 .76 - 1.70 
                   HADS-Anxiety  .229 .148 .122 1.26 .94 - 1.68 .265 .212 .210 1.30 .86 - 1.98 
          MCQ-307  -.308 .041 .357 .96 .89 -1.04  -.031 .047 .518 .97 .88 - 1.06 
Age       .066 .083 .424 1.07 .91 - 1.26 
           Education8       1.353 1.247 .278 3.87 .34 - 44.59 
1Regression coefficient;2Standard error;3two-tailed test;4Odds ratio;595% confidence interval;6Hospital Anxiety and Depression 
Scale;7Metacognitive Questionnaire-30;8Illiteracy or primary level education 
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Section Fourteen: Summary of results 
  The control group participants have proportional risk factors of hypertension, diabetes, 
hyperlipidaemia, and atrial fibrillation to the case group participants. Higher rates of smoking 
among the case group was reported. 
 In comparison to their control group counterparts, the case group participants had higher rates of 
illiteracy and lower education (47% vs 26%) and higher rates of manual labour (31% vs 11%). 
 A greater number of the control group participants were living with family or friends in comparison 
to the case group (95% vs 70%). Similarly, a greater number of the control group participants were 
married in comparison to the case group (94% vs 72%) with a larger proportion of the case group 
being widowed. 
 The average MMSE score in the stroke participants was 23.99 ± 4.85 with 41% classified as having 
normal performance and 17%, 33%, and 9% falling into the categories of mild/early, moderate and 
severe cognitive impairment respectively.  
 The average MoCA score in the stroke participants was 20.32 ± 6.47 with 25% classified as having 
normal performance and 43%, 23%, and 9% falling into the categories of mild, moderate or severe 
cognitive impairment respectively. 
 The aǀeƌage ΔTMT sĐoƌe iŶ stƌoke paƌtiĐipaŶts ǁas ϭϰϬ ± 129 seconds with 30% classified as having 
good executive function, 45% with intermediate executive function and 25% with poor executive 
function.  
 Stratifying cognitive function with the above assessment tools classified 52% of the stroke 
participants with no cognitive vascular impairment, 28% with mild vascular cognitive impairment 
and 20% with moderate cognitive impairment. 
 The stroke participants overall performed poorer in the MMSE, MoCA and TMT in comparison to 
the control group. 
 Greater stroke severity was more significantly associated with worse overall cognitive impairment.  
 Haemorrhagic strokes were more likely to be associated with poorer cognitive function. 
 No statistically significant correlations were reported between stroke location and global cognitive 
function or executive function. 
 Poorer performance on global cognition was correlated with executive dysfunction and more 
functional dependency.  
94 
 
 No statistically significant correlations were reported between stroke location, type and/or severity 
and total metacognition scores. 
 Stroke patients with more severe strokes reported lower levels of cognitive self-consciousness, 
expressing that they are less likely to be constantly aware of their thinking, less likely to monitor 
their thoughts, and less likely to constantly examine their thoughts.  
 Stroke patients with higher levels of cognitive impairment were more also likely to report lower 
cognitive self-consciousness levels. This finding was not observed in the control group. 
 No statistically significant relationships between executive function and metacognition were 
observed in either the case group or the control group. 
 In the stroke group, 48% were able to recall all 3 objects on the MMSE, 28% were able to recall two 
objects and 13% and 11% were able to recall one object and no object respectively. This classifies 
77.5% of the case group classified as having a good performance and 23.5% would be classified as 
having poor performance. 
 In the case group, only 11% of the case group were able to recall all five words on the MoCA, with 
15% recalling four words, 12% recalling recall two and three words each, 17% recalling one word 
and 32% unable to recall any words. This classifies 38% as having good performance and 62% would 
be classified as having poor performance. 
 The stroke group performed worse in both the recall component of the MMSE (77.5% vs 98%) and 
the delayed recall component of the MoCA (38% vs 60%) than their control group counterparts. 
 Stroke participants who performed poorly in the memory components of cognitive testing and had 
higher stroke severity tended to subjectively report higher confidence in their memory skills.  
 No statistically significant correlations were reported between HADS Anxiety scores and global 
cognition or executive function. 
 Cognitive impairment was associated with a greater likelihood of reporting depressive symptoms in 
the case group, this finding was not observed in the control group. 
 Approximately twice as many stroke participants reported depressive symptoms in comparison to 
their age-matched counterparts (31% vs 16%). 
 Statistically significant correlations were reported between the MCQ-30 and the anxiety and 
depression scores on the HADS. 
 Age, education and occupation emerged as the variables correlating with cognitive function in both 
the case group and the control group. 
 No significant associations were found between cognitive impairment and ApoE polymorphisms. 
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Chapter 4: Discussion 
 
Introduction 
The purpose of this study was to examine global cognitive function, executive function and metacognition 
in a stroke population and to determine any significant relationships amongst these three components of 
cognition with a specific focus on memory impairments. The relationship of these components of 
cognition in relation to depression and anxiety was also examined. In addition, any relationships between 
stroke type, localization, severity and other associated correlates were also examined. This chapter aims 
to discuss the study findings in comparison to the current available literature.  
Section Fifteen: Socio-demographic Profiles and Clinical Characteristics of the Stroke Population 
Similar demographic trends were seen in the stroke population recruited for this study in comparison to 
the latest literature on stroke epidemiology in Bahrain.(17) For example, gender and age demographics 
were comparable with a higher proportion of males than females and a mean age at admission of 
approximately 59-60 years. Similar trends were also observed in terms of living situation with the majority 
of the stroke population living amongst family or friends prior to admission. The major co-morbidities to 
emerge and their frequencies in the study also matched the available epidemiological data. This included 
hypertension, diabetes mellitus, hyperlipidemia and atrial fibrillation. This indicates that the stroke 
sample group was representative of the stroke population in Bahrain. 
However, some differences did emerge. For example, ischemic strokes were represented in a larger 
proportion in this study in comparison to prior epidemiological figures previously published on stroke in 
Bahrain. A possible explanation for this might be because haemorrhagic stroke patients usually present 
with a greater stroke severity or with decreased levels of consciousness and therefore, patients admitted 
with haemorrhagic strokes during the time of recruitment may have been ineligible to participate in the 
study. Another difference noted was that there was greater proportion of non-Bahrainis recruited relative 
to the proportion of non-Bahraini nationals admitted with stroke in previous demographic data published 
in the literature.(17) Stroke classification using the OCSP or the TOAST classifications of stroke and data 
in relation to marital status, education or employment prior to the current study was unavailable for 
comparison. 
When compaƌiŶg the deŵogƌaphiĐ pƌofile of this studǇ͛s saŵple gƌoup ǁith the epidemiological trends of 
stroke worldwide, this population group is approximately 10 to 15 years younger than its Western 
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comparators (18-20) with similar mean ages in comparison to countries in the developing world.(18, 251) 
In relation to previous data reported on stroke co-morbidities worldwide, the population in this study had 
higher rates of diabetes, hypertension, hyperlipidemia, and TIA or a previous history of stroke, and had 
similar rates of cardiovascular disease and lower rates of atrial fibrillation.(18-20) All of these factors 
reemphasize the possibility of seeing a continuing rise in the incidence of stroke in the region.(17) The 
population study sample group had a greater proportion of males than females with stroke in contrast to 
worldwide epidemiological data.(18, 20, 252) Although rates of strokes subtypes differed from previous 
epidemiological data published in Bahrain with a greater percentage of ischaemic strokes reported in this 
study, rates were similar in comparison to data from the United States and Europe.(253, 254) 
When examining the demographic and clinical characteristics of the case group in comparison to the age-
matched control group, the mean age was comparable in both groups. However, men were represented 
in a larger proportion in the case group and Bahrainis were represented in a larger proportion in the 
control group. The greater proportion of men may indicate an increased risk of stroke in males in the 
Bahraini population. However, other possible factors for both these findings may be the demographic 
characteristics of frequent attenders to local health centres. A greater proportion of Bahrainis and a 
greater proportion of women may be utilizing the health centres in which control group participants were 
recruited. Rates of diabetes, hypertension, hyperlipidemia and cardiovascular disease between the case 
and control groups were comparable with smoking as the only statistically significant risk factor to emerge 
as a difference where there were higher rates of smoking in the case group. This may also be due to the 
fact that individuals with chronic disease are more likely to be local health centre utilizers and attendees 
in comparison to the general population. However, another rationale may be that individuals not affected 
by stroke have proportional risk factors and a similar likelihood of developing a stroke. This possibility, in 
line with an ageing population,(17) indicates that Bahrain is likely to see a continuing rise and increase 
burden of stroke. 
In comparison to the control group, the case group had overall lower socio-economic status, indicated by 
higher illiteracy rates and higher rates of manual labour occupations. This finding is in line with previous 
studies that also report an association between stroke and low socio-economic status.(87, 255) The 
control group were also more likely to be living amongst family or friends and more likely to be married 
instead of widowed, divorced or never married. This indicates that prior to the stroke, the case group had 
less social support than their control group counterparts. High levels of family support or other social 
support are associated with a faster recovery and more extensive improvement of functional status after 
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stroke.(256, 257) Social support is a major prognostic factor in recovery after stroke and patients with low 
levels of social support are at risk for a worse outcome.(256, 257) This indicates that our stroke population 
are at particular risk for poorer outcomes due to a less likelihood of having good social support.(130, 256, 
257) 
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Section Sixteen: Cognition in the Stroke Population 
16.1 The cognitive profile of a stroke population  
Cognitive impairment was more prevalent in the stroke sample group in comparison to the case group 
with approximately 48% of the stroke group having some degree of cognitive impairment and only 11% 
of the control group being categorized as having mild cognitive impairment with the remaining sample 
having normal function. The mean average scores of both the MMSE and MoCA fell into the mild cognitive 
impairment category in the stroke group and in the normal/no cognitive impairment category in the 
control group. This indicates that cognitive impairment occurs more frequently in patients with stroke in 
the Bahraini population.  
 
The average MMSE score in the stroke group was 23.99 ± 4.85. Stratification based on total scores 
classified 41% of the sample with normal performance and 17%, 33%, and 9% with mild/early, moderate 
and severe cognitive impairment respectively. Due to the wide range of sample sizes and variation in 
methodology examining performance on the MMSE in different studies,(83, 258, 259) comparison of 
performance on MMSE between the case group and other stroke sample groups is difficult with a wide 
range performance scores and stratifications reported. No prior studies on cognitive performance post-
stroke in Bahrain have been conducted. A study by Khedr et al. on the prevalence and risk factors of stroke 
in a community in Egypt,(260) conducted the MMSE on 57 stroke patients reporting a mean score of 25 ± 
3.9 similar to the findings in this study. However, in comparison to the Kedhr et al. study, the stroke sample 
in this study had had greater proportions in the mild, moderate or severe cognitive impairment categories 
in comparison to those individuals with normal cognitive performance scores. 
 
Similar interpretations may be made regarding the mean MoCA score and variation and sample size, 
methodology and range of performance scores in other studies.(261, 262) The average score in the MoCA 
in the case group was 20.32 ± 6.47. Based on the MOCA scoring system, 25% of the case group was 
classified as having normal performance whereas 43%, 23%, and 9% had fell into the categories of mild, 
moderate or severe cognitive impairment respectively. 
 
Interestingly when stratification of cognitive function between the MMSE and MoCA is compared in the 
case group (refer to Table 8.1, Section 8), a higher proportion of the case group population is classified as 
having mild cognitive impairment in the MoCA when compared to the MMSE (43% vs 17%), with a lower 
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percentage of case group participants being classified as having normal cognitive function in the MoCA 
than the MMSE (25% vs 41%). This may indicate that the MoCA was a more sensitive tool in detecting 
early/mild cognitive impairment in this stroke cohort. This finding supports the current evidence that 
indicates that the MoCA is more sensitive than the MMSE in screening for cognitive impairment after 
stroke and that it is designed to be more sensitive to other deficits overlooked in MMSE assessment such 
as visuospatial and executive function especially in individuals with milder stroke severity.(261-267) 
 
Factors to consider that may have influenced global cognition measures include the applicability of the 
MMSE and MoCA in the context of limited education and cultural differences.(268, 269) Both of these 
assessment tools, in addition to the majority of neuropsychological assessment tools developed, have 
been designed in Europe and North America in the English language and are geared towards Western 
culture.(270) Translated versions of these tools that were initially designed for use in developed countries 
require modification or substitution of some of the items with culturally relevant counterparts and 
validation for use in the population in which they are used.(268) The MMSE is the most widely validated 
quantitative assessment tool for screening of cognitive impairment.(271) However, age, education, 
language, as well as ethnicity and cultural differences have been reported to influence performance 
outcome on the MMSE.(86, 268, 270, 272, 273) Therefore, the prevalence of cognitive impairment may 
be overestimated in populations with high rates of illiteracy in an elderly population leading to 
inappropriate referral or diagnosis.(268, 274) This may be the case in the Middle East, and in this present 
study, in which illiteracy rates among older people were high.(275) 
 
Despite the fact that the MoCA is available and has been validated in multiple languages, some items used 
in parts of the assessment such as the word lists and picture naming, require adaptation before they are 
applicable to other cultures.(276) Suggestions have been proposed in order to eliminate the cultural and 
education bias of these tools. Some validation studies have adapted items on these cognitive assessment 
tools to suit their local culture.(268, 270, 276) However, validated diagnostic tools for dementia in the 
Arabic language are lacking.(275) Rajeh et al. proposed different cut-off scores according to the 
educational status of the participants.(270) However, such recommendations lead to differences in test 
scores between countries with different cut-off scores utilized for the classification of dementia and 
cognitive impairment. Phung et al. proposed the use of the 10/66 Dementia Research Group diagnostic 
assessment.(275) This eliminates the ability to compare performance scores across different regions 
worldwide. A review of cognitive assessment tools used in Asia conducted by Roshashlina et al. suggested 
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the development of new culturally and educationally sensitive instruments to suit the needs to the 
surveyed population.(268) Although the development of culturally and educationally sensitive tools 
tailored to the population examined provide more accurate data, this makes comparisons between 
different population groups across different geographical regions more difficult. 
 
When examining executive function in the stroke sample group based on performance in the Trail Making 
Test, 30% had good executive function, 45% had intermediate executive function and 25% had poor 
executive function. The case group performed poorer in the Trail Making Test in comparison to the control 
group with only 2% of the control group displaying poor executive function and 31% and 67% having 
intermediate and good executive function respectively. A wide range of performance scores in the TMT 
was expected based on the nature of the assessment tool, but it is apparent that executive dysfunction 
was higher among the stroke population in comparison to the control group. This is in line with current 
literature linking executive dysfunction with stroke.(119) As executive function involves processing speed, 
mental flexibility and working memory,(119, 228) screening for executive function deficits is an important 
step that would then facilitate access to compensatory rehabilitation techniques for patients affected with 
executive dysfunction to allow them to obtain maximal benefits from early therapies.(119) 
 
Interestingly, reports of post-stroke cognitive impairment prevalence ranges from 20% to 80%.(277-280) 
This wide range may be due to differences in applying the diagnostic criteria of cognitive impairment 
suggesting a need to unify this criteria.(277) Nevertheless, despite the high prevalence of post-stroke 
cognitive impairment, some evidence supports the notion that some criteria may underestimate the 
frequency of cognitive decline and dementia in stroke survivors.(265, 277, 281) 
16.2 Stroke type and severity in relation to global cognitive and executive function 
Higher stroke severity, indicated by a greater NIHSS score, was significantly associated with lower MMSE 
and MoCA scores and worse overall cognitive impairment. This finding is supported by previous data in 
the literature which has shown the NIHSS to be a sensitive predictor for cognitive impairment in 
stroke.(282) In addition, previous literature has repeatedly shown that functional impairment and 
dependent living after discharge is greater with cognitive impairment (94) with stroke severity and 
executive dysfunction being major contributing factors to poor functional outcome.(283) This indicates 
that cognitive impairment plays a major role and impacts functional consequences and independent living 
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after discharge and therefore, rehabilitative intervention should take into account the cognitive 
consequences after stroke.(70)  
Correlations between lesion location and cognitive impairment post-stroke has previously been reported 
in the literature. For example, Mehool et al. identified cognitive impairment as being independently 
associated more with left hemispheric strokes.(284) Other studies have also suggested a predilection for 
cognitive impairment with left hemispheric strokes, particularly with infarctions in left anterior and 
posterior cerebral artery territories and major cortical syndromes.(94, 285) However in the present study, 
no statistical significant correlations were reported between stroke location and either global cognitive 
function or executive function were found. 
Statistically significant correlations were found between stroke type and global cognitive function. 
Haemorrhagic strokes were more likely to be associated with poorer performance on the MMSE and 
MoCA and therefore a greater level of cognitive impairment. This is another finding that is in line with the 
current literature, as haemorrhagic stroke is an independent predictor of neurologic outcome that nearly 
doubles the odds of long-term disability (286) and so is likely to be associated with a poorer cognitive 
outcome. Previous epidemiological data on stroke subtypes in Bahrain has shown that the proportion of 
intracerebral haemorrhage is relatively higher in comparison to other parts of the world, particularly the 
West.(16, 17, 254) The higher incidence of haemorrhagic strokes in the region therefore suggests an 
additional increased associated likelihood of cognitive impairment in Bahrain as a result. 
16.3 The association between global cognition and executive function in a stroke population  
In the stroke group, poorer performance on the MMSE and MoCA, measures of global cognition, 
correlated with poorer performance in the TMT, a measure of executive function. Despite statistically 
significant correlations emerging between performance on the MMSE and MoCA and the TMT in the case 
group, indicating a relationship between global cognition and executive function, this trend was not 
observed in the control group. This could be because only 11% of the control group were classified as 
having mild cognitive function with no participants showing moderate or severe cognitive function and 
therefore stronger correlations emerged in the case group. Another possibility for this finding could be 
that stroke tends to have a larger detrimental impact on executive function and attention than other 
domains.(119, 287, 288) This finding is supported by previous studies examining the impact of stroke on 
specific cognitive domains. For example, in a community-based study by Srikanth et al. comparing stroke 
patients with a control group, stroke patients were more frequently impaired than the control group in 
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executive function, attention and spatial ability but were not more impaired in other measures of global 
cognitive function such as orientation.(289, 290) Some studies reported that executive function difficulties 
can impact up to 75% of patients after stroke.(73) Also, the Trail Making Test measures speed of 
information processing and cognitive slowing which are frequently exhibited as a complaint post-
stroke.(291) In both groups a significant trend was observed between the total MoCA score and Trail A, a 
measure of cognitive processing speed. A possible explanation for this finding is that testing for executive 
function is included in the MoCA but not the MMSE.  
 
Executive dysfunction greatly impacts activities of daily living.  This was indicated in the present study as 
stroke patients with poorer performance on the Trail Making Test tended to have lower Barthel Index 
scores representing more functional dependency. Other studies support this finding.(73, 292) These 
results suggest that screening for executive dysfunction is imperative to help identify stroke patients who 
are at risk for functional impairment in order to provide adequate and early cognitive rehabilitation 
therapy with the aim of improving their disability and facilitating their return to functional capacity. 
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Section Seventeen: Metacognition in the Stroke Population 
The Cognitive Self-consciousness subscale in the MCQ-30 emerged as the prominent subscale correlating 
with global cognition measures in the stroke population. Cognitive Self-consciousness is a subscale 
measuring how closely individuals pay attention to their thoughts and how aware of them they are.(293) 
Higher levels in Cognitive Self-consciousness indicates that the individual subjectively reports that they 
are more constantly aware of their thinking, pay close attention to the way their mind works, constantly 
examine and monitor their thoughts and are aware of the way their mind works when they are thinking 
through a problem. The study findings suggest that stroke patients with higher levels of cognitive 
impairment were more likely to report lower cognitive self-consciousness levels, indicating an impairment 
in this feature of metacognition. This finding was more strongly observed in the stroke population in 
comparison to the case group. This subscale also correlated with specific domains such as attention and 
calculation, abstraction and orientation. Impairment in this domain was also significantly associated with 
higher levels of stroke severity. 
 
Limited research has been done regarding the relationship between cognitive function and impaired self-
awareness after stroke.(178, 180, 182, 184) Some studies have evaluated this relationship in other 
neurological disorders such as multiple sclerosis, PaƌkiŶsoŶ͛s disease, schizophrenia and traumatic brain 
injury.(163, 294-297) For example, Goverover et al. examined twenty-six patients with multiple sclerosis 
usiŶg the patieŶts͛ aŶd iŶfoƌŵaŶts͛ FƌoŶtal “Ǉsteŵs Behaǀiouƌ “Đale ;Fƌ“BeͿ aŶd ĐoŶĐluded that the leǀel 
of self-awareness of neurobehavioral symptoms is related to the level of cognitive impairment.(294) 
Studies of subjective cognitive complaints in an older population free of neurological disease have also 
been conducted. These studies suggest that subjective cognitive complaints may be an early indicator of 
Alzheiŵeƌ͛s disease oƌ dementia pathology prior to detectable significant objective impairment (298) and 
are related to the risk of future cognitive decline.(299) However, these studies also conclude that the 
determinants of subjective cognitive complaints are complex and have a strong relationship to 
psychological factors.(299, 300) Further research needs to be conducted to further support these findings 
especially after a vascular insult such as stroke. Moreover, using unified measures to assess cognitive 
function in line with metacognition is also imperative. 
 
Despite the fact that this current study could not validate the MCQ-30 constructs with objective cognitive 
assessments, evaluating metacognitive deficits is a valuable and necessary assessment post-stroke 
because reduced levels of self-awareness in association with cognitive impairment can have great 
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implications for the rehabilitative stage post-stroke.(178, 180, 182, 184) A lack of cognitive self-
consciousness could impede aŶ iŶdiǀidual͛s aďilitǇ to ƌeĐogŶize theiƌ defiĐits and cause them to 
overestimate their level of function.(201) This will lead to engagement in activities that are beyond their 
capabilities, the setting of unrealistic performance goals and failure in utilizing adaptive strategies that 
compensate for their deficits.(156, 157) Therefore, metacognitive deficits need to be primarily addressed 
in order for patients to reach their potential for independent functioning and improve their cognitive 
abilities. Assessments only evaluating cognitive impairment as an objective primary measure might fail to 
detect and incorporate the impact of metacognition on the rehabilitative process and hinder maximal 
progress. Some studies have suggested that treatments focused on improving metacognitive processes in 
acquired brain injury could lead to better functional and rehabilitation outcomes (206, 209) and further 
evaluation of the outcomes of metacognitive rehabilitative therapy needs to be addressed. There have 
been some descriptions of the intervention approaches utilized to manage metacognitive deficits in 
patients with acquired brain injury.(181) However, a critical debate about the value, implications and most 
suitable types of interventions to utilize is currently lacking.(181) A review by Ownsworth and McFarland 
(181) identified a variety of metacognitive rehabilitative approaches including compensatory facilitatory 
approaches, direct feedback, behavioural intervention, cognitive therapy and psychotherapy. The authors 
concluded that the best intervention for any particular individual depends upon the factors which 
contribute to the disorder of unawareness.(181) Further research on tailored metacognitive therapeutic 
interventions for stroke individuals alongside the factors contributing to their deficits is an area that needs 
to be addressed and further evaluated. 
 
A few other key clinical issues need to be considered regarding rehabilitation for individuals with 
metacognitive deficits. These include how metacognition is conceptualized and determined and the 
impact of metacognitive deficits and the possible adverse effects of targeting them. A unified and 
standardized approach is necessary for the conceptualization of metacognition and the subsequent 
determination of metacognitive deficits. Due to the multifaceted nature of the concept, a 
multidimensional approach for measuring metacognition needs to be employed both in research and in 
clinical practice as indications of metacognition based on some available measures may only be a partial 
reflection of the phenomenon in any given individual.(206) The current study findings revealed that better 
metacognition and awareness predicts anxiety and depression. However, depression and anxiety may 
negatively impact the rehabilitative process. This is a critical treatment issue that relates to the possible 
adverse effect of targeting metacognitive deficits. Some authors have argued that in some circumstances 
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individuals who regain their metacognitive function may develop heightened emotional distress and that 
this can have a detrimental impact on their functional outcome (301) especially early on in the adjustment 
process (302). Other authors have also suggested that individuals can achieve behavioural gains without 
an associated improvement in metacognitive deficits.(303) Despite this, other researchers suggest that 
persisting metacognitive deficits pose a greater risk of long-term emotional dysfunction due to their 
unrealistic expectations of recovery, lack of success in particular pursuits and inability to understand the 
reason for certain restrictions imposed upon them.(163) A review by Ownsworth et al. (206) revealed that 
in the majority of studies that addressed this issue, the process of improving metacognition in the context 
of rehabilitation was not necessarily associated with emotional distress, anxiety or depression thus 
supporting the value of therapeutic intervention. Moreover, the risk of emotional distress is relatively low 
in the context of positive social support for the individual and adaptive coping strategies.(206) 
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Section Eighteen: Memory and Metamemory in the Stroke Population 
18.1 Memory performance in the stroke population 
The stroke population performed poorer in the memory components of both the MoCA and the MMSE in 
comparison to the case group. Memory problems may have a profound impact post-stroke and are usually 
a major concern for patients (25, 47) with stroke survivors reporting memory complaints years after the 
stroke.(128, 129) A systematic review examining memory function post-stroke reported that the 
prevalence of post-stroke memory dysfunction varied from 23% to 55% at 3 months after the acute 
event.(123) As opposed to some previous studies that reported a relation between post-stroke memory 
function and stroke characteristics, such as location of the infarct,(280, 291, 304-306) no such findings 
were seen in our stroke sample. For example, several studies in the literature reported lower post-stroke 
memory function in left-sided stroke compared with right hemispheric stroke,(280, 307) but this finding 
was not seen in our sample group. In our study, 43% of the stroke sample comprised of right hemispheric 
strokes in comparison to only 29% of left hemispheric strokes with the remaining sample comprising of 
posterior circulation infarcts and it is possible that a larger sample size would have been necessary for a 
correlation to be delineated.  
 
Interestingly, 48% of the case group were able to identify all 3 objects in the MMSE but only 11% were 
able to recall all 5 objects of the MoCA. After stratifying performance on the recall components of both 
cognitive assessments, 77.5% of the case group were classified as having good performance based on the 
recall component of the MMSE, but only 38% of the same group would be classified as having good 
performance on the MoCA. This finding reiterates the evidence in support of the MoCA being a more 
sensitive screening tool for mild cognitive impairment.(261-267, 308) It is also important to note that the 
MoCA item recall could have included more culturally sensitive word lists as part of the recall assessment.  
18.2 Objective recall as a function of memory and metacognition in the stroke population 
Stroke patients with more severe scores, based on higher NIHSS scores, tended to perform worse in the 
recall components of the MMSE and MoCA. Despite this, they also tended to report higher levels of 
cognitive confidence on the Metacognitive Questionnaire-30, indicating that they perceive themselves to 
have good memory skills and trust their memory. This indicates an impairment in a component of 
metamemory in the metacognitive domain. Just as global metacognition is an important component in 
guiding the rehabilitative process and predicting improvement in cognitive outcome (163, 183, 185, 206), 
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metamemory is an important component of memory performance. If individuals with poor memory have 
erroneous perceptions of their memory skills, they will lack the motivation needed to address their deficits 
and this impedes their recovery. Metamemory, and more specifically memory self-efficacy, which is 
defiŶed as oŶe͛s seŶse of ŵasteƌǇ aŶd ĐapaďilitǇ to use ŵeŵoƌǇ effeĐtiǀelǇ,(127, 128) is what has mostly 
been reported in the neuropsychological literature. However, metamemory and its relation to memory 
has not been frequently studied in populations with neurological impairments, especially stroke.(127) 
Studies on traumatic brain injury patients have shown that this population tends to overestimate memory 
performance in comparison to control group populations which underestimate their performance.(309) 
The few studies that have examined this relationship in stroke reported that subject and objective 
memory performances are related.(127, 161) Studies exploring the relationship between stroke severity 
and metamemory are scarce. 
Approximately one in three stroke survivors will suffer from memory complaints causing a detriment to 
their quality of life.(291) Involving metamemory in memory training has been shown to improve memory 
healthy elderly adults (310) and in cognitively impaired nursing home residents.(311) By incorporating 
metamemory training into rehabilitative memory training programs, memory complaints may be reduced 
in stroke. Metamemory components are related to quality of life, depressive symptoms, coping, activity 
level and neurological disability.(312, 313) Therefore, interventions tailoring memory in conjunction with 
effective and efficient rehabilitative programmes addressing awareness of memory capacity, memory 
self-efficacy and subjective memory complaints are vitally needed in improving this outcome and in turn 
patieŶts͛ ƋualitǇ of life. 
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Section Nineteen: Anxiety and Depression in the Stroke Population 
19.1 Anxiety symptoms and global cognitive, executive function, and metacognition in a stroke 
population 
Twenty-nine percent of the stroke sample group had some anxiety symptoms ranging from mild to severe. 
This finding is in line with the current literature in which it is estimated that approximately 25% of stroke 
survivors suffer from anxiety post-stroke.(131, 145) Though these figures are the result of assessment via 
use of a rating scale and not through formal assessment using DSM criteria, studies have shown that 
people with subthreshold symptoms assessed through rating scales such as the HADS and those diagnosed 
with anxiety disorders are equally affected by the anxiety.(145, 314) Stroke patients commonly report 
anxiety related to recurrent stroke, falls or return to baseline activities of daily living.(145) These fears 
would unlikely constitute a diagnosis of anxiety but greatly impact quality of life and daily living.(145, 315, 
316) 
 
No statistically significant correlations were reported between HADS Anxiety scores and global cognition 
(MMSE, MoCA, cognitive impairment stratification) or subscales of global cognition measures in the case 
group. No statistically significant correlations were reported between the HADS-A and executive function 
(Trail Making Test) either. However, statistically significant correlations were reported between the MCQ-
30 and HADS-A. Higher scores on the HADS-A correlated with higher total MCQ-30 scores. More 
specifically, the Cognitive Confidence, Cognitive Self-consciousness, and Uncontrollability and Danger 
subscales on the MCQ-30 correlated significantly with the HADS-A score. This indicates that the 
Metacognitive Questionnaire- 30 can be used as a predictor for anxiety post-stroke.  
 
It has been suggested that anxiety is frequently undiagnosed in stroke patients and can have a detrimental 
impact on recovery after the acute event.(145) Stroke survivors suffering from anxiety tend to be more 
dependent on others in carrying out activities of daily living and have a reduced quality of life.(145, 317) 
These factors are likely to exacerbate cognitive impairment and hinder the rehabilitative process as the 
individual may find it difficult to engage in treatment activities.(7, 146) Limited previous research has been 
done examining the correlations between anxiety post-stroke, its risk factors, and other variables such as 
timing of onset and overall outcome.(145, 318, 319) There also remains a lack of consensus regarding 
management strategies tackling anxiety post-stroke.(145, 320) Given the high prevalence rates of anxiety 
after stroke, more attention should be given to this finding in addition to greater understanding of its 
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iŵpaĐt oŶ stƌoke suƌǀiǀoƌs͛ ƋualitǇ of life aŶd foĐus oŶ pƌeǀeŶtatiǀe aŶd ƌehaďilitatiǀe strategies should 
be a priority. 
19.2 Depressive symptoms and global cognition, executive function and metacognition in a stroke 
population 
Thirty-one percent of the stroke sample group reported depressive symptoms ranging from mild to severe 
with approximately twice as many stroke participants reporting depressive symptoms in comparison to 
their age-matched counterparts. Both these findings are supported by previous similar reports in the 
literature, (321-327) however previous studies also seem to indicate an improvement in depressive 
symptoms at follow up at 6 months to 2 years.(91, 326, 327) There was no significant correlation between 
lesion location and likelihood or degree of depressive symptoms and this is in keeping with a systematic 
review by Carson et al. that reported limited evidence in support of the hypothesis that risk of depression 
post-stroke is influenced by lesion location.(134) However, the neuropsychological literature reports 
conflicting evidence regarding post-stroke depression and lesion location.(91)  
 
Poorer performance on the MMSE and MoCA was associated with a greater likelihood of reporting 
depressive symptoms indicating a relationship between cognitive function and depression in the stroke 
population. This was especially prominent in the orientation, attention and calculation and 
visuospatial/executive components tested. Although this significant pattern between performance on 
global cognition measures and depression was reported in the case group it finding was not seen in the 
control group. These findings are also comparable with the current literature.(91, 122, 324, 328) For 
example, Kauhanen et al. examined 106 patients with a first-ever ischaemic stroke and reported an 
association between post-stroke depression and cognitive impairment, with memory, non-verbal problem 
solving, attention and psychomotor speed being the most commonly defective domains.(328) Some 
studies also reported a correlation between executive dysfunction and depression, (122) however this 
finding was not replicated in our stroke sample group.  
Significant correlations were reported between the MCQ-30 and HADS-D with higher scores on the HADS-
D correlating with higher MCQ-30 scores, especially with the Cognitive Confidence, Uncontrollability and 
Danger and Cognitive Self-consciousness subscales. This indicates that the MCQ-30 is a good predictor for 
depressive symptoms post-stroke. It also indicates that greater awareness of deficits is associated with a 
higher likelihood of depressive symptoms post-stroke. Although this finding has been reported with 
traumatic brain injury patients (163, 185, 329) little research has been conducted on mood symptoms and 
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metacognition in individuals with acute vascular insults and further research needs to be conducted to 
examine this relationship. 
 
Independent predictors of depression post-stroke include lower quality of life, disability and cognitive 
impairment.(324) Patients with cognitive impairment require focused attention as their risk of depression 
may be particularly increased and they may be unable to report their symptoms. This subgroup of patients 
require closer monitoring and more concentrated preventative interventional rehabilitation methods in 
order to improve their overall stroke outcome and reduce their risk of depressive symptoms.(324, 330) 
 
Additionally, the co-morbidity of anxiety and depression is common and well correlated in the literature 
(145, 318, 319, 331, 332) and this was also reported in the present study. Furthermore, comorbid anxiety 
and depression was also associated with greater disability than in subjects with depression alone including 
impairment in activities of daily living and social dysfunction.(318, 333) As the same assessment tool was 
utilized to detect both anxiety and depression in the present study, the sensitivity of detecting symptom 
severity could be questioned, as individuals may have a predilection to agree to both domains assessed 
by the questionnaire. However, the HADS has been found to perform well as a primary assessment tool 
for screening for both anxiety and depression.(147, 239) 
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Section Twenty: Other Associated Correlates to Cognitive Impairment in the Stroke Population 
Other associated correlates to cognitive function in stroke in this sample group included age and lower 
socio-economic status (indicated by lower level education and manual occupations). These correlations 
were stronger and more statistically significant be in the case group rather than the control group. These 
findings correspond with previous reports in the literature linking increased age and lower socio-economic 
status with both a higher incidence of stroke and with cognitive impairment, with lower socio-economic 
status being commonly reported as a predictor of poorer outcome post-stroke.(334-336) 
 
Social and economic conditions play a significant role in impacting the risk of and outcomes following a 
disabling condition such as stroke. Individuals with a low socioeconomic status face a disproportionate 
advantage and therefore policies aimed at providing resources for this population group should be a 
priority. As a population ages, as is expected in the Bahraini population, the burden of social and economic 
disadvantages is likely to increase alongside a rise in the societal impact of stroke.(334) Thus, providing 
resources and interventions focused towards the elderly and the socially disadvantaged is likely to aid in 
diminishing the higher burden of stroke.(87, 255, 334) Long-term data relating to the socio-economic 
profile and burden of stroke in the Middle East is sparse (15) and there is significant potential for 
expanding this field of study in the region to further outline and combat the influence of lower 
socioeconomic status on stroke risk and overall outcome. 
 
Regarding biomarker correlates, previous literature has indicated that the ApoE E4 allele and carriers of 
E4 are more frequent among patients with ischaemic cerebrovascular disease in comparison to 
controls,(337) indicating a role for ApoE in the pathogenesis of cerebrovascular disease. In our sample 
group, the E3/E3 polymorphism was more prevalent in the stroke group in comparison to the control 
group with no E4/E4 polymorphism detected in either group with a comparable incidence of the E3/E4 
polymorphism among both groups.  
 
No significant associations were found between cognitive impairment and ApoE polymorphisms in our 
stroke population either. There has been conflicting evidence in the literature regarding the association 
of ApoE with cognitive decline in stroke. For example, Ballard et al. examined 137 stroke patients in 
dementia and found that the presence of an ApoE E4 allele is associated with greater progression of 
cognitive decline especially in older patients.(103) A cross-sectional study by Wagle et al. examining 152 
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in-hospital stroke rehabilitation patients also found that the presence of the E4 allele (either the 
homozygous or heterozygous type) was associated with cognitive impairment 2-3 weeks after the 
insult.(104) However, Slooter et al. examined a larger population sample (n=6,852) and concluded that 
ApoE was weakly associated with myocardial infarction but not stroke.(338) Inconsistent findings in the 
literature indicate that it is unclear whether or not the ApoE genotype contributes to the incidence of 
vascular diseases and dementia. The precise relationship between stroke and ApoE mechanisms remain 
inconclusive. A possible reason for a lack of association of ApoE polymorphisms, stroke and cognitive 
impairment in the current study could be the relatively small number of subjects investigated and further 
studies need to be conducted to determine an association and pathophysiology.(99, 104, 105, 337) 
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Section Twenty-one: Study Limitations, Further Recommendations and Conclusions 
21.1 Limitations of the Study 
Metacognition is a broad and complex concept that spans many different domains from learning, memory 
and mood to motor functional limitations and any activity of daily living requiring higher-order 
thought.(199, 232) As a consequence, difficulties arise in examining metacognitive function due to a lack 
of consistent definitions and a deficiency in the use of an appropriate metacognitive theoretical 
framework as a basis for clinical research.(232) As there has been no consensus on the definition or use 
of a standard theoretical framework or assessment tool for metacognition which has made examining the 
concept in a stroke population difficult. The Metacognitive Questionnaire-30 was utilized to assess 
metacognition in this sample group. However, there is currently a lack of validation and reliability of the 
MCQ-30 in stroke patients. In addition, a further limitation is that many of the stroke participants had 
cognitive impairment based on the global cognition measures and this could have had an impact on 
understanding and answering the questions posed in the MCQ-30. 
The present study included other methodological limitations as well. The cross-sectional nature of the 
study design makes it difficult to make causal inferences on the associations or relationships between the 
variables examined. All consecutive admissions to Salmaniya Medical Complex with a diagnosis of stroke 
that deemed eligible based on the inclusion and exclusion criteria were approached to participate in the 
study. Despite SMC being the largest tertiary center in the country, the identified risk factors and 
demographic profile may have been unique to SMC thus weakening the generalizability of the study 
findings. The exposure of the control group to the same risk factors and co-founding variables with the 
case group indicates that the sample was representative of the population at risk of stroke. However, a 
convenience sample of the control group was selected based on attendance to two local health centers 
in Bahrain and willingness to participate in the research study. Due to this, the control group population 
was age-matched with the case group but not gender or nationality matched. However, having a control 
group for comparisons with the stroke group strengthened the study findings especially for determining 
the risk factors for cognitive impairment in stroke.  
Another limitation of the present study is the exclusion of patients with aphasia or dysphasia due to their 
communication deficits. This difficulty is faced by many studies investigating stroke and its 
consequences.(339, 340) This exclusion limits generalizability of the findings as approximately one-third 
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of people that will experience stroke will also experience aphasia.(339) In addition, the role of language 
in higher-order thought and metacognition is a feature that warrants further investigation. 
Despite attempts to measure pre-cognitive function using the Informant Questionnaire on Cognitive 
Decline in the Elderly, there was a poor response rate from caregivers to complete the questionnaire and 
therefore an insufficient sample was gathered and not enough data could be used and included as part of 
the analysis. Therefore, the study was unable to exclude patients who suffered from mild cognitive 
impairment prior to the stroke sufficiently which might have influenced study findings. The same concept 
can be applied to mood as no pre-stroke baseline measurement of mood was determined.  
Measures were used that were translated from the English to the Arabic language with no prior data on 
their psychometric properties or validation in Arabic which is another limitation of the study. Also, strong 
multivariate analysis relationships were not found as the small sample size could have violated the 
assumptions of multivariate analysis which may be considered as an additional  limitation of the 
study.(341) 
21.2 Recommendations for further study  
A longitudinal study evaluating temporal changes in cognitive function, metacognition, mood from the 
acute to the chronic stage in a post-stroke population would aid in strengthening the findings of the study. 
Long-term follow up studies involving a larger sample group would be the ideal way to explore this 
alongside studies designed to examine the outcomes of the various metacognitive intervention strategies. 
This could also give insight into the effectiveness of rehabilitation interventions for cognition and 
metacognition at different time intervals post-stroke. A larger sample size would justify further use of 
multivariate analysis and provide more robust statistical conclusions. In addition, other statistical analysis 
examining inferences of relationships such as mediations and moderations could also be 
investigated.(342) 
In addition, despite the present study assessments having good inter-rater reliability, validating the newly 
translated tools from the English to the Arabic language was not conducted due to time constrains. A 
future recommendation would be validating these tools by having a group of bilingual controls perform 
each assessment in both the English and Arabic language to confirm the reliability and validity of the 
Arabic versions.  
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21.3 Conclusion and future developments 
In conclusion, this was the first study conducted in Bahrain examining global cognitive function, executive 
function and metacognition in a stroke population, determining the relationships amongst these 
components and their relationship to mood.  The study found that, with the exception of socio-economic 
status, individuals not affected by stroke have proportional risk factors to a stroke population in Bahrain. 
This indicates that Bahrain is likely to see a continuing rise in stroke incidence especially with an ageing 
population. Approximately 48% of the stroke sample group had some degree of cognitive impairment 
with greater stroke severity being more significantly associated with worse overall cognitive impairment. 
Poorer performance on global cognition was correlated with executive dysfunction and more functional 
dependency. Stroke patients with higher levels of cognitive impairment were more likely to report lower 
cognitive self-consciousness levels, indicating an impairment in their metacognitive thought processes. 
Similarly, participants who performed poorly in the memory components of cognitive testing tended to 
subjectively report higher confidence in their memory skills, indicating an impairment in metamemory. 
Though no statistically significant correlations were reported between total MCQ-30 scores and executive 
function and global cognition, the MCQ-30 was shown to be a good predictor of anxiety and depression 
post-stroke. Cognitive impairment was associated with a greater likelihood of reporting depressive 
symptoms in our population. 
 
Cognitive rehabilitation interventions aim to reinforce, strengthen and re-establish learned patterns of 
behavior and establish new patterns of cognitive activity through internal and external compensatory 
mechanisms in order to facilitate individuals to adapt to their cognitive disability.(73, 343) Impairments in 
higher-order cognitive functions hinder an iŶdiǀidual͛s aďilitǇ to ƌeĐogŶize theiƌ defiĐits aŶd fail to use 
these adaptive compensatory mechanisms.(344) Therefore, stroke patients with cognitive deficits can 
only reach their full potential for independent functioning if metacognitive deficits are initially 
investigated.(232) As of yet, there has been no consensus on the definition or use of a standard theoretical 
framework for metacognition with limited clarification of the term and the use of it interchangeably with 
self-awareness, subjective cognitive complaints and at times executive function which made adequate 
assessment of this novel construct difficult. Assessment tools that have attempted to address 
metacognition have mainly focused on a single dimension of the concept and limited studies have 
examined metacognition in stroke studies. Metacognitive deficits should be one of the primary 
assessments undertaken in cognitive rehabilitation after stroke. In order to achieve this objective, the 
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development of a tool that can consolidate both subjective and global objective assessment and thereby 
measure the full breadth of metacognitive function is necessary. Including metacognition assessment in 
cognitive rehabilitation tailors treatment to a more patient centered approach, focusing on the 
iŶdiǀidual͛s oǁŶ goal setting abilities and their own recognition of their deficits. This may have important 
implications for future rehabilitation by providing more clarity on rehabilitative decisions. 
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Appendix 2:  Participant Information and Consent Form (English)
  
 
Participant Information and Consent Form 
 
 
Study title: Metacognition function in stroke patients and age matched healthy volunteers  
 
Site where the study will be conducted: 
Salmaniya Health Complex, Local Health Centres  
 
You are being asked to participate in a clinical research study conducted in Bahrain. Please take 
time to read the following information carefully before you decide whether you want to take part 
in this study or not.  Feel free to ask your doctor or the researcher involved if you need more 
information or clarification about what is stated in this form and the study as a whole. 
 
1) Purpose of the research study and overview of participation: The aim of the study is to 
examine the extent of impairment to higher-order thinking including self-awareness and self-
regulation that can occur following a stroke and to compare this type of thinking with other 
healthy older adults. 
 
2) Procedure: You will be asked to complete some cognitive tasks along with some questions on 
how you think about your ability to make every day plans and decisions and also some questions 
about how you are feeling generally. In addition, we will also need to take one blood sample from 
you to find out if some proteins in the blood may be related to some problems people may have 
with their thinking and memory after a stroke. The results from the blood test will have no 
significance for you individually as we are only researching what the presence of certain proteins 
mean for large groups of patients collectively at this time. We will be storing the blood samples 
taken and may use these at a later time for further research.  
 
3) Eligibility: We are inviting participants of 18 years old and above who may have experienced 
a stroke within the last month and also participants of a similar age and gender to the participants 
who have experienced a stroke, to be the healthy volunteer matched controls. 
 
4) Inclusion Criteria: Participants should be Arabic or English speaking and able to participate in 
an interview assessment with sufficient language and cognitive function.  
 
5) Exclusion Criteria: Participants who have had a mini stroke or have any difficulties with 
speaking, vision or hearing to participate in an interview assessment. 
 
6) Right to Refuse or Withdraw: The participation is this study is entirely voluntary and includes 
the right to withdraw at any time. It is your choice whether to participate or not. Whether you 
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choose to participate or not, will not interfere with any health services that you currently receive.  
 
7) Risks and Confidentiality: There are no health-associated risks associated with this study. All 
information as part of this study will remain confidential.   
Unless required by law, only the study researchers through the permission of your treating 
Doctor will have direct access to your medical records.  
 
8) Any benefits as a result of participating in the study: The study is aimed to increase the 
knowledge regarding the effect of stroke on higher-order thinking and other cognitive functions.  
 
9) Any alternative treatment: We are not offering any treatments in this study. 
 
10) Compensation: In case of any adverse event as a result of the study, there will be no 
compensation to cover such expenses in case it is not covered by a third party or governmental 
insurance.  
 
11) Further Information: If you have any further questions about the study, or are interested in 
participating in the study please contact one of the following: 
Dr Noor Abdulla on 36007399 or noorabdullar@gmail.com  
Dr Mona Al Banna on 37740550 or maa070221@rcsi-mub.com     
Dr Claire Donnellan on 35567239 or cdonnellan@rcsi-mub.com 
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Consent Form 
 
Study title: Metacognition function in stroke patients and age 
matched healthy volunteers  
 
IŶǀestigator’s “tateŵeŶt: 
 
I have reviewed, in detail, the informed consent document for this research study with   
     (name of patient or legal representative) the purpose of the study 
aŶd its ƌisks aŶd ďeŶefits. I haǀe aŶsǁeƌed to all the patieŶt͛s ƋuestioŶs ĐleaƌlǇ.  I ǁill iŶfoƌŵ the 
participant in case of any changes to the research study. 
 
_______________________         
Name of Investigator or designee    Signature 
 
     
Date & Time 
 
PatieŶt’s or VoluŶteer’s PartiĐipatioŶ: 
 
I have read and understood all aspects of the research study and all my questions have been 
answered.  I voluntarily agree to be a part of this research study and I know that I can contact 
anyone involved in the study in case of any questions. I understand that I am free to withdraw 
this consent and discontinue participation in this project at any time, even after signing this form, 
and it will not affect my care or benefits.  I know that I will receive a copy of this signed informed 
consent. 
 
__________________________        
Name of Patient or Legal Representative    Signature 
 
      
Date & Time 
 
             
WitŶess͛s Naŵe        WitŶess͛s “igŶatuƌe 
(if patient or representative does not read)      
 
        
Date & Time 
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 اƃموافقة وا  ستمارة اƃمشارك معلومات
 اƃعمرية اƃفئة نفس من اƃصحيين واƃمتطوعيين اƃدماغية اƃجلطة مرضى عند اƃعاƃية اƃمعرفية اƃوظيفة: اƃدراسة عنوان
  اƅطبي اƅسلماƊية مجمع : اƃبحث إجراء مكان
 
 أن قبل بعƊاية اƅتاƅية اƅمعلومات ƅقراءة اƅƄافي اƅوقت أخذ يرجىي اƅبحرين في تجرȐ  سريرية بحثية دراسة في اƅمشاركة مƊك يطلب
 اƅمعلومات من اƅمزيد إƅى حاجتك عƊد اƅباحث أو طبيبك حرية بكل تسأل أن يمكƊكي اƅدراسة هذƋ في اƅمشاركة في رغبتك تقّرر
 .ككل واƅدراسة  اإستمارة هذƋ في ورد ما حول اƅتوضيح أو
 
 على ƅلتفكير باƅƊسبة اƅضعف مدȐ مƊاقشة هو اƅدراسة هدف: ƃلمشاركة عامة ونظرة اƃبحثية اƃدراسة من اƃهدف )1
 اƅƊوع هذا ومقارƊة اƅدماغية اƅجلطة بعد يحدث أن يمكن اƅذȑ اƅذاتي واƅتƊظيم اƅذاتي اƅوعي ويشمل اƗعلى، اƅمستوȐ 
 ي اƅصّحيين سƊّا اƗƄبر اآخرين اƅباƅغين مع اƅتفكير من
 
 وضع في وقدراتك تفكيرك بكيفية اƅمتعلقة اƗسئلة بعض جاƊب إƅى اإدراƄية اƅمهام بعض إƄمال مƊك يطلب: اإجراءات )2
 احتماƅية من ƅلتأƄد واحدة دم عيƊة أخذ اƅدراسة تتطلب ذƅك، إƅى باƗضافةي عام بشكل وشعورك اƅيومية واƅقرارات اƅخطȌ
 بعد اƅذاƄرة أو باƅتفكير اƅمتعلقة اƅمشاƄل ببعض صلة ƅها يكون  ان اƅممكن من اƅتي اƅبروتيƊات من معيƊة اƊواع وجود
 ƅها ƅيس اƅتحليل هذا Ɗتائج فإن واƅمعرفة، ƅلبحث اƅبروتيƊات أƊواع تحليل هو اƅدراسة هذة من اƅهدف أن وبماي اƅجلطة
 وسيتمي اƅوقت هذا في ƅلفرد اهمية أȑ ƅها وƅيس جماعي بشكل ستدرس اƅعيƊات هذة Ɗتائج إني عليك مترتب أثر أȑ
 يمستقبلية بحوث Ɨجراء أستخدامها Ɨحتماƅية اƅعيƊات بتلك اƗحتفاȍ
 
    اƅماضي، اƅشهر خال دماغية بجلطة اصيبوا اƅذين فوق  وما سƊة ϴϭ اƅعمرية اƅفئة من اƅمرضى: ƃلبحث اƃمؤهليين )3
 ي اƅمرضى مع أجƊاسهم و أعمارهم تتطابق اƅتي اƅصّحيين واƅمتطوعيين
 
 اƅƄافية واƅلغوية اإدراƄية اƅقدرة ƅديه تƄون  وأن اإƊجليزية أو اƅعربية باƅلغة اƅتحدث اƅمشترك على :اƃمشاركة معايير )4
 ي اƅتقييمة اƅمقابلة أثƊاء ƅلتجاوب
 أثƊاء اƅتجاوب من تمƊعهم إعاقة من يعاƊون  اƅذين أو قصيرة دماغية بجلطة أصيبوا اƅذين اƅمشاركون : اإستثناء معايير )5
 .اإستماع أو اƅرؤية أو اƅتحدث في كصعوبة اƅتقييمية اƅمقابلة
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 جميع إني وقت أȑ في ااƊسحاب حق وƅلمشارك تطوعية اƅدراسة هذƋ في اƅمشاركة: اإنسحاب أو اƃرفض في اƃحق  )6
 ي  اإƊسحاب أو اƅمشاركة حاƅة في تأثير أȑ دون  ستستمر تتلقاها اƅتي اƅصحية اƅخدمات
 
 اƅمعلومات كل فإن اƅمشاركة على اƅموافقة عƊدي اƅدراسة بهذƋ تتعلق صحية محاذير أȑ توجد ا :واƃخصوصية اƃمخاطر )7
 خال من وذƅك اƅدراسة باحثي عدȐ ما اƅصحية سجاتك على أو عليها اإطاع شخص Ɨȑ يحق وا سرية، ستبقى
 ي  ƅك اƅمباشر اƅطبيب من صادر تصريح
 
 اƅدماغية باƅجلطات اƅمتعلقة اƅمعرفة زيادة هي اƅدراسة هذة من اƅغاية :اƃدراسة في اƃمشاركة من اƃمتوقعة اƃفوائد  )8
 ي اƗخرȐ  معرفية وظائف إƅى باإضافة اƅعاƅي واإدراك اƅتفكير مستوȐ  على وتأثيرها
 
 ي اƅدراسة هذƋ في عاج أȑ بتقديم اƅبحثي اƅفريق يقوم ا :اƃعاجية اƃبدائل )9
 
 يرتب جاƊبي تأثير اȑ فإن حكومي، تأمين أو ثاƅث طرف قبل من اƅƊفقات ƅتغطية اتفاق هƊاك يكن ƅم ما:  اƃتعويض  )01
 ي عƊه اƅتعويض يتم ƅن اƅدراسة هذƋ من
 
: Ɗقال هاتفط اƅبƊاء مƊى باƅدكتورة اƗتصال اƅرجاء اƅدراسة، هذƋ حول اƗستفسار من ƅلمزيد: أخرȎ  معلومات )11
: Ɗقال هاتفط عبده Ɗور اƅدكتورة أو) iscr@122070aam-moc.bum: اƗƅƄتروƊي اƅبريد ϬϱϱϬϰϳϳϯ
 أو) moc.liamg@ralludbarooniscr@122070aam:otliam-moc.bum: اƗƅƄتروƊي اƅبريد ϵϵϯϳϬϬϲϯ
 (iscr@nallennodc-moc.bum: اإƅƄتروƊي اƅبريد ϵϯϮϳϲϱϱϯ: اƅƊقال هاتفط دوƊيلون  كلير دكتورةاƅ
 841
 
 اƃموافق إستمارة
 
 من اƃصحيين واƃمتطوعيين اƃدماغية اƃجلطة مرضى عند اƃعاƃية اƃمعرفية اƃوظيفة: اƃدراسة عنوان
 اƃعمرية اƃفئة نفس
  :باƃباحث خاص
 اƅممثل أو اƅمريض اسم__________________________ ط مع اƅبحثية باƅدراسة اƅمتعلقة اƅموافقة وثيقة مراجعة تمت
 من أو اƅمريض إباغ يتم سوف تغيير أȑ حدوث وعƊدي باƅدراسة اƅمرتبطة اƗسئلة جميع على اƅرد مع تفصيلي بشكل) اƅقاƊوƊي
 .قاƊوƊيا   عƊه يƊوب
 ________________________     _________________
 اƅتوقيع      اƅمرّشح أو اƅباحث توقيع اسم
 
 ___________________
 واƅوقت  اƅتاريخ
 
 :اƃمتطّوع أو باƃمريض خاص
 جزء   أƄون  أن تطوعي بشكل أوافقي إستفساراتي جميع على اƅرد تم وƅقد اƅبحثية اƅدراسة هذƋ وا  جراءات أهداف على إطلعت ƅقد
 اƅوثيقة هذƋ على اƅتوقيع بعد حتى وقت أȑ في اƅمشاركة عن اƅتوقف في اƅحرية مطلق ƅدȑ أنب علم على أƊاي اƅدراسة هذƋ من
 ي  اƅعاج مرحلة في اتلقاها اƅتي واƅعƊاية اƅصحية اƅخدمات على اƅمشاركة نع توقفي يؤثر ƅن وأن
 .اإستمارة هذƋ من سخةƊ سأستلم بأƊƊي علم على إƊƊي
 
 __________________      _________________
 اƅتوقيع        اƅقاƊوƊي اƅممثل أو اƅمريض إسم
 
       ____________________
 اƅوقت و اƅتاريخ
 
 __________________      _________________
 اƅشاهد توقيع        اƅشاهد إسم
 )يقرأ اƅقاƊوƊي اƅممثل أو اƅمريض يكن ƅم إذاط 
 ____________________
 واƅوقت اƅتاريخ
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1- Patient Clinical Background Information 
1.1 General Details 
1.1.1: Gender -  M    F        1.1.2: Age _____________ 
1.1.3: Date of Birth ___/____/____              
1.1.4: Date of Admission ___/____/____        1.1.5: Date of Stroke___/____/____     
1.1.6: Nationality -  Bahraini    Non-Bahraini (If so, specify____________) 
1.1.7: Living status - Alone With spouse/family Other (If so, specify ___________)    
1.1.8: If not alone, number of people in residence ___________ 
1.1.9: List others (relationship to the patient) ___________________________________ 
1.1.10: Education - Primary  Secondary  Third level ( Cert  Diploma  Degree or higher) 
1.1.11: Occupation ____________________________________ 
 Manual Non-Manual/Self-employed  Unemployed/Retired (indicate previous occupation) 
Other__________________ 
1.1.12: Marital status - Married  Not married  Widowed  Divorced  
1.1.13: Date of Discharge   ___/____/20         1.1.14: Length of Stay__________ (days)  
1.1.15: Date of Death (if applicable)  ___/____/20                   
1.2 Medical History 
1.2.1: Smoker - Yes  No                 1.2.2: BMI - ______________  
 
1.3 Co-morbidities: 
Previous history of:  
1.3.1: TIA - Yes  (Number of TIAs _________)       No   
1.3.2: Stroke - Yes   (Number of Stokes ________)    No   
1.3.3: Cardiovascular disease/surgeries - Yes    No  
1.3.4: Atrial fibrillation - Yes    No  
1.3.5: Hypertension - Yes    No  
1.3.6: Diabetes - Yes    No  
1.3.7: Hypercholesterolemia - Yes    No  
1.3.8: Psychiatric Conditions - Yes  (__________________________)      No  
1.3.9: Other - Yes  (__________________________)      No  
Weight ________ (kg) 
Height ________ (cm) 
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1.4 Stroke Classification 
1.4.1: Cause of Stroke - Acquired    Traumatic  
1.4.2: Stroke type - Ischaemic   Haemorrhagic   
1.4.3: Stroke subtype: 
1.4.3A - OCSP Classification:  
Total Anterior Circulation Infarct    Lacunar  Partial Anterior Circulation Infarct   Posterior 
Circulation Infarct  
1.4.3B - TOAST Classification:  
Large-artery atherosclerosis  Cardioembolism  Small-artery occlusion (lacunar)  Stroke 
of other determined etiology  (specify) ___________  
Stroke of undetermined etiology  
1.4.4: Lesion location - Right hemispheric   Left hemispheric  Brain stem  
1.4.5: Dominant Arm ______________________  
 
1.5 Medications 
Pre-admission Medications 
1.5.1: Anti-hypertensives – Yes   (Specify_____________________)    No  
1.5.2: Anti-diabetic medication – Yes   (Specify_____________________)    No  
1.5.3: Aspirin/clopidogrel/other antiplatelet - Yes   (Specify_____________)    No  
1.5. 4: Statin/other lipid lowering – Yes   (Specify_____________________)    No  
1.5.5: Other - Yes   (Specify_____________________)    No  
 
Current Medications  
1.5.6: Anti-hypertensives – Yes   (Specify_____________________)    No  
1.5.7: Anti-diabetic medication – Yes   (Specify_____________________)    No  
1.5.8: Aspirin/clopidogrel/other antiplatelet - Yes   (Specify_____________)    No  
1.5. 9: Statin/Other lipid lowering – Yes   (Specify_____________________)    No  
1.5.10: Other - Yes   (Specify_____________________)    No  
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1.6 Imaging 
CT Scan  
1.6.1: Date of scan – ___/____/____ 
1.6.2: What did the scan show? 
Infarct    Haemorrhage  No abnormality   Other  (_____________________) 
 
 
 
 
 
 
 
Carotid Doppler  
1.6.3: Date of carotid doppler – ___/____/____ 
1.6.4: Carotid doppler results: 
Normal study    <70% stenosis  > 70% stenosis  
 
 
 
 
 
Other Imaging (CTA/MRA): 
 
 
 
 
  
Please include details from CT/MRI report: 
Please include details from carotid doppler report: 
Please include details of other imaging: 
153 
 
 
1.7 Laboratory 
  Result  Units 
1.7.1 Total cholesterol  mmol/l 
1.7.2 LDL  mmol/l 
1.7.3 HDL  mmol/l 
1.7.4 Triglycerides  mmol/l 
1.7.5 HbA1c  % 
1.7.6 White blood count  X109 /l 
1.7.7 Red blood cells  X1012/l 
1.7.8 Haemoglobin  g/dl 
1.7.9 Mean cell volume  Fl 
1.7.10 Platelet count  X109/l 
 
 
 
1.8 Biomarkers 
  Result  
1.8.1 ApoE  
1.8.2 sRAGE  
1.8.3 BACE1  
1.8.4 NEP  
 
 
Additional Notes:  
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MINI-MENTAL STATE EXAMINATION (MMSE) 
Date of assessment: ___/____/____    
Days post-stroke: ___/____/____    
Person administering assessment: __________________ 
 
 Score 
Time Orientation  
What is the (year) (season) (345) (date) (month)?  
/5 
Place Orientation  
Where are we: (state) (county) (town) (hospital) (floor)?  
/5 
Registration  
Name three unrelated objects. Allow one second to say each. Then ask the 
patient to repeat all three after you have said them. Give one point for each 
correct answer. Repeat them until he or she learns all three. Count trials and 
record. Trials: _____ 
 
 
 
/3 
Attention and Calculation  
Ask patient to count backwards from 100 by sevens. Give one point for each 
correct answer. Stop after five answers. Alternatively, spell world backwards. 
 
/5 
Recall  
Ask patient to recall the three objects previously stated. Give one point for each 
correct answer. 
 
/3 
Language  
Show patient a wrist watch; ask patient what it is. Repeat for a pencil. /2 
Ask patient to repeat the following: "No ifs, ands, or buts."  /1 
Ask patient to follow a three-stage command: "Take a paper in your right hand, 
fold it in half, and put it on the floor."  
 
/3 
Ask patient to read and obey the following sentence which you have written on a 
piece of paper: "Close your eyes." 
 
/1 
Ask patient to write a sentence.  /1 
Drawing  
Ask patient to copy a design.  
  
 
 
 
 
 
 
/1 
 
Total Score: _______ 
Assess level of consciousness along a continuum: Alert – Drowsy- Stupor – Coma 
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The Barthel Index 
 
Activity Score 
Feeding  
0= unable 
5= needs help cutting, spreading butter, etc., or requires modified diet 
10= independent 
 
Bathing  
0= dependent 
5= independent (or in shower) 
 
Grooming  
0= dependent 
5= independent face/hair/teeth/shaving (implements provided) 
 
Dressing  
0= needs help with personal care 
5= needs help but can do about half unaided 
10= independent (including buttons, zips, laces, etc.) 
 
Bowels  
0= incontinent (or needs to be given enemas) 
5= occasional accident 
10= continent 
 
Bladder  
0= incontinent, or catheterized and unable to manage alone 
5= occasional accident 
10= continent 
 
Toilet use  
0= dependent 
5= needs some help, but can do something alone 
10= independent (on and off, dressing, wiping) 
 
Transfers (Bed to chair and back)  
0= unable, no sitting balance 
5= major help (one or two people, physical), can sit 
10= minor help (verbal or physical) 
15= independent 
 
Mobility (on level surfaces)  
0= immobile or <50 yards 
5= wheelchair independent, including corners, >50 yards 
10= walks with help of one person (verbal or physical) >50 yards 
15= independent (but may use aid; for example, stick) >50 yards 
 
Stairs  
0= unable 
5= needs help (verbal, physical, carrying aid) 
10= independent 
 
           
          Total (0-100): ____ 
End of Part i 
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2- Frenchay Aphasia Screening Test 
2.1 Comprehension 
“hoǁ patieŶt Đaƌd ǁith ƌiǀeƌ sĐeŶe. “aǇ ͚Look at the piĐtuƌe. ListeŶ ĐaƌefullǇ to ǁhat is said aŶd poiŶt to 
the things I tell you to. Score 1 for each correctly performed. If instructions require repeating, score as 
error. Unprompted self-correction may be scored as correct.  
Score range 0 - 10. 
2.1.1 River Scene 
2.1.1.1: Point to a boat __ /1  
2.1.1.2: Point to the tallest tree. __ /1 
2.1.1.3: Point to the man and point to the dog. __ /1 
2.1.1.4: PoiŶt to the ŵaŶ͛s left leg aŶd theŶ to the ĐaŶoe. __ /1 
2.1.1.5: Before pointing to a duck near the bridge, show me the middle hill __ /1 
Total Score __ /5 
2.1.2 Shapes 
2.1.2.1: Point to the square. __ /1 
2.1.2.2: Point to the cone. __ /1 
2.1.2.3: Point to the oblong and the square. __ /1 
2.1.2.4: Point to the square, the cone and the semi-circle. __ /1 
2.1.2.5: Point to the one that looks like a pyramid and the one that looks    
              like a segment of orange. 
__ /1 
Total Score __ /5 
2.2 Expression  
2.2.1 Show patient the river scene aŶd saǇ : ͞Tell ŵe as ŵuĐh aďout the piĐtuƌe as Ǉou ĐaŶ. ͚If patieŶt 
does Ŷot appeaƌ to uŶdeƌstaŶd, saǇ: ͞Naŵe aŶǇthiŶg Ǉou ĐaŶ see iŶ the piĐtuƌe. “Đoƌe ƌaŶge Ϭ - 5 
 
Unable to name any objects intelligibly 0 
Names 1-2 objects 1 
Names 3-4 objects 2 
Names 5-7 objects 3 
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Names 8 or 9 objects or uses phrases and sentences, but performance not normal 
(e.g. hesitations, inappropriate comments etc.) 
4 
Normal – uses phrases and sentences, naming 10 items 5 
Score  
 
2.2.2 Remove picture card from view and inform patient that you are now going to attempt  something 
a little different. Then ask him/her to name as many animals as he/she can think of in 1 minute. If the 
name sof any kind of animal, wild or domestic, and not just those which may have been seen in the picture. 
Commence timing as soon as patient names first animal and allow 60 seconds. Score 0-5 
None named 0 
Names 1-2  1 
Names 3-5 2 
Names 6-9 3 
Names 10-14 4 
Names 15 or more 5 
Score  
2.3 Reading  
Check that the patient is wearing correct spectacles for reading purposes. Show patient river 
scene and first reading card. Ask him/her to read the sentence to himself, not aloud, and do 
whatever it instructs him/her to do. Proceed in the same manner with the remaining four reading 
cards. Score range 0-5 
2.3.1: Points to the dog __ /1 
2.3.2: Points to the bridge __ /1 
2.3.3: Points to the man standing in the barge __ /1 
2.3.4: Touches the left-hand corner of the card __ /1 
2.3.5: Touches the bottom of the card and then the top of it __ /1 
 Total Score __ /5 
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2.4 Writing  
“hoǁ patieŶt ƌiǀeƌ sĐeŶe aŶd saǇ: ͞Please ǁƌite as ŵuĐh as Ǉou ĐaŶ aďout ǁhat is happeŶiŶg iŶ 
the picture. If he/she does not appear to understand say: ͞Wƌite aŶǇthiŶg that Ǉou ĐaŶ see iŶ 
the picture. If dominant hand is affected ask patient to attempt with non-dominant hand. 
Encourage if he/she stops prematurely. Allow a maximum of 5 minutes. Score 0-5.  
Able to attempt task but does not write any intelligible or appropriate words 0 
Writes 1 or 2 appropriate words 1 
Writes down names of 3 objects or a phrase including 2 or 3 objects 2 
Writes down names of 4 objects (correctly spelled), or 2 or 3 phrases including names of 4 items 3 
Uses phrases and seŶteŶĐes, iŶĐludiŶg Ŷaŵes of ϱ iteŵs, ďut Ŷot ĐoŶsideƌed ͚Ŷoƌŵal͛ peƌfoƌŵaŶĐe 
e.g. sentence not integrating people or actions 
4 
Definitely normal performance, e.g. sentence integrating people and actions 5 
Score  
 
 
 
 
 
 
 
 
 
 
Comprehension _______/10 
Expression _______/10 
Reding _______/5 
Writing _______/5 
Overall Total Score _______/30 
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3-Trial Making Test (TMT) Parts A & B 
Instructions: 
 Both parts of the Trail Making Test consist of 25 circles distributed over a sheet of paper. 
In Part A, the circles are numbered 1 – 25, and the patient should draw lines to connect 
the numbers in ascending order. In Part B, the circles include both numbers (1 – 13) and 
letters (A – L); as in Part A, the patient draws lines to connect the circles in an ascending 
pattern, but with the added task of alternating between the numbers and letters (i.e., 1-A-
2-B-3-C, etc.). The patient should be instructed to connect the circles as quickly as 
possible, without lifting the pen or pencil from the paper. Time the patient as he or she 
connects the "trail." If the patient makes an error, point it out immediately and allow the 
patient to correct it. Errors affect the patient's score only in that the correction of errors is 
included in the completion time for the task. It is unnecessary to continue the test if the 
patient has not completed both parts after five minutes have elapsed 
 
Procedure  
 Step 1   Give the patient a copy of the Trail Making Test Part A worksheet and a pen 
or pencil. 
 Step 2  Demonstrate the test to the patient using the sample sheet (Trail Making Part 
A – SAMPLE). 
 Step 3  Time the patient as he or she follows the “trail” made by the numbers on the 
test. 
 Step 4  Record the time. 
 Step 5  Repeat the procedure for Trail Making Test Part B. 
 
Scoring: 
 Results for both TMT A and B are reported as the number of seconds required to 
complete the task; therefore, higher scores reveal greater impairment. 
 
 Average Deficient Rule of Thumb 
Trial A 29 seconds > 78 seconds Most in 90 seconds 
Trial B 75 seconds > 273 seconds Most in 3 minutes 
 
Trial Score  
Trail A _______________ Seconds 
Trial B ________________ Seconds  
Final 
Score  
(Trial B – Trial A) = ____ Seconds 
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3.1 Trial Making Test Part A- Sample: 
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3.1 Trial Making Test Part A (For Patient) 
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3.2 Trial Making Test Part B- Sample: 
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3.2 Trial Making Test Part B (For Patient): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
176 
 
4- Hospital Anxiety and Depression Scale (HADS) 
 
Patients are asked to choose one response from the four given for each interview. They should give an 
immediate response and be dissuaded from thinking too long about their answers. The questions 
relating to anxiety are marked "A", and to depression "D". The score for each answer is given in the right 
column. Instruct the patient to answer how it currently describes their feelings. 
Scoring: 
(Add the As = Anxiety. Add the Ds = Depression). The norms below will give you an idea of the level of 
anxiety and depression. 
0 – 7 = Normal 
8 – 10 = Borderline abnormal 
11 – 21 = Abnormal 
4.1 I feel tense or wound up:   4.2 I feel as if I am slowed down:  
A 
Most of the time 3 
D 
Nearly all the time 3 
A lot of the time 2 Very often 2 
From time to time, occasionally 1 Sometimes 1 
Not at all 0 Not at all 0 
 
4.3 
I still enjoy the things I used to enjoy: 
 
 
4.4 
I get a sort of frightened feeling 
like ͞ďutterflies͟ iŶ the 
stomach: 
 
D 
Definitely as much 0 
A 
Not at all 0 
Not quite so much 1 Occasionally 1 
Only a little 2 Quite often 2 
Hardly at all 3 Very often 3 
 
4.5 
I get a sort of frightened feeling as if  
something awful is about to happen: 
 
 
4.6 
I have lost interest in my 
appearance: 
 
A 
Very definitely and quite badly 3 
D 
Definitely 3 
Yes but not too badly 
2 
I doŶ͛t take as much care as I 
should 
2 
A little, ďut it doesŶ͛t ǁoƌƌǇ ŵe 
1 
I may not take quite as much 
care 
1 
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Not at all 0 I take as much care as ever 0 
4.7 
I can laugh and see the funny side of 
things: 
 
 
4.8 
I feel restless as I have to be on 
the move: 
 
D 
As much as I always could 0 
A 
Very much indeed 3 
Not quite so much now 1 Quite a lot 2 
Definitely not so much now 2 Not very much 1 
Not at all 3 Not at all 0 
 
4.9 Worrying thoughts go through my 
mind  
 4.10 I look forward with enjoyment to things  
A 
A great deal of the time 3 
D 
As much as I ever did 0 
A lot of the time 2 Rather less than I used to 1 
From time to time, but not too often 1 Definitely less than I used to 2 
Only occasionally 0 Hardly at all 3 
 
4.11 I feel cheerful   4.12 I get sudden feeling of panic:  
D 
Not at all 3 
A 
Very often indeed 3 
Not often 2 Quite often 2 
Sometimes 1 Not very often 1 
Most of the time 0 Not at all 0 
 
4.13 I can sit at ease and feel relaxed   4.14 I can enjoy a good book or 
radio or TV program:  
A 
Definitely 0 
D 
Often 0 
Usually 1 Sometimes 1 
Not often 2 Not often 2 
Not at all 3 Very seldom 3 
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5- Metacognition Questionnaire (MCQ) -30 
 
5.1: Cognitive confidence 
1 
Do not 
agree 
2 
Agree 
slightly 
3 
Agree 
moderately 
4 
Agree very 
much 
5.1.1   I do not trust my memory     
5.1.2  I have a poor memory     
5.1.3 
I have little confidence in my memory 
for actions 
    
5.1.4  
I have little confidence in my memory 
for places 
    
5.1.5 
I have little confidence in my memory 
for words and names 
    
5.1.6 My memory can mislead me at times     
 
 
5.2: Positive Beliefs 
1 
Do not 
agree 
2 
Agree 
slightly 
3 
Agree 
moderately 
4 
Agree 
very 
much 
 
5.2.1  
Worrying helps me to get things 
sorted out in my mind 
    
 
5.2.2 Worrying helps me cope      
5.2.3 
I need to worry in order to work 
well 
    
 
5.2.4 
Worrying helps me to solve 
problems 
    
 
5.2.5 
I need to worry in order to remain 
organized 
    
 
5.2.6 
Worrying helps me to avoid 
problems in the future 
    
 
 
5.3: Cognitive Self-consciousness 
1 
Do not agree 
2 
Agree 
slightly 
3 
Agree 
moderately 
4 
Agree very 
much 
5.3.1  I am constantly aware of my thinking     
5.3.2 
I pay close attention to the way my mind 
works 
    
5.3.3 I think a lot about my thoughts     
5.3.4 I constantly examine my thoughts     
5.3.5 I monitor my thoughts     
5.3.6 
I am aware of the way my mind works 
when I am thinking through a problem 
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5.4: Uncontrollability and Danger 
1 
Do not 
agree 
2 
Agree 
slightly 
3 
Agree 
moderately 
4 
Agree very 
much 
5.4.1  
My worrying thoughts persist, no 
matter how I try to stop them 
    
5.4.2 When I start worrying I cannot stop     
5.4.3 I could make myself sick with worrying     
5.4.4 I cannot ignore my worrying thoughts     
5.4.5 My worrying could make me go mad     
5.4.6 My worrying is dangerous for me     
 
 
5.5: Need To Control Thoughts 
1 
Do not 
agree 
2 
Agree 
slightly 
3 
Agree 
moderately 
4 
Agree very 
much 
5.5.1  
If I could not control my thoughts, I 
would not be able to function 
    
5.5.2 
Not being able to control my thoughts 
is a sign of weakness 
    
5.5.3 
I should be in control of my thoughts 
all of the time 
    
5.5.4 It is bad to think certain thoughts     
5.5.5 
If I did not control a worrying thought 
and then it happened, it would be my 
fault 
    
5.5.6 
I will be punished for not controlling 
certain thoughts 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
180 
 
6- Checklist for Cognitive and Emotional Consequences Following Stroke (CLCE-24) 
 
6.1 Patient 
Cognitive: 
Since the stroke, I have had problems 
 
Yes, 
severely 
hindering 
daily life 
Yes, but 
not severe 
No I am not sure 
6.1.1 Doing two things at once 
    
6.1.2 Attending to things 
    
6.1.3 Keeping up; has become slower 
    
6.1.4 Remembering new information 
    
6.1.5 Remembering old information 
    
6.1.6 Taking initiative 
    
6.1.7 Planning and organizing things 
    
6.1.8 Performing daily activities 
    
6.1.9 Perceiving time 
    
6.1.10 Orienting to places or persons 
    
6.1.11 Understanding language 
    
6.1.12 Speaking or writing 
    
6.1.13  Attending to a part of the body or 
space 
    
 
Emotional: 
Since the stroke, I have been: 
 
Yes, 
severely 
hindering 
daily life 
Yes, but 
not severe 
No I am not sure 
6.1.14 Depressed 
    
6.1.15 In fear of things to come 
    
6.1.16 Less oriented socially 
    
6.1.17 Not realistic about things 
    
6.1.18 Emotionally less stable, cry easily 
    
6.1.19 Irritated, angry more easily 
    
6.1.20 Less emotional, uninterested 
    
6.1.21 Less in control of my own 
behavior 
    
6.1.22 Tired quickly 
    
 
Are there any other problems? 
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6.2 Caregiver 
Cognitive: 
Since the stroke, the patient has had problems: 
 Yes, 
severely 
hindering 
daily life 
Yes, but 
not 
severe 
No I am not sure 
6.2.1 Doing two things at once     
6.2.2 Attending to things     
6.2.3 Keeping up; has become 
slower 
    
6.2.4 Remembering new 
information 
    
6.2.5 Remembering old 
information 
    
6.2.6 Taking initiative     
6.2.7 Planning and organizing 
things 
    
6.2.8 Performing daily activities     
6.2.9 Perceiving time     
6.2.10 Orienting to places or 
persons 
    
6.2.11 Understanding language     
6.2.12 Speaking or writing     
6.2.13  Attending to a part of the 
body or space 
    
 
Emotional: 
Since the stroke, the patient has been: 
 Yes, 
severely 
hindering 
daily life 
Yes, but 
not 
severe 
No I am not sure 
6.2.14 Depressed     
6.2.15 In fear of things to come     
6.2.16 Less oriented socially     
6.2.17 Not realistic about things     
6.2.18 Emotionally less stable, 
cries easily 
    
6.2.19 Irritated, angry more easily     
6.2.20 Less emotional, 
uninterested 
    
6.2.21 Less in control of his/her 
own behavior 
    
6.2.22 Tired quickly     
 
Are there any other problems? 
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7 - Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) 
 
Now we want you to remember what your friend or relative was like 10 years ago and to compare it with 
what he/she is like now. 10 years ago was in 2004. Below are situations where this person has to use 
his/her memory or intelligence and we want you to indicate whether this has improved, stayed the same, 
or got worse in that situation over the past 10 years. Note the importance of comparing his/her present 
performance with 10 years ago. So if 10 years ago this person always forgot where he/she had left things, 
and he/she still does, then this would be considered 'Hasn't changed much'. Please indicate the changes 
you have observed by circling the appropriate answer. 
 
Compared with 10 years ago how is this person at: 
 
 1 2 3 4 5 
7.1 Recognizing the faces of 
family and friends 
Much 
improved 
A bit 
improved 
Not much 
change 
A bit 
worse 
Much 
worse 
7.2. Remembering the names of 
family and friends 
Much 
improved 
A bit 
improved 
Not much 
change 
A bit 
worse 
Much 
worse 
7.3 Remembering things about 
family and friends e.g. 
occupations, birthdays, 
addresses 
Much 
improved 
 
 
A bit 
Improved 
 
 
Not much 
Change 
 
 
A bit 
Worse 
 
 
Much 
Worse 
 
 
7.4 Remembering things that 
have happened recently 
Much 
improved 
A bit 
improved 
Not much 
change 
A bit 
worse 
Much 
worse 
7.5 Recalling conversations a 
few days later 
Much 
improved 
A bit 
improved 
Not much 
change 
A bit 
worse 
Much 
worse 
7.6 Forgetting what he/she 
wanted to say in the middle of 
a conversation 
Much 
Improved 
 
A bit 
Improved 
 
Not much 
Change 
 
A bit 
Worse 
 
Much 
Worse 
 
7.7 Remembering his/her 
address and telephone number 
Much 
improved 
A bit 
improved 
Not much 
change 
A bit 
worse 
Much 
worse 
7.8 Remembering what day and 
month it is 
Much 
improved 
A bit 
improved 
Not much 
change 
A bit 
worse 
Much 
worse 
7.9 Remembering where things are 
usually kept 
Much 
improved 
A bit 
improved 
Not much 
change 
A bit 
worse 
Much 
worse 
7. 10 Remembering where to 
find things which have been 
put in a different place from 
usual 
Much 
Improved 
 
 
A bit 
Improved 
 
 
Not much 
Change 
 
 
A bit 
Worse 
 
 
Much 
Worse 
 
 
7.11 Adjusting to any change in 
his/her day-to-day routine 
 
Much 
Improved 
 
A bit 
Improved 
 
Not much 
Change 
 
A bit 
Worse 
 
Much 
Worse 
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7.12 Knowing how to work 
familiar machines around the 
house 
Much 
improved 
 
A bit 
Improved 
 
Not much 
Change 
 
A bit 
Worse 
 
Much 
Worse 
 
7.13 Learning to use a new 
gadget or machine around the 
house 
Much 
Improved 
 
A bit 
Improved 
 
Not much 
Change 
 
A bit 
Worse 
 
Much 
Worse 
 
7.14 Learning new things in 
general 
Much 
improved 
A bit 
improved 
Not much 
change 
A bit 
worse 
Much 
worse 
7.15 Remembering things that 
happened to him/her when 
he/she was young 
Much 
improved 
A bit 
improved 
Not much 
change 
A bit 
worse 
Much 
worse 
7.16 Remembering things 
he/she learned when he/she 
was young 
Much 
improved 
A bit 
improved 
Not much 
change 
A bit 
worse 
Much 
worse 
7.17 Understanding the 
meaning of unusual words 
Much 
improved 
A bit 
improved 
Not much 
change 
A bit 
worse 
Much 
worse 
7.18 Understanding magazine 
or newspaper articles 
Much 
improved 
A bit 
improved 
Not much 
change 
A bit 
worse 
Much 
worse 
7.19 Following a story in a 
book or on TV 
Much 
improved 
A bit 
improved 
Not much 
change 
A bit 
worse 
Much 
worse 
7.20 Composing a letter to 
friends or for business 
purposes 
Much 
improved 
A bit 
improved 
Not much 
change 
A bit 
worse 
Much 
worse 
7.21 Knowing about important 
historical events of the past 
Much 
improved 
A bit 
improved 
Not much 
change 
A bit 
worse 
Much 
worse 
7.22 Making decisions on 
everyday matters 
 
Much 
improved 
A bit 
improved 
Not much 
change 
A bit 
worse 
Much 
worse 
7.23 Handling money for 
shopping 
Much 
improved 
A bit 
improved 
Not much 
change 
A bit 
worse 
Much 
worse 
7.24 Handling financial matters, 
e.g. the pension, dealing with 
the bank 
Much 
improved 
A bit 
improved 
Not much 
change 
A bit 
worse 
Much 
worse 
7.25 Handling other everyday 
arithmetic problems, e.g. 
knowing how much food to 
buy, knowing how long 
between visits from family or 
friends 
Much 
Improved 
 
 
A bit 
Improved 
 
 
Not much 
Change 
 
 
A bit 
Worse 
 
 
Much 
Worse 
 
 
7.26 Using his/her intelligence 
to understand what's going on 
and to reason things through 
Much 
Improved 
 
A bit 
Improved 
 
Not much 
Change 
 
A bit 
Worse 
 
Much 
Worse 
 
 
End of Part II 
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Appendix 5: Data Collection Package (Arabic) 
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1- Patient Clinical Background Information 
1.1 General Details 
1.1.1: Gender -  M    F        1.1.2: Age _____________ 
1.1.3: Date of Birth ___/____/____              
1.1.4: Date of Admission ___/____/____        1.1.5: Date of Stroke___/____/____     
1.1.6: Nationality -  Bahraini    Non-Bahraini (If so, specify____________) 
1.1.7: Living status - Alone With spouse/family Other (If so, specify ___________)    
1.1.8: If not alone, number of people in residence ___________ 
1.1.9: List others (relationship to the patient) ___________________________________ 
1.1.10: Education - Primary  Secondary  Third level ( Cert  Diploma  Degree or higher) 
1.1.11: Occupation ____________________________________ 
 Manual Non-Manual/Self-employed  Unemployed/Retired (indicate previous occupation) 
Other__________________ 
1.1.12: Marital status - Married  Not married  Widowed  Divorced  
1.1.13: Date of Discharge   ___/____/20         1.1.14: Length of Stay__________ (days)  
1.1.15: Date of Death (if applicable)  ___/____/20                   
1.2 Medical History 
1.2.1: Smoker - Yes  No                 1.2.2: BMI - ______________  
 
1.3 Co-morbidities: 
Previous history of:  
1.3.1: TIA - Yes  (Number of TIAs _________)       No   
1.3.2: Stroke - Yes   (Number of Stokes ________)    No   
1.3.3: Cardiovascular disease/surgeries - Yes    No  
1.3.4: Atrial fibrillation - Yes    No  
1.3.5: Hypertension - Yes    No  
1.3.6: Diabetes - Yes    No  
1.3.7: Hypercholesterolemia - Yes    No  
1.3.8: Psychiatric Conditions - Yes  (__________________________)      No  
1.3.9: Other - Yes  (__________________________)      No  
Weight ________ (kg) 
Height ________ (cm) 
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1.4 Stroke Classification 
1.4.1: Cause of Stroke - Acquired    Traumatic  
1.4.2: Stroke type - Ischaemic   Haemorrhagic   
1.4.3: Stroke subtype: 
1.4.3A - OCSP Classification:  
Total Anterior Circulation Infarct    Lacunar  Partial Anterior Circulation Infarct   Posterior 
Circulation Infarct  
1.4.3B - TOAST Classification:  
Large-artery atherosclerosis  Cardioembolism  Small-artery occlusion (lacunar)  Stroke 
of other determined etiology  (specify) ___________  
Stroke of undetermined etiology  
1.4.4: Lesion location - Right hemispheric   Left hemispheric  Brain stem  
1.4.5: Dominant Arm ______________________  
 
1.5 Medications 
Pre-admission Medications 
1.5.1: Anti-hypertensives – Yes   (Specify_____________________)    No  
1.5.2: Anti-diabetic medication – Yes   (Specify_____________________)    No  
1.5.3: Aspirin/clopidogrel/other antiplatelet - Yes   (Specify_____________)    No  
1.5. 4: Statin/other lipid lowering – Yes   (Specify_____________________)    No  
1.5.5: Other - Yes   (Specify_____________________)    No  
 
Current Medications  
1.5.6: Anti-hypertensives – Yes   (Specify_____________________)    No  
1.5.7: Anti-diabetic medication – Yes   (Specify_____________________)    No  
1.5.8: Aspirin/clopidogrel/other antiplatelet - Yes   (Specify_____________)    No  
1.5. 9: Statin/Other lipid lowering – Yes   (Specify_____________________)    No  
1.5.10: Other - Yes   (Specify_____________________)    No  
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1.6 Imaging 
CT Scan  
1.6.1: Date of scan – ___/____/____ 
1.6.2: What did the scan show? 
Infarct    Haemorrhage  No abnormality   Other  (_____________________) 
 
 
 
 
 
 
 
Carotid Doppler  
1.6.3: Date of carotid doppler – ___/____/____ 
1.6.4: Carotid doppler results: 
Normal study    <70% stenosis  > 70% stenosis  
 
 
 
 
 
Other Imaging (CTA/MRA): 
 
 
 
 
 
 
 
 
Please include details from CT/MRI report: 
Please include details from carotid doppler report: 
Please include details of other imaging: 
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1.7 Laboratory 
  Result  Units 
1.7.1 Total cholesterol  mmol/l 
1.7.2 LDL  mmol/l 
1.7.3 HDL  mmol/l 
1.7.4 Triglycerides  mmol/l 
1.7.5 HbA1c  % 
1.7.6 White blood count  X109 /l 
1.7.7 Red blood cells  X1012/l 
1.7.8 Haemoglobin  g/dl 
1.7.9 Mean cell volume  Fl 
1.7.10 Platelet count  X109/l 
 
 
 
1.8 Biomarkers 
  Result  
1.8.1 ApoE  
1.8.2 sRAGE  
1.8.3 BACE1  
1.8.4 NEP  
 
 
Additional Notes:  
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 الساϡ عϠيكϡ 
 
 
 
 الϘϠΏ الصΎفي 
 
 ϭصϠΕ إلϰ المنزل من العمل.
 
 
 
 بجΎنΏ الطΎϭلΔ في غرفΔ الطعΎϡ. 
 
 
 
 سمعϭه يتحدث في اإذاعه ليϠΔ أمس. 
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 بسϡ ه الرحمن الرحيϡ
 
 مΎمΎ
 
 ثاثΔ ϭثاثين
 
 ستΔ ϭستين
 
 الϔϭاكه مϔيدة
 
 أخاϕ
 
197 
 
MINI-MENTAL STATE EXAMINATION (MMSE) 
ΔيϠϘعلا ΔلΎحلا رΎبتخأ 
 
Date of assessment: ___/____/____  Days post-stroke: ___/____/____ 
Person administering assessment: __________________ 
 
 Score 
     )هيجوΘلا( Time Orientation  
 )رϬشلا( )لμفلا( )ΔϨسلا( :هيجوΘلا)خيέΎΘلا( )ϡويلا(  
What is the (year) (season) (345) (date) (month)? 
 
/5 
 )ϥΎϜϤلا( Place Orientation  
( :ϥΎϜϤلا)قبΎطلا( )ىفشΘسϤلا( )ΔϨيΪϤلا( )ΔظفΎحϤلا( )ΔلϭΪلا  
Where are we: (state) (county) (town) (hospital) (floor)? 
 
/5 
 )ليΠسΘلا( Registration  
 عيطΘسي ىΘح ΎϬتءارق ΩΎعت ΎϬتΩΎعإ عيطΘسي مل اΫإϭ ،ΓرشΎΒم ΎϬتΩΎعأ هϨم بϠطيϭ ضيرϤلا ىϠع ΔيلΎΘلا ΕΎϤϠك Ιاثلا أرقت
ك ΎϬتΩΎعإ)ΓέΎيس ،ΡΎفت ،ΔلϭΎط( .ΕΎϤϠϜلا ΓΩΎعإ Εارم ΩΪع لΠستϭ ΔϠمΎ  
Name three unrelated objects. Allow one second to say each. Then ask the patient to repeat 
all three after you have said them. Give one point for each correct answer. Repeat them 
until he or she learns all three. Count trials and record.  
 
 
 
/3 
Trials:_____ 
 )ΏΎسحلاϭ ϩΎΒΘنإا( Attention and Calculation  
 Ρرطي ϥأ ضيرϤلا نم بϠطي7  نم100 .Εارم سϤخ اάϜهϭ جتΎϨلا نم  
Ask patient to count backwards from 100 by sevens. Give one point for each correct answer. 
Stop after five answers. Alternatively, spell world backwards. 
 
/5 
 )ءΎعΪΘساا( Recall  
.ΎقبΎس ΎϬϤϠعت يΘلا ΕΎϤϠϜلا ءΎعΪΘسا ضيرϤلا نم بϠطي  
Ask patient to recall the three objects previously stated. Give one point for each correct 
answer. 
 
/3 
 )ΔغϠلا( Language  
.ΔعΎس ،مϠق ،)صحΎفلا ΎϬيلإ ريشي( ΔيلΎΘلا ءΎيشأا يϤسي ϥأ ضيرϤلا نم بϠطي :ΔيϤسΘلا 
Show patient a wrist watch; ask patient what it is. Repeat for a pencil. 
/2 
نϜلϭ Ώرش مث لكأ{ :ΎمΎϤت يه ΎϤك ΎϬتΩΎعإ هϨم بϠطيϭ ΔيلΎΘلا هϠϤΠلا ضيرϤلا ىϠع أرقت :ΓΩΎعإا .}ΩΎع  
Ask patient to repeat the following: "No ifs, ands, or buts."  
/1 
.νέأا ىϠع ΎϬعض مث )فμϨلا( صϨلا نم ΎϨϬثا ىϨϤيلا ΪيلΎب Δقέولا ϩάه άخ :يϠي ΎϤب ϡوقي ϥأ ضيرϤلا نم بϠطي :مϬفلا    
Ask patient to follow a three-stage command: "Take a paper in your right hand, fold it in 
half, and put it on the floor."  
 
/3 
.}كϨيع قϠغا{ :ΎϬيف Ύم قΒطيϭ ΔيلΎΘلا ΔϠϤΠلا أرقي ϥأ ضيرϤلا نم بϠطي :Γءارقلا 
Ask patient to read and obey the following sentence which you have written on a piece of 
paper: "Close your eyes." 
 
/1 
.)ΎϬيف رϜفت ϥأ ϥϭΪب كلΎΒب رطΨت ΔϠϤج ϝϭأ( .ΓΪيفم ΔϠϤج بΘϜي ϥأ ضيرϤلا نم بϠطي :ΔبΎΘϜلا 
Ask patient to write a sentence.  
/1 
 )مسرلا( Drawing  
 )ϡيمصتلا اذه لϘني نأ ضيرملا نم ΏϠطي( Ask patient to copy a design.  
  
 
 
 
 
 
 
/1 
 
Total Score: _______ 
Assess level of consciousness along a continuum: Alert – Drowsy- Stupor – Coma 
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The Barthel Index 
Activity Score 
Feeding  
0= unable 
5= needs help cutting, spreading butter, etc., or requires modified diet 
10= independent 
 
Bathing  
0= dependent 
5= independent (or in shower) 
 
Grooming  
0= dependent 
5= independent face/hair/teeth/shaving (implements provided) 
 
Dressing  
0= needs help with personal care 
5= needs help but can do about half unaided 
10= independent (including buttons, zips, laces, etc.) 
 
Bowels  
0= incontinent (or needs to be given enemas) 
5= occasional accident 
10= continent 
 
Bladder  
0= incontinent, or catheterized and unable to manage alone 
5= occasional accident 
10= continent 
 
Toilet use  
0= dependent 
5= needs some help, but can do something alone 
10= independent (on and off, dressing, wiping) 
 
Transfers (Bed to chair and back)  
0= unable, no sitting balance 
5= major help (one or two people, physical), can sit 
10= minor help (verbal or physical) 
15= independent 
 
Mobility (on level surfaces)  
0= immobile or <50 yards 
5= wheelchair independent, including corners, >50 yards 
10= walks with help of one person (verbal or physical) >50 yards 
15= independent (but may use aid; for example, stick) >50 yards 
 
Stairs  
0= unable 
5= needs help (verbal, physical, carrying aid) 
10= independent 
 
           
            Total (0-100): ____ 
End of Part I 
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 )TSAFإمتحان فرنتشي ƃلƂشف عن عدم اƃقدرة على اƃƂام ( -2
 اƃفهم  2-1
أبرز ƅلمريض بطاقة مƊظر اƅƊهري قل " أƊظر إƅى اƅصورةي إستمع بعƊاية ƅما يقال وأشر إƅى اƗشياء اƅتي أقوƅها ƅكي سجل 
ؤديه اƅمريض بشكل صحيحي إذا تتطلبت اƅتعليمات اƅتƄرار، سّجل درجة خطأي قد يسجل اƅتصحيح يƅƄل عمل  1درجة 
 اƅذاتي اƅعفوȑ صحيحاي 
 ي01ى0Ɗطاق اƅدرجات 
  اƅƊهر مƊظر 1.1.2
 ___ /1 : أشر إƅى اƅقارب1ي1ي1ي2
 ___ /1 : أشر إƅى أطول شجرة2ي1ي1ي2
 ___ /1 : أشر إƅى اƅرجل وأشر إƅى اƅƄلب3ي1ي1ي2
 ___ /1 : أشر إƅى اƅساق اƅيسرȐ ƅلرجل4ي1ي1ي2
 ___ /1 : قبل اإشارة إƅى اƅبطة قرب اƅجسر، أرƊي اƅتل اƗوسȌ5ي1ي1ي2
 ___ /5 مجموع اƅدرجات 
 
 اƗشكال 2.1.2
 ___ /1 : أشر إƅى اƅمربع1ي2ي1ي2
 ___ /1 : أشر إƅى اƅمخروط2ي2ي1ي2
 ___ /1 : أشر إƅى اƅمستطيل واƅمربع3ي2ي1ي2
 ___ /1 : أشر إƅى اƅمربع واƅمخروط وشبه اƅدائرة4ي2ي1ي2
 ___ /1 : أشر إƅى اƅشيء اƅذȑ يشبه اƅهرم واƅشيء اƅذȑ يشبه قطعة اƅبرتقال5ي2ي1ي2
 ___ /5 اƅدرجاتمجموع  
 اƃتعبير    2-2
أبرز ƅلمريض مƊظر اƅƊهر وقل: " أخبرƊي ما تعرفه عن اƅصورة ما أمكني " إذا ƅم يبدȑ اƅمريض فهم ذƅك، قل: " أذكر أسم   1ي2ي2
  5ى0أȑ شيء تراƋ في اƅصورةي Ɗطاق اƅدرجة 
 
 0 غير قادر على تسمية أȑ من اƗشياء بوضوح
 1 : اƗشياء 2ى1
 2 : اƗشياء4ى3
 3 : اƗشياء7ى5
أستخدم عبارات  –أشياء أو أستخدم عبارات أو جمل ، ƅƄن اƗداء غير عادȑ  9أو  8تسمية 
 أو جمل ط مثا، اƅتردد، اƅتعليقات غير اƅمائمة، ييي اƅخ)
 4
 5 أشياء 01أستخدم عبارات وجمل، أعطي أسماء  –عادȑ 
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إƊزع بطاقة اƅصورة من اƅمƊظر وأخبر اƅمريض بأƊك ستحاول شيء مختلف إƅى حد ماي ثم إسأƅه/ إسأƅها بتسمية اƅƄثير من  2ي2ي2
اƅحيواƊات قدر ما يستطيع / تستطيع  أن تفكر في ذƅك بدقيقة واحدةي إذا كاƊت أسماء أȑ Ɗوع من اƅحيوان، برȑ أو أƅيف، وƅيس مجرد تلك 
 ي 5ى0ثاƊيةي اƅدرجة  06في اƅصورةي  إبدأ باƅتوقيت بمجرد أن يقوم اƅمريض بتسمية اƅحيوان اƗول وأسمح ƅه بـ  اƅتي يمكن مشاهدتها
 0 ا شيء تم تسميته
 1 2ى1تسمية 
 2 5ى3تسمية 
 3 9ى6تسمية 
 4 41ى01تسمية 
 5 أو أƄثر 51تسمية 
  اƅدرجة  
 
 اƃقراءة    2-3
Ɨغراض اƅقراءةي أظهر ƅلمريض مƊظر اƅƊهر وبطاقة اƅقراءة اƗوƅىي إسأƅه/ إسأƅها بأن تقرأ اƅجملة تأƄد من أن اƅمريض يلبس Ɗظارته  
بƊفسه، ƅيس بصوت مرتفع، وأعمل بما يطلب مƊه/ مƊها  أن يقوم بهي إستمر بƊفس اƗسلوب مع بطاقات اƅقراءة اƗربع اƅمتبقية بƊفس 
 5ى0اƗسلوبي Ɗطاق اƅدرجات 
 
 1___/ اƅƄلب: أشر إƅى 1ي3ي2
 1___/ : أشر إƅى اƅجسر2ي3ي2
 1___/ : أشر إƅى اƅرجل اƅواقف في اƅمركب3ي3ي2
 1___/ : إƅمس اƅزاوية  اƅيسرȐ من اƅبطاقة4ي3ي2
 1___/ إƅمس أسفل هذة اƅبطاقة، وثم أعاهاي: 5ي3ي2
 5___/ مجموع اƅدرجات 
   
 اƃƂتابة    2-4
كتابة ما تستطيع حول ما يحدث في اƅصورةي إذا  ƅم يبدȑ / تبدȑ فهما فهما ƅذƅك، قل: " أظهر ƅلمريض مƊظر اƅƊهر وقل: " أرجو 
أƄتب أȑ شيء يمكƊك مشاهدته في اƅصورةي إذا كاƊت اƅيد اƅمهيمƊة متأثرة ، إطلب من اƅمريض أن يحاول مع اƅيد غير اƅمهيمƊةي قم 
 ي5ى0أقصىي اƅدرجة دقائق كحد  5بتشجيع إذا توقف هو / هي قبل اآواني أسمح  بـ 
 0 قادر على محاوƅة اƅمهمة ƅƄن ا يكتب كلمات واضحة  أو مƊاسبةي
 1 يكتب كلمة  واحدة أو اثƊتين
 2 أشياء أو عبارة بما فيها شيئين أو ثاثة أشياء 3يكتب أسماء 
 3 أشياء 4أشياءط بأحرف صحيحة)، أو عبارتين أو ثاث بما فيها أسماء  4يكتب أسماء 
أشياء، ƅƄن ا يعتبر أداء طبيعي، مثا جملة ا تتƄامل مع  5عبارات أو جمل ، تشمل  يستخدم
 اƅƊاس أو اƗفعال
 4
 5 أداء طبيعي باƅتأƄيد، مثا جملة تتƄامل مع اƅƊاس واƗفعال
  مجموع اƅدرجات 
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Comprehension _______ /10 
Expression _______/10 
Reading _______/5 
Writing _______/5 
Overall Total Score           /30 
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3-Trial Making Test (TMT) Parts A & B 
Instructions: 
 Both parts of the Trail Making Test consist of 25 circles distributed over a sheet of paper. In Part 
A, the circles are numbered 1 – 25, and the patient should draw lines to connect the numbers in 
ascending order. In Part B, the circles include both numbers (1 – 13) and letters (A – L); as in Part 
A, the patient draws lines to connect the circles in an ascending pattern, but with the added task of 
alternating between the numbers and letters (i.e., 1-A-2-B-3-C, etc.). The patient should be 
instructed to connect the circles as quickly as possible, without lifting the pen or pencil from the 
paper. Time the patient as he or she connects the "trail." If the patient makes an error, point it out 
immediately and allow the patient to correct it. Errors affect the patient's score only in that the 
correction of errors is included in the completion time for the task. It is unnecessary to continue the 
test if the patient has not completed both parts after five minutes have elapsed 
 
Procedure  
 Step 1   Give the patient a copy of the Trail Making Test Part A worksheet and a pen or pencil. 
 Step 2  Demonstrate the test to the patient using the sample sheet (Trail Making Part A – 
SAMPLE). 
 Step 3  Time the patient as he or she follows the “trail” made by the numbers on the test. 
 Step 4  Record the time. 
 Step 5  Repeat the procedure for Trail Making Test Part B. 
 
Scoring: 
 Results for both TMT A and B are reported as the number of seconds required to complete the 
task; therefore, higher scores reveal greater impairment. 
 
 Average Deficient Rule of Thumb 
Trial A 29 seconds > 78 seconds Most in 90 seconds 
Trial B 75 seconds > 273 seconds Most in 3 minutes 
 
Trial Score  
Trail A _______________ Seconds 
Trial B ________________ Seconds  
Final Score  (Trial B – Trial A) = ____ Seconds 
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3.1 Trial Making Test Part A- Sample: 
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3.1 Trial Making Test Part A (For Patient) 
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3.2 Trial Making Test Part B- Sample: 
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3.2 Trial Making Test Part B (For Patient): 
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 )SDAHاƃƂآبة ( مقياس اƃمستشفى ƃلقلق و -4
اƅتفكير اƅطويل يƊصح أن يقلع عن ّد فورȑ و يجب عليهم إعطاء ر مقابلةي  ردود مقدمة ƅƄلمن أربع   واحدرّد إختيار يطلب من اƅمرضى 
قدم اƅعمود اƅصحيحي وتعطى درجة كل إجابة في "ي D" وا  ƅى اƅƄآبة " A"  باƅقلقاƅمتعلقة  أسئلة ƅ اإشارةيتم ي ابتهمجدا حول أج
 مشاعرهم حاƅيايعن كيفية وصف إجابة تعليمات ƅلمريض في ا
 
  أشعر كما ƃو كنت متباطئا: 2.4   أبدو متشنجا ومتوترا:   1.4
 
 
 A
  3 أغلب اƗوقات
 D
 3 تقريبا في جميع اƗوقات
 2 في أغلب اƗحيان 2 أƄثر اƗوقات
 1 أحياƊا 1 من وقت آخر، أحياƊا
 0 ا على اإطاق 0 ا على اإطاق
 
ينتابني نوع من اƃشعور باƃخوف مثل  4.4   ا زƃت أستمتع باأشياء اƃتي إعتدت عليها:   3.4
 اƃتوتر
 
 
 
 D
  0 باƅتأƄيد كثيرا
 A
 0 ا على اإطاق
 1 من وقت آخر 1 ƅيس باƅضبȌ كثيرا
 2 غاƅبا 2 فقȌ قليا
 3 في أغلب اƗحيان 3 قليا جدا
 
ينتابني نوع من اƃشعور باƃخوف كما ƃو كان  5.4
   هناك شيء مرعب على وشك أن يحدث: 
  فقدت اإهتمام بمظهرȏ: 6.4  
 
 A
  3 جدا وبشكل سيء تماماباƅتأƄيد 
 D
 3 باƅتأƄيد
 2 ƅم آخذ عƊاية كما يجب   2 Ɗعم ƅƄن ƅيس بشكل سيء جدا 
 1 تماما Ɗفس قدر اƅعƊايةƅم آخذ  1 قليا ، ƅƄƊه ا يقلقƊي
 0 أعƊتƊي كثيرا عن أȑ وقت مضى 0 ا على اإطاق
 
يمكنني أن أضحك وأرȎ اƃجانب اƃمضحك من  7.4
   اأشياء: 
  أشعر باأضطراب وباƃي دائما مشغول: 8.4  
 
 D
  0 كثيرا جدا باƅفعل
 A
 3 أغلب اƗحيان باƅفعل
 2 غاƅبا جدا 1 كثيرا جدا 
 1 ƅيس في أغلب اƗوقات 2 ƅيس كثيرا
 0 ا على اإطاق 3 ا على اإطاق
 
  ƃاستمتاع إƃى اأشياءأتطلع  01.4   تمر اأفƂار اƃمثيرة ƃلقلق إƃى ذهني  9.4
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 A
   3 بقدر كبير من اƅوقت 
 D
 0 أƄثر مما عملت
 1 بأقل إƅى حد ما مما إعتدت عليه  2 اƅƄثير من اƅوقت
 2 مما إعتدت عليه باƅتأƄيد أقل  1 من وقت ƅƖخر ، وƅƄن ƅيس كثيرا جدا
 3 قليل جدا  0 أحياƊا فقȌ
 
  على شعور مفاجئ من اƃهلع:أحصل  21.4   أشعر باإبتهاج 11.4
 
 D
   3 ا على اإطاق
 A
 3 أغلب اƗحيان باƅفعل
 2 غاƅبا جدا  2 ƅيس في أغلب اƗحيان
 1 ƅيس في أغلب اƗوقات  1 أحياƊا
 0 ا على اإطاق  0 أغلب اƅوقت
أو راديو أو  يمكنني اإستمتاع بكتاب 41.4   أستطيع أن أجلس في راحة وأشعر بااسترخاء  31.4
 برنامج تلفزيوني جيد:
 
 
 A
   0 باƅتأƄيد
 D
 0 غاƅبا
 1 أحياƊا  1 عادة
 2 ƅيس غاƅبا  2 ƅيس غاƅبا
 3 Ɗادرا جدا  3 ا على اإطاق
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 )03-QCM( eriannoitseuQ evitingocateMستبيان ما وراء اƃمعرفة إ-5
 1 : اƃثقة اإدراƂية1.5
 ا أوافق
 2
 أوافق قليا
 3
 أوفق بإعتدال
 4
 أوافق كثيرا جدا
     ا أثق بذاƄرتي ϭ.ϭ.ϱ
     عƊدȑ ذاƄرة ضعيفة Ϯ.ϭ.ϱ
     عƊدȑ ثقة قليلة بذاƄرتي ƅأعمال ϯ.ϭ.ϱ
     عƊدȑ ثقة قليلة بذاƄرتي ƅأماƄن ϰ.ϭ.ϱ
     عƊدȑ ثقة قليلة بذاƄرتي ƅلƄلمات واƗسماء ϱ.ϭ.ϱ
     أحياƊا تخدعƊي ذاƄرتي  ϲ.ϭ.ϱ
 
 1 : ااعتقادات اإيجابية2.5
 ا أوافق
 2
 أوافق قليا
 3
 أوفق بإعتدال
 4
 أوافق كثيرا جدا
     يساعدƊي اƅقلق ƅترتيب اƗشياء في ذهƊي ϭ.Ϯ.ϱ
     يساعدƊي اƅقلق في أن أتحّمل Ϯ.Ϯ.ϱ
     Ƅي أعمل بشكل جيدƅأن أقلق  أحتاج ϯ.Ϯ.ϱ
     اƅمشاƄليساعدƊي اƅقلق في حّل  ϰ.Ϯ.ϱ
     Ƅي أظل مƊظماƅأن أقلق  أحتاج ϱ.Ϯ.ϱ
     يساعدƊي اƅقلق  ƅتجƊب اƅمشاƄل في اƅمستقبل ϲ.Ϯ.ϱ
 : اƃوعي اƃذاتي اإدراƂي3.5
 
 1
 ا أوافق
 2
 أوافق قليا
 3
 أوفق بإعتدال
 4
 أوافق كثيرا جدا
     إƊƊي على وعي دائم بتفكيرȑ  ϭ.ϯ.ϱ
     أبدȑ إهتماما كبيرا بطريقة عمل ذهƊي   Ϯ.ϯ.ϱ
     أفكر كثيرا حول أفكارȑ  ϯ.ϯ.ϱ
     أدرس أفكارȑ بإستمرار ϰ.ϯ.ϱ
     أراقب أفكارȑ  ϱ.ϯ.ϱ
إƊƊي على وعي بطريقة عمل ذهƊي عƊدما أفكر  ϲ.ϯ.ϱ
 من خال مشكلة
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 1 عدم قابلية اƃتحكم واƃخطر: 4.5
 ا أوافق
 2
 قلياأوافق 
 3
 أوفق بإعتدال
 4
 أوافق كثيرا جدا
     امهما أحاول إيقافهأفكارȑ اƅمثيرة ƅلقلق تستمر  ϭ.ϰ.ϱ
     فا أستطيع اƅتوق ّ قلقباƅعƊدما أبدأ  Ϯ.ϰ.ϱ
     ƅقلقمع اأن أمرض Ɗي يمكƊ ϯ.ϰ.ϱ
     اƅمثيرة ƅلقلقأفكارȑ تجاهل ا أستطيع  ϰ.ϰ.ϱ
     قلقي أن أƄون مجƊوƊا يمكن أن يجعلƊي ϱ.ϰ.ϱ
     ليعقلقي خطر  ϲ.ϰ.ϱ
 
 1 اƃحاجة إƃى اƃسيطرة على اأفƂار: 5.5
 ا أوافق
 2
 أوافق قليا
 3
 أوفق بإعتدال
 4
 أوافق كثيرا جدا
ƅن أƄون فإƊƊي أفكارȑ، اƅتحكم في أستطع ƅم إذا  ϭ.ϱ.ϱ
 اƅعملعلى  اقادر 
    
هي  أفكارȑ اƅتحكم في قادر على كوƊي غير  Ϯ.ϱ.ϱ
 ضعفمؤشر 
    
     يجب أن أƄون في تحكم بأفكارȑ طوال اƅوقت ϯ.ϱ.ϱ
     من اƅسيئ اƅتفكير بأفكار معيƊة ϰ.ϱ.ϱ
وبعد ذƅك تحكم في اƅفكرة اƅمثيرة ƅلقلق إذا ƅم أ ϱ.ϱ.ϱ
 خطأȑسيكون فإƊه حدث، 
    
 أƊا سأعاقب ƅعدم اƅسيطرة على بعض اƗفكار ϲ.ϱ.ϱ
 في اƅمستقبل
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 الدمΎغيΔ السكته بعد ϭالمزاجيΔ المعرفيΔ العϭاقΏ قΎئمΔ -
 )42-ECLC( ekortS gniwolloF secneuqesnoC lanoitomE dna evitingoC rof tsilkcehC 
 
 المريض ϭ.6
 :المعرفΔ
 :في مشΎكل عندϱ السكته، منذ
 ليس لكن نعϡ، ا  أعϠϡ ا
  حΎد بشكل
 ϭي΅ثر نعϡ،
 عϠϰ بشدة
  اليϭميه حيΎتي
 
 ϭقΕ في بشيئين الϘيΎϡ   1.1.6     
  ϭاحد
 بΎأشيΎء اأعتنΎء  2.1.6    
 ابط΄ اصبحΕ: التϘدϡ  ϯ.ϭ.6    
 جديدة معϠϭمΎΕ تذكر4.1.6     
 قديمΔ معϠϭمΎΕ تذكر5.1.6     
 المبΎدرة اخذ6.1.6     
 اأمϭر ϭتنظيϡ تخطيط7.1.6     
 اليϭميΔ اأنشطΔ أداء8.1.6     
 الϭقΕ إدراϙ9.1.6     
 أϭ لأمΎكن التϭجيه01.1.6     
 اأشخΎص
 الϠغΔ فϬϡ11.1.6     
 الكتΎبΔ أϭ التحدث21.1.6     
 من جزء عϠϰ التركيز31.1.6     
 مΎ مسΎحΔ أϭ الجسϡ
 
 :المزاج
 :ب΄نني اشعر السكته، منذ
 ليس لكن نعϡ، ا  أعϠϡ ا
  حΎد بشكل
 ϭي΅ثر نعϡ،
 عϠϰ بشدة
  اليϭميه حيΎتي
 
 مكتئΏ 41.1.6     
 المستϘبل من خΎئف51.1.6     
 اجتمΎعي غير61.1.6     
 ϭاقعي غير71.1.6    
 ، ًعΎطϔيΎ مستϘر غير81.1.6     
 بسϬϭلΔ ابكي
 اغضΏ منزعج،91.1.6     
 بسϬϭلΔ
 مϬتϡ غير العΎطϔΔ، قϠيل02.1.6     
 سيطرة عϠϰ قΎدر غير12.1.6     
 تصرفΎتي
 بسرعΔ اتعΏ22.1.6     
 
  أخرى؟ مشاكل اي هناك هل
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 الدمΎغيΔ السكته بعد ϭالمزاجيΔ المعرفيΔ العϭاقΏ قΎئمΔ -
 )42-ECLC( ekortS gniwolloF secneuqesnoC lanoitomE dna evitingoC rof tsilkcehC 
 
 :الرعΎيΔ  2.6
 :المعرفΔ
 :في مشΎكل عنده المريض السكته، منذ
 ليس لكن نعϡ، ا  أعϠϡ ا
  حΎد بشكل
 ϭي΅ثر نعϡ،
 عϠϰ بشدة
  اليϭميه حيΎته
 
 ϭقΕ في بشيئين الϘيΎϡ   1.1.6     
  ϭاحد
 بΎأشيΎء اأعتنΎء  2.1.6    
 ابط΄ اصبح: التϘدϡ  ϯ.ϭ.6    
 جديدة معϠϭمΎΕ تذكر4.1.6     
 قديمΔ معϠϭمΎΕ تذكر5.1.6     
 المبΎدرة اخذ6.1.6     
 اأمϭر ϭتنظيϡ تخطيط7.1.6     
 اليϭميΔ اأنشطΔ أداء8.1.6     
 الϭقΕ إدراϙ9.1.6     
 أϭ لأمΎكن التϭجيه01.1.6     
 اأشخΎص
 الϠغΔ فϬϡ11.1.6     
 الكتΎبΔ أϭ التحدث21.1.6     
 من جزء عϠϰ التركيز31.1.6     
 مΎ مسΎحΔ أϭ الجسϡ
 
 :المزاج
 :المريض أن تشعر السكته، منذ
 ليس لكن نعϡ، ا  أعϠϡ ا
  حΎد بشكل
 ϭي΅ثر نعϡ،
 عϠϰ بشدة
  اليϭميه حيΎته
 
 مكتئΏ 41.1.6     
 المستϘبل من خΎئف51.1.6     
 اجتمΎعي غير61.1.6     
 ϭاقعي غير71.1.6    
 ، ًعΎطϔيΎ مستϘر غير81.1.6     
 بسϬϭلΔ يبكي
 بسϬϭلΔ يغضΏ منزعج،91.1.6     
 مϬتϡ غير العΎطϔΔ، قϠيل02.1.6     
 سيطرة عϠϰ قΎدر غير12.1.6     
 تصرفΎته
 بسرعΔ يتعΏ22.1.6     
 
  أخرى؟ مشاكل اي هناك هل
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 مخبريه عن اƃهبوط اإدراƂي ƃدȎ اƃمسنين إستبانة 7-
  )EDOCQI( ylredlE eht ni enilceD evitingoC no eriannoitseuQ tnamrofnI
ي 4002سƊوات مضت تعƊي في عام  01ومقارƊة ذƅك مع  حاƅه اآني  سƊوات  01قبل   أو صديقك قريبككيف كان  أن تتذّكر Ɗطلب مƊك 
إذا كان هƊاك سواء بأن تشير إƅى ذƅك  كذكائه ، وƊطلب مƊذاƄرته أو خدم هذا اƅشخص أن يستيجب على حيث تجدون أدƊاƋ اƅحاات 
 01قبل مع أدائه مقارƊة أدائه اƅحاƅي  سƊوات اƅماضيةي احظ أهمية 01خال اƅـ اƃحاƃة ƃأسوأ تردتأو  ظل اƃحاƃة كما هيأو ، تحّسن
 يسنوات
 باƅتاƅي يعتبر ذƅك "ƅم يتغير ، ذƅك يعمليزال  ن يضع اƗشياء، وايسƊوات دائما يƊسى أ 01قبل هذا اƅشخص  إذا كان، ﹰمثا
 اƅجواب اƅمائمياƅتي تاحظها بوضع دائرة على إƅى اƅتغييرات اإشارة جاء كثيرا"ي اƅر 
 
 :عƊدهذا اƅشخص كيف يكون سƊوات  01قبل ذƅك قارن 
 5 4 3 2 1 
 أسوأ بكثير أسوأ قليا تغيير ƅيس باƅƄثير تحسن قليل تحسن أƄثر اƅتعرف على وجوƋ اƅعائلة واƗصدقاء 1.7
 أسوأ بكثير أسوأ قليا تغيير ƅيس باƅƄثير تحسن قليل تحسن أƄثر تذّكر أسماء اƅعائلة واƗصدقاء2.7 
تذكر أشياء عن اƅعائلة واƗصدقاء، مثل 3.7 
 اƅمهن، تواريخ اƅمياد، واƅعƊواƊين
 أسوأ بكثير أسوأ قليا تغيير ƅيس باƅƄثير تحسن قليل تحسن أƄثر
 أسوأ بكثير قلياأسوأ  تغيير ƅيس باƅƄثير تحسن قليل تحسن أƄثر تذكر اƗشياء اƅتي حدثت مؤخرا4.7 
 أسوأ بكثير أسوأ قليا تغيير ƅيس باƅƄثير تحسن قليل تحسن أƄثر استدعاء محادثات بعد عدة أيام قليلة5.7 
 أسوأ بكثير أسوأ قليا تغيير ƅيس باƅƄثير تحسن قليل تحسن أƄثر Ɗسيان ما يريد قوƅه في مƊتصف اƅمحادثة 6.7 
 أسوأ بكثير أسوأ قليا تغيير ƅيس باƅƄثير تحسن قليل أƄثر تحسن تذّكر عƊواƊه أو رقم هاتفه 7.7 
 أسوأ بكثير أسوأ قليا تغيير ƅيس باƅƄثير تحسن قليل تحسن أƄثر تذّكر اƅيوم واƅشهر اƅذȑ فيه 8.7 
 أسوأ بكثير أسوأ قليا تغيير ƅيس باƅƄثير تحسن قليل تحسن أƄثر تذّكر  أين توضع اƗشياء عادة9.7 
تذّكر أين يجد اƗشياء اƅتي توضع عادة 01.7 
 في أماƄن مختلفة  
 أسوأ بكثير أسوأ قليا تغيير ƅيس باƅƄثير تحسن قليل تحسن أƄثر
 
اƅتأقلم مع أȑ تغيير في روتين حياته 11.7 
 اƅيومية 
 أسوأ بكثير أسوأ قليا تغيير ƅيس باƅƄثير تحسن قليل تحسن أƄثر
اآات اƅمأƅوفة معرفة كيفية استعمال 21.7 
  في اƅمƊزل
 أسوأ بكثير أسوأ قليا تغيير ƅيس باƅƄثير تحسن قليل تحسن أƄثر
 أسوأ بكثير أسوأ قليا تغيير ƅيس باƅƄثير تحسن قليل تحسن أƄثر تعّلم استخدام آƅة أو ماƄƊة حول اƅبيت 31.7 
 أسوأ بكثير أسوأ قليا باƅƄثير تغيير ƅيس تحسن قليل تحسن أƄثر  تعّلم أشياء جديدة بشكل عام41.7 
تذّكر اƗشياء اƅتي حدثت ƅه أو ƅها 51.7 
  عƊدما كان أو كاƊت شابة
 أسوأ بكثير أسوأ قليا تغيير ƅيس باƅƄثير تحسن قليل تحسن أƄثر
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تذّكر اƗشياء اƅتي تعلمها عƊدما كان 61.7 
  شابا
 أسوأ بكثير أسوأ قليا تغيير ƅيس باƅƄثير تحسن قليل تحسن أƄثر
 أسوأ بكثير أسوأ قليا تغيير ƅيس باƅƄثير تحسن قليل تحسن أƄثر  فهم معاƊي اƅƄلمات غير اƅعادية71.7 
 أسوأ بكثير أسوأ قليا تغيير ƅيس باƅƄثير تحسن قليل تحسن أƄثر  فهم مقاات اƅمجلة أو اƅصحيفة81.7 
 أسوأ بكثير أسوأ قليا تغيير ƅيس باƅƄثير تحسن قليل أƄثرتحسن   متابعة اƅقصة في اƅƄتاب أو اƅتلفزيون 91.7 
عرض رساƅة إƅى اƗصدقاء أو 02.7 
  Ɨغراض اƅعمل
 أسوأ بكثير أسوأ قليا تغيير ƅيس باƅƄثير تحسن قليل تحسن أƄثر
معرفة اƗحداث اƅتاريخية اƅمهمة في 12.7 
  اƅماضي
 أسوأ بكثير قلياأسوأ  تغيير ƅيس باƅƄثير تحسن قليل تحسن أƄثر
 أسوأ بكثير أسوأ قليا تغيير ƅيس باƅƄثير تحسن قليل تحسن أƄثر  اتخاذ قرارات حول اƅمسائل اƅيومية22.7 
 أسوأ بكثير أسوأ قليا تغيير ƅيس باƅƄثير تحسن قليل تحسن أƄثر اƅتعامل مع اƅمال ƅلتسوق 32.7 
اƅتعامل مع اƅمسائل اƅماƅية، مثل 42.7 
  اƅتقاعدȑ ، واƅتعامل مع اƅبƊكاƅراتب 
 أسوأ بكثير أسوأ قليا تغيير ƅيس باƅƄثير تحسن قليل تحسن أƄثر
 
اƅتعامل في كل يوم آخر في اƅمسائل 52.7 
اƅحسابية، مثل معرفة مقدار اƅغذاء اƅمطلوب، 
 ومعرفة كم اƅمدة بين زيارات اƅعائلة واƗصدقاء 
 أسوأ بكثير أسوأ قليا باƅƄثيرتغيير ƅيس  تحسن قليل تحسن أƄثر
يدور حوƅه إستخدام ذكائه في فهم ما 62.7 
   واƅتفكير في اƗشياء من خال ذƅك
 أسوأ بكثير أسوأ قليا تغيير ƅيس باƅƄثير تحسن قليل تحسن أƄثر
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Appendix 6: Standard Operating Procedure for DNA Purification 
STANDARD OPERATING PROCEDURE FOR DNA PURIFICATION 
DNA Purification  
DNA purification is a process that entails isolating DNA from a sample via chemical and/or physical means. The 
objective of the process is to disrupt the cellular structure, thereby creating a lysate that separates the soluble 
DNA from cell debris and other insoluble material and purifying the DNA of interest from other nucleic acids 
and soluble proteins.(346) The purpose of this SOP is to describe both the automated and manual 
procedures used to isolate genomic DNA for the purposes of our study. 
Magna Pure Compact Nucleic Acid Isolation Kit I Protocol (Automated) 
Instruments: 
Procedure: 
1. Prepare buffy coat by centrifuging whole blood at 2500 x g for 10 minutes at room temperature (15–
25°C). 
Ϯ. Isolate DNA as peƌ ŵaŶufaĐtuƌeƌ͛s pƌotoĐol.  The Magna Pure Compact Instrument© was used in this 
study and the Magna Pure Compact Nucleic Acid Isolation Kit I protocol was followed (see below).  
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QIAGEN Protocol (Manual) 
Instruments: 
Procedure: 
1. Prepare buffy coat by centrifuging whole blood at 2500 x g for 10 minutes at room temperature (15–
25°C). 
2. Pipet 20 µl QIAGEN Protease (or proteinase K) into the bottom of a 1.5 ml microcentrifuge tube.  
3.  Add 200 µl of buffy coat of sample to the microcentrifuge tube.  
4. Add 200 µl Buffer AL to the sample. Mix by pulse-vortexing for 15 s.  
5. Incubate at 56°C for 10 min.  
6. Briefly centrifuge the 1.5 ml microcentrifuge tube to remove drops from the inside of the lid.  
7. Add 200 µl ethanol (96–100%) to the sample, and mix again by pulse-vortexing for 15 s. After mixing, 
briefly centrifuge the 1.5 ml microcentrifuge tube to remove drops from the inside of the lid.  
8. Carefully apply the mixture from step 7 to the QIAamp Mini spin column (in a 2 ml collection tube) 
without wetting the rim. Close the cap, and centrifuge at 8000rpm for 1 min. Place the QIAamp Mini spin 
column in a clean 2ml collection tube (provided), and discard the tube containing the filtrate. 
9. Carefully open the QIAamp Mini spin column and add 500 µl Buffer AW1 without wetting the rim. Close 
the cap and centrifuge at 8000 rpm for 1 min. Place the QIAamp Mini spin column in a clean 2 ml collection 
tube (provided), and discard the collection tube containing the filtrate. 
10. Carefully open the QIAamp Mini spin column and add 500 µl Buffer AW2 without wetting the rim. 
Close the cap and centrifuge at full speed (14,000 rpm) for 3 min.  
11. Place the QIAamp Mini spin column in a new 2 ml collection tube (not provided in kit) and discard the 
old collection tube with the filtrate. Centrifuge at full speed for 1 min.  
12. Place the QIAamp Mini spin column in a clean 1.5 ml microcentrifuge tube (not provided), and discard 
the collection tube containing the filtrate. Carefully open the QIAamp Mini spin column and add 200 µl 
Buffer AE or distilled water. Incubate at room temperature (15–25°C) for 1 min, and then centrifuge at 
8000 rpm for 1 min.  
13. Incubate the QIAamp Mini spin column loaded with Buffer AE or water for 5 min at room temperature. 
Carefully open the QIAmp Mini spin column and add a further 50 µl Buffer AE. Incubate at room 
temperature for 5 min and then centrifuge at 8000 rpm for 1 min.   
 
1. Aljanabi SM, Martinez I. Universal and rapid salt-extraction of high quality genomic DNA for PCR-based 
techniques. Nucleic acids research. 1997;25(22);4692-3. 
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Appendix 7: Standard Operating Procedure for Apolipoprotein E Genotyping Using PCR-RFLP 
STANDARD OPERATING PROCEDURE FOR APOLIPOPROTEIN E GENOTYPING 
USING PCR-RFLP 
PURPOSE 
The purpose of this SOP is to and to describe the procedure for detecting ApoE genotypes by conventional 
polymerase chain reaction – restriction fragment length polymorphism (PCR-RFLP).  
For PCR-RFLP 
1. MATERIALS 
1. General 
i. Micropipets and tips 
ii. PCR tubes with caps 
iii. Disposable gloves 
iv. Fine tip marker pens 
v. Nuclease free water 
2. PCR 
i. Gotaq Green Master Mix 
ii. DSMO  
iii. Primers 
 Primer (forward): TCC-AAG-GAG-CTG-CAG-GCG-GCG-CA 
 Primer (reverse): GCC-CCG-GCC-TGG-TAC-ACT-GCC-A 
3. RFLP 
i. Restriction enzymes: 
 HAE III 
 FAE II 
ii. 10x digestion buffer 
4. Agarose gel electrophoresis 
i. Loading dye 
ii. Agarose 
iii. TBE buffer 
iv. 50 bp ladder 
5. Equipment 
i. Thermocycler 
ii. Gel electrophoresis apparatus 
iii. Pulse centrifuge and vortex 
iv. Microwave to meltagarose 
 
2. METHODS 
1. Preparation of Primer Stocks and Gotaq Green Master Mix 
i. Prepare forward and reverse primer aliquot tubes  
ii. Pulse centrifuge both forward and reverse primer stocks for 15 sec. each 
iii. Add 438µl of nuclease free H2O to the forward primer stock 
iv. Add 377µl of nuclease free H2O to the reverse primer stock 
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v. Pulse vortex each primer for 20 sec. 
vi. Pulse centrifuge each primer for 15 sec. 
vii. Add 900µl distilled H2O to each aliquot tube 
viii. Add 100µl of primer stock to each assigned aliquot tube 
ix. Aliquot 100µl of mixture into 10 tubes each and store non-working stock in -20°C.  
x. For the Master Mix, aliquot 1000 µl per tube into 10 tubes. 
2. PCR 
i. Dilute DNA concentrations of all samples to 50ng each. 
ii. Prepare the PCR Master Mixes in a 1.5 mL centrifuge tubes according the volumes 
calculated in Table 1. 
Table 1. Master Mix Calculation for PCR 
Reagent Volume per sample Volume per 10 samples 
Master Mix 12.5 µl 125 µl 
Primer-F 1 µl (10 pmol) 10 µl (100 pmol) 
Primer-R 1 µl (10 pmol) 10 µl (100 pmol) 
DSMO 0.5 µl 5 µl (100 pmol) 
H2O 8 µl 80 µl 
Total  23 µl 230 µl 
 
iii. Label PCR tubes and add 23µl of PCR Master Mixes to eachtube. 
iv. Add 1µl of DNA to each tube.  
v. Add 1µl of distilled H2O to one tube ensuring a negative control. 
vi. Pulse vortex and pulse centrifuge samples. 
vii. Seal and run PCR in thermocycler according to the conditions listen in Table 2.  
viii. Run an agarose gel (1%) of undigested PCR product to ensure amplification has 
been successful. 
Table 2. PCR thermocycling conditions for ApoE PCR. 
Step Cycle Temperature (°C) Time (min) Number of Cycles 
1 Initial Denaturation 95 2:00 1 
2 Denaturation 94 00:30 40 
3 Annealing 58 00:30 
4 Extension 70 1:30 
5 Final extension 72 7:00 1 
6 Hold 4   
 
3. RFLP 
i. Prepare the restriction digest Master Mix according to the volumes calculated 
using Table 3.  
ii. Label PCR tubes and add 5 µl of restriction digest master mix to each tube. 
iii. Add 5 µl of PCR product to each tube. 
iv. Seal and run in thermocycler at 37°C for 30 minutes. 
v. Run agarose gel to view digested products. 
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Table 3. Restriction digest Master Mix for ApoE 
Reagent Volume per 
sample 
Volume per 10 samples 
10X NEB Buffer 1 µl 10 µl 
HAE II 0.5 µl  5 µl  
AFE III 1 µl  10 µl  
H2O 2.5 µl 25 µl 
Total  5 µl 50 µl 
 
4. Agarose gel electrophoresis 
i. Make a 1.5% agarose gel: 
 Dissolve 1.5 g of agarose and 100 mL 1X TBE in the microwave until it is 
transparent in colour. 
 Cool then add 10 µl of Sybr Green dye and gently swirl to mix. 
 Pour into assembling casting tray with comb(s) and leave at room 
temperature for 30 minutes to set. 
ii. Load the gel: 
 Load 4-6µl of 50 bp ladder in the first well. 
 Carefully pipet 5 µl of undigested PCR product or 3µl of digested 
product to each well. 
 Place the gel in electrophoresis gel apparatus and fill to line with 1X 
TBE. 
iii. Run gel at 100 volts for 60 minutes and view using a UV transilluminator.  
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Appendix 8: Standard Operating Procedure for Apolipoprotein E Genotyping Using RT-PCR 
STANDARD OPERATING PROCEDURE FOR APOLIPOPROTEIN E GENOTYPING 
USING RT-PCR 
PURPOSE 
The purpose of this SOP is to and to describe the procedure for detecting ApoE genotypes Real Time – 
Polymerase Chain Reaction (RT-PCR).  
This was completed by a second researcher involved in the project who followed the LightMix Kit ApoE 
C112R R158C (Molbiol©) product data sheet protocol provided below. 
For RT-PCR using LightMix® Kit ApoE C112R R158C (Molbiol©) 
1. MATERIALS 
1. ApoE genotyping kit 
i. Set contents: 
 6 Vials with red caps containing premixed lyophilized primers and probes 
for 16 PCR reactions each of ApoE C112R R158C 
 1 Vial with colorless cap containing control DNA (ApoE 112C/C 158C/C), 
105 target equivalents per reaction 
 1 Vial with colorless cap containing control DNA (ApoE 112R/R 158R/R), 
105 target equivalents per reaction 
 1 Vial with colorless cap containing control DNA (ApoE 112C/R 158R/C), 
105 target equivalents per reaction 
 1 Vial with white cap containing DMSO 
ii. Additional reagents and items: 
  LightMix Kit – Color Compensation 530/640  
 LightCycler FastStart DNA Master  
 High Pure PCR Template Preparation Kit  
 LightCycler Capillaries (20 μl)  
 LightCycler 480 Multiwell Plate 96 
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2. Protocol 
 
3. Programming 
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